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ABSTRACT 
IDENTIFICATION AND CHARACTERIZATION OF A NOVEL CLASS OF 
PHARMACOLOGIC AGENTS FOR THE REVERSAL OF MULTIDRUG 
RESISTANCE. James M. Ford and William N. Hait. Section of Medical Oncology, 
Departments of Internal Medicine and Pharmacology, Yale University School of Medicine, 
New Haven, CT. 
Phenothiazines and structurally related compounds inhibit cellular proliferation and 
sensitize multidrug resistant (MDR) cells to chemotherapeutic agents. To identify more 
potent pharmaceuticals, the structure-activity relationships of a series of phenothiazines 
and related compounds were studied in MDR MCF-7/DOX human breast cancer cells. 
Spectrophotometric microtiter assays were used to determine the antiproliferative and anti- 
MDR effects of drugs alone or in combination with chemotherapeutic agents. Substitutions 
on the phenothiazine ring that increased hydrophobicity increased antiproliferative and anti- 
MDR activities. For example, -Cl and -CF3 groups increased whereas -OH groups 
decreased potency. Modifying the length of the alkyl bridge (4 C > 3 or 2) and the type of 
amino side chain (piperazinyl > non-cyclic) also influenced potency. Compounds with 
tertiary amines were better anti-MDR agents than those with secondary or primary amines, 
but were equipotent antiproliferative agents. The effects of these substituents w'ere 
unrelated to hydrophobicity. The structure-activity relationships suggest that an ideal 
structure for reversing MDR by phenothiazines has a hydrophobic nucleus w’ith a -CF3 ring 
substitution at position 2, connected by a 4 carbon alkyl bridge to a para-methyl substituted 
piperazinyl amine. Related compounds having certain of these properties were studied and 
the thioxanthene class of antipsychotics were identified as having increased activity and 
potency as chemosensitizers. For example, rrans-flupenthixol, the most effective of these 
compounds, decreased doxorubicin, vinblastine and colchicine resistance, respectively, by 
15-, 36-, and 8-fold in MCF7/DOX cells; by 35-, 40-, and 20-fold in the MDR human 

carcinoma line KB-V1; and by 7-fold (doxorubicin) and 4-fold (vinblastine) in the murine 
leukemia line P388/DOX. Trans-flupenthixol fully reversed 20-fold doxorubicin and 100- 
fold colchicine resistance in an NIH 3T3 fibroblast line transfected with an expression 
vector containing the mdr 1 gene. Equimolar concentrations of rrans-flupenthixol caused 
1.5- to 2-fold greater antagonism of MDR than its stereoisomer m-flupenthixol, 1- to 3- 
fold greater than the calcium channel blocker verapamil, and 2- to 12-fold greater than the 
phenothiazine homolog fluphenazine. None of these agents altered drug resistance or 
cross-resistance in a non-P-glycoprotein expressing MCF-7 cell line selected with 
mitoxantrone, nor any of the parental drug-sensitive cell lines. 7>art.s-flupenthixol was not 
accumulated more than c/5-flupenthixol in MDR cells, implying that their stereospecific 
anti-MDR effects were not the result of selective differences in the access of the drugs to 
intracellular targets. Both drugs caused increased accumulation of doxorubicin in MDR 
cells, but not in sensitive cells, suggesting that they modulate MDR by interacting with a 
uniquely overexpressed cellular target in these resistant cells. The cis- and trans- 
stereoisomers were equally active antagonists of protein kinase C and calmodulin. The 
apparent lack of clinical toxicity of traAtf-flupenthixol makes it an attractive drug for further 
investigation, and a pilot in vivo trial was performed in a murine tumor model, which 
showed rra/is-flupenthixol caused increased doxorubicin accumulation in MDR ascites 
cells in vivo, but was toxic to mice at the doses tested. This thesis shows that trans- 
flupenthixol, a drug that lacks extrapyramidal side effects in humans, is a potent, 
stereospecific antagonist of MDR in cells that overexpress P-gp. 

ACKNOWLEDGEMENTS 
A great number of individuals contributed immeasurably to the conception, execution, 
interpretation and presentation of the research presented in this thesis. In particular, I 
would like to extend by gratitude and appreciation to my labmates Joan Gesmonde and 
Sanjeewani Palayoor, for their technical expertise, patience and many helpful ideas, Mae 
Day for her unfailing assistance, and Dana Aftab for his intellectual comradery and 
friendship. I wish to thank Regina Loomis for her help with the animal studies, and 
Michael Escabar for his helpful discussions regarding the statistical analyses. I am 
indebted to Dr. John Forrest, Betsy Winters, the Office of Student Research, and the 
American Heart Association Student Fellowship Program for their generous support and 
cooperation, which enable me to spend an extremely valuable additional year in the 
laboratory. I would like to thank Drs. Walter Prozialeck and John Hyttel for generously 
supplying the many drugs involved in these studies, and Drs. Ken Cowan, Michael 
Gottesman, and William Dalton for kindly providing the cell lines. In addition, I wish to 
especially thank my parents for their many years of encouragement and support throughout 
my education. 
Finally, I wish to express my deep gratitude and admiration for my advisor, Bill Hait. 
His constant encouragement and belief, innumerable ideas, and obvious love of scientific 
research served as a tremendous source of inspiration for me. I am proud to count him as 
both my mentor and friend. 

DEDICATION 




TABLE OF CONTENTS 
Page 
ABSTRACT . i 
ACKNOWLEDGEMENTS.iii 
DEDICATION.iv 
TABLE OF CONTENTS.v 
LIST OF TABLES  vii 
LIST OF IGURES. viii 
LIST OF ABBREVIATIONS.ix 
I. INTRODUCTION 
A. Overview of the Cellular and Molecular Biology of Multidrug Resistance . . 1 
1. Definition and Characteristics of the Multidrug Resistant Phenotype ... 1 
2. Cellular Pharmacology of Multidrug Resistance .2 
3. Molecular Biology of Multidrug Resistance.3 
B. Clinical Relevance of Multidrug Resistance.4 
1. Expression of P-glycoprotein in Normal Human Tissues.5 
2. Expression of P-glycoprotein in Human Tumors.6 
C. Alternative Mechanisms Involved in Multiple Drug Resistance.7 
D. Pharmacologic Reversal of Multidrug Resistance by Chemosensitizers ... 9 
1. Introduction.9 
2. In Vitro Effects of Chemosensitizing Agents. 11 
3. In Vivo Effects of Chemosensitizing Agents. 26 
4. Mechanism of Action of Chemosensitizers in Multidrug Resistance . . 31 
5. Future Directions. 40 
E. Tables  42 
II. STRUCTURE ACTIVITY RELATIONSHIPS OF PHENOTHIOZINES AND 
RELATED DRUGS FOR THE INHIBITION OF CELL GROWTH AND 
REVERSAL OF MULTIDRUG RESISTANCE 
A. Introduction. 53 
B. Materials and Methods. 54 
C. Results  57 
D. Discussion. 63 
E. Tables and Figures . 70 

VI 
III. IN VITRO CHARACTERIZATION OF THE CHEMOSENSITIZING EFFECTS 
OF 77MVS-FLUPENTHIXOL 
A. Introduction. 85 
B. Materials and Methods. 86 
C. Results  92 
D. Discussion. 97 
E. Tables and Figures .103 
IV. IN VIVO EFFECTS OF 7VMVS-FLUPENTHIXOL ON MULTIDRUG RESISTANCE 
A. Introduction.112 
B. Materials and Methods.113 
C. Results .115 
D. Discussion.116 




LIST OF TABLES 
Paee 
1-1 Summary of studies using verapamil to reverse multidrug resistance ... 42 
1 -2 Summary of studies using verapamil analogs and other calcium channel 
blockers to reverse multidrug resistance. 44 
1-3 Summary of studies using calmodulin antagonists to reverse multidrug 
resista ce. 46 
1-4 Summary of studies using anthracycline and Vinca alkaloid analogs, 
lysosomotropic agents, and other drugs to reverse multidrug resistance . . 48 
1-5 Summary of studies using cyclosporines to reverse multidrug resistance . 50 
1- 6 Summary' of in vivo studies to reverse multidrug resistance .  51 
2- 1 Effect of modifying the phenothiazine nucleus on activity against cell growth 
and multidrug resistance. 70 
2-2 Effect of modifying the type of side chain amino group on activity against 
cell growth and multidrug resistance . 72 
2-3 Effect of modifying the length of the side chain amino group on activity 
against cell growth and multidrug resistance. 74 
2-4 Effect of specific inhibitorsof calmodulin and protein kinase C on cell growth 
and mulltidrug resistance. 76 
2-5 Effect of compounds structurally related to the phenothiazines on cell growth 
and multidrug resistance. 78 
2- 6 Effect of thioxanthene stereoisomers on cell growth and multidrug resistance 79 
3- 1 Inhibition of cellular proliferation by chemosensitizers alone. 103 
3-2 Relative resistance of cells to cytotoxic drugs. 104 
3-3 Reversal of multidrug resistance by chemosensitizers. 105 
3- 4 Inhibition of calmodulin and protein kinase C by chemosensitizers .... 106 
4- 1 In vivo chemosensitizing activity of rran^-flupenthixol. 121 
4-2 Effect of rrans-flupenthixol on in vivo doxorubicin accumulation in 
sensitive and MDR tumor bearing mice. 122 

Vlll 
LIST OF FIGURES 
Page 
2-1 Correlation between absorbance of stained cellular protein and cell count . 80 
2-2 Relationship between hydrophobicity and activity of phenothiazine derivatives 
as antiproliferative and anti-MDR agents. 81 
2-3 Relationship between anti-calmodulin activity and antiproliferative or 
anti-MDR activity for phenothiazine derivatives. 82 
2- 4 Effect on the sensitivity of MDR cells to doxorubicin by phenothiazines and 
structurally related modifiers . 84 
3- 1 Effect of equitoxic concentrations of thioxanthene isomers on the accumulation 
of doxorubicin in sensitive MCF-7 and MDR MCF-7/DOX cells .... 107 
3-2 Effect of equimolar concentrations of chemosensitizers on the accumulation 
of doxorubicin in sensitive MCF-7 and MDR MCF-7/DOX cells .... 108 
3-3 Isobologram analysis of the interaction between doxorubicin and 
rra/tf-flupenthixol. 109 
3-4 MDR isobologram analysis of the chemosensitizing interaction between 
verapamil and rnmy-flupenthixol. 110 
3- 5 Potency of chemosensitizing activity for rra/u-flupenthixol and verapamil 
in MDR cells . Ill 
4- 2 Toxicity of fra/tf-flupenthixol in mice. 123 

IX 
























Acute Nonlymphoblastic Leukemia 
Central Nervous System 
Calcium 
Calmodulin 





Increased Life Span 
lntraperitoneal 
Multidrug Resistance 
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl Tetrazolium Bromide 
N-(p-azidosalicyl) aminomethyl verapamil 
A/-(p-azidosalicyl-A,'-((3-aminoethyl) vindesine 
P-glycoprotein 











A. Overview of the Cellular and Molecular Biology of Multidrug Resistance 
1. Definition and Characteristics of the Multidrug Resistant Phenotype 
Tumor cell resistance to chemotherapeutic drugs is considered to be a major problem in 
the clinical treatment of cancer. One form of drug resistance, termed multidrug resistance 
(MDR), is defined as the ability of cells exposed to a single cytotoxic agent to develop 
resistance to a broad range of structurally and functionally unrelated drugs (24). 
Experimental models of MDR have been obtained by growing cultured human, murine or 
hamster neoplastic cell lines in progressively increasing concentrations of cytotoxic drugs, 
although MDR transplantable tumors have been developed in vivo (48). Cells selected for 
resistance to one drug display significant cross-resistance to the other drugs within the MDR 
phenotype, which mainly include the "natural product" anti-cancer drugs such as the 
anthracyclines, the Vinca alkaloids, the epipodophyllotoxins, colchicine, and actinomycin 
D, but not drugs such as bleomycin, methotrexate or alkylating agents. The level of cross- 
resistance displayed by MDR cells to individual drugs varies between cell lines. However, 
the qualitative similarity in the pattern of drug resistance suggests a single underlying 
mechanism is responsible for MDR. Since many of the drugs affected by MDR are believed 
to possess different mechanisms of cellular toxicity', investigations into the determinants of 
MDR have focused on the identification of a unifying cellular defense mechanism against 
toxic agents rather than on individual alterations in target enzymes. The most consistent 
changes found in MDR cell lines are an increased expression of a high molecular weight cell 
surface glycoprotein (P-glycoprotein) and a decreased accumulation and retention of 
cytotoxic drugs (186). 
Several excellent and thorough reviews of MDR have been recently published (14, 27, 
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168). Thus, a brief summary’ of the current understanding of the cellular pharmacology and 
molecular biology of this form of drug resistance will be presented. Following this will be a 
detailed discussion of the pharmacological reversal of MDR, since this field of research has 
not been adequately reviewed. 
2. Cellular Pharmacology of Multidrug Resistance 
The first experiments demonstrating that MDR cells were associated with a relative 
decrease in intracellular cytotoxic drug accumulation when compared to sensitive, parental 
cells were performed independently by Victor Ling and June Biedler, using Chinese hamster 
ovary cells resistant to colchicine and daunomycin, respectively (138, 184). Subsequently, 
every well-characterized MDR cell line has been shown to display decreased drug 
accumulation, generally ascribed to enhanced efflux rather than diminished influx (107, 
108). A number of investigators explored the basis for this decreased drug retention, and 
found an energy-dependent mechanism responsible for the enhanced efflux. Accordingly, 
experiments in which MDR cells were depleted of ATP-energy by removing glucose or 
adding metabolic inhibitors caused a reversal of the accumulation defect, while replacing 
glucose restored MDR (49). In contrast, anthracycline drug influx appeared to occur by 
simple passive diffusion, and to be similar in sensitive and MDR cells (128). These and 
other observations led to the acceptance of the still unproven hypothesis that an active efflux 
pump of broad specificity is responsible for the transport defect in MDR cells and results in 
altered sensitivity to multiple drugs (212). 
It is important to note that alternative explanations have been advanced to explain 
decreased efflux, including alterations in the binding of drugs to cellular proteins or 
organelles, particularly for colchicine (14). The determinants of altered drug transport in 
MDR cells are complex and remain to be fully defined. However, the drug efflux pump 




3. Molecular Biology of Multidrug Resistance 
3a. Overexpression of P-glycoprotein 
An approximately 170 kDa plasma membrane glycoprotein associated with MDR cells, 
but not detectable in drug-sensitive cells, was first identified by Ling’s group (121), and 
found to correlate with both decreased drug accumulation and degree of resistance in 
Chinese hamster ovary cells (125). Since then, several monoclonal antibodies to P- 
glycoprotein (P-gp) have been developed, and nearly every established MDR cell line from 
mouse, hamster, or human origin has been shown to express a 150 - 180 kDa membrane 
protein immunologically cross-reactive with the originally described P-gp (124, 125, 126). 
A great deal of evidence has accumulated suggesting that P-gp may be the active efflux 
pump of broad specificity as predicted by studies of the cellular pharmacology of MDR. 
For instance, purified, solubilized P-gp has been shown to possess an ATPase function 
(93). A number of radiolabelled drugs, such as [3H]-vinblastine, and photoactivatable drug 
analogs, have been shown to bind in a specific, saturable manner to MDR plasma membrane 
vesicles, but not to sensitive cell vesicles (43, 45). Furthermore, the major labelled 
membrane protein has a molecular weight of 170 kDa and is immuno-cross-reactive with 
monoclonal antibodies to P-gp (43, 44, 198). Structural analyses of P-gp accomplished by 
sequencing cDNA clones from P-gp encoding genes are particularly provocative (38, 82). 
The deduced amino acid sequence of P-gp reveals it to be dimer consisting of 6 
transmembrane segments, and bearing striking homology to the ATP-binding domains of a 
group of multicomponent bacterial periplasmic transport proteins, including the bacterial 
membrane a-hemolysin export pump (hylB) (100). Taken together, this experimental 
evidence strongly suggests that expression of P-gp forms the genetic basis for MDR. 
However, whether the protein binds and exudes drugs by an active transport process, 
physically opens channels in membranes through which drugs pass, or even irreversibly 
binds drugs and is removed altogether from the cell is not known. 
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3b. Overexpression of mdr Genes 
In certain MDR cell lines, such as the human epidermal KB lines, the amplification of 
gene(s) coding for P-gp allowed the use of in-gel renaturation (187) to isolate and ultimately 
clone mdr genes from hamster, mouse and human cell lines (83, 188). Cloned gene 
segments from the human KB cells (mdr 1 gene) hybridized to a 4.5 kb mRNA present in 
MDR cells in proportion to the degree of drug resistance, to which complementary cDNAs 
were prepared (38). Alternatively, monoclonal antibodies to P-gp were used as probes to 
screen a cDNA expression library for P-gp encoding clones from a Chinese hamster ovary 
MDR cell line (76). The cDNA clones obtained by these two methods were found to be 
highly homologous and to hybridize strongly to each other, indicating that P-gp is the 
product of the mdr 1 gene (236). Sequencing these cDNAs revealed the structural 
characteristics of P-gp discussed above. 
Perhaps the most compelling evidence demonstrating that MDR is due to the expression 
of a single gene came from transfection experiments. Transfer of total genomic DNA from 
MDR human cells (207), and more recently transfection and expression of retroviral vectors 
containing full length cDNAs coding for P-gp (235) into sensitive cells conferred the full 
MDR phenotype in the wild-type cells. 
B . Clinical Relevance of Multidrug Resistance 
An important question posed by the tremendous advances made in understanding the 
cellular and molecular biology of MDR is whether the expression of the mdr 1 gene product 
and the MDR phenotype occur in human tumors and are responsible for intrinsic or acquired 
anti-cancer drug resistance. Most experimentally induced MDR cell lines have been selected 
for 100-fold or greater levels of drug resistance, whereas clinical drug resistance is generally 
thought to be on the order of 2- to 5-fold (23). Therefore, it is possible that the 
pharmacologic characteristics displayed by highly MDR cell lines are a laboratory 
phenomenon only, exploiting otherwise functionally unrelated cellular mechanisms, and 
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bearing no relevance to clinical drug resistance. Nevertheless, the common observation that 
patients who relapse from therapy with certain drugs often become refractor}' to treatment 
with virtually all drugs is particularly suggestive of the MDR phenotype, and demands 
careful exploration. 
1 . Expression of P-glycoprotein in Normal Human Tissues 
Critical to the understanding of the clinical importance of MDR is the determination of 
the normal physiologic role and tissue distribution of P-gp, particularly as a baseline to 
which tumor expression may be compared. A variety of normal human tissues samples 
have been studied for P-gp expression using immunohistochemical or immunoperoxidase 
staining methods with monoclonal antibodies against P-gp. High levels of P-gp have been 
found in adult adrenal glands, kidney and placenta (218), and more abundantly in adrenal 
cortex than adrenal medulla (219). At a cellular level, P-gp has been localized to the luminal 
or apical surface of liver, pancreas, kidney, colon, and jejunum (222), suggesting a possible 
role in secretory' processes. Immunoblot assays have also demonstrated the presence of P- 
gp in liver, and low levels in small bowel (27). It was recently reported that endothelial 
cells of human capillary blood vessels at the blood-brain barrier and blood-testis barrier also 
express P-gp, but cells from larger blood vessels or other tissue capillaries do not, 
suggesting that P-gp may assist these tissues in their known function of excluding various 
soluble polar compounds from the CNS and other pharmacologic sanctuaries (42). 
Examination of P-gp expression in non-neoplastic tissues has also been carried out at the 
genetic level, utilizing mdr 1 gene hybridization probes and Northern or slot blot analysis. 
An initial survey of tissue types found low levels of mdr 1 mRNA in most samples, with 
higher levels in adrenal, kidney, liver and colon (65), although significant variability 
existed. 
Based on these findings, it is reasonable to believe that P-gp possesses a normal 
physiologic function in human tissues, perhaps related to secretion and/or protection of 
tissues from various naturally occurring toxins or even commonly encountered xenobiotics 
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structurally related to the natural product antibiotic drugs. It is likely that the continued 
analysis of this problem will eventually yield a natural substrate for P-gp, since it is doubtful 
that evolution would have selected for and highly conserved across species a protein whose 
primary function is to bind or extrude chemotherapeutic drugs. 
2. Expression of P-glycoprotein in Human Tumors 
Identical methods to those just described have been used to analyze P-gp and mdr 1 
mRNA expression in human tumor samples. Immunoblot assays have revealed 
overexpression of P-gp in 2 of 5 cases of advanced non-responsive ovarian cancer (18), and 
in sequential biopsies from 2 patients with acute nonlymphoblastic leukemia (ANLL) 
progressing on therapy (142). Similar findings of a relationship between P-gp expression 
and clinical resistance to anti-cancer therapy was reported by Carulli et al (31) for 2 patients 
with chronic myeloid leukemia (CML) in blast crisis and one patient with ANLL. Gerlach 
et al (75) reported that approximately 20% of biopsies specimens from 46 patients with 12 
different types of sarcomas expressed increased levels of P-gp, though a correlation was 
not found between prior chemotherapy and P-gp expression. 
Measurement of mdr\ mRNA has revealed high levels of expression independent of 
treatment in certain tumors derived from tissues known to overexpress P-gp normally, such 
as pheochromocytomas (from adrenal medulla) and adrenocortical tumors (from adrenal 
cortex) (65). Similarly, mdr 1 mRNA expression in untreated renal cell carcinomas was 
higher than in other urogenital tumors derived from tissues w'hich do not normally express 
P-gp (122). Interestingly, the levels of mRNA from tumors in this study were shown to 
correlate inversely with tumor cell vinblastine sensitivity, but not doxorubicin or cisplatin 
sensitivity, as determined by an in vitro cellular toxicity assay. 
The most extensive study of mdr 1 expression reported to date analyzed over 400 
tumor samples taken from patients both treated and untreated with chemotherapeutic drugs 
(79). Expression was found to be high in untreated colon cancer, renal cell carcinoma, 
hepatoma, adrenocortical carcinoma, pheochromocytoma and CML in blast crisis, while 
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untreated breast cancer, non-small cell lung cancer, CML in chronic phase and many other 
tumor types had low or undetectable levels of mdr\ mRNA. Expression in tumors from 
patients who initially responded but subsequently relapsed on chemotherapy was high in 
non-Hodgkin's lymphoma, neuroblastoma, pheochromocytoma, breast cancer, and acute 
lymphocytic leukemia. Therefore, P-gp overexpression was observed independent of 
treatment in a number of intrinsically resistant tumors, and seen to increase in frequency in 
several tumor types which received treatment. However, to prove an association between 
intrinsic or acquired drug resistance and P-glycoprotein expression, pre- and post-treatment 
P-gp levels from individual patients must be determined, and careful analyses of the 
possible correlations between P-gp levels and treatment responses performed. 
These important initial studies have proven that P-gp is expressed in both normal and 
neoplastic human tissues. Whether P-gp expression is a marker for intrinsic drug 
resistance; whether its increased expression is related to the development of acquired 
resistance; or what its funcdonal role is in normal tissues, are all questions which will be the 
focus of future studies. In addition, this work demonstrates that immunological and 
molecular diagnostic techniques may be successfully used to detect P-gp and mdr\ gene 
expression in clinical samples, and suggests their use for identifying individual patients who 
may be appropriate candidates for trials designed to circumvent or modify MDR in humans. 
C. Alternative Mechanisms Involved in Multiple Drug Resistance 
While the study of MDR has focused most extensively on P-gp associated experimental 
models, a rapidly increasing number of biochemical and molecular alterations have been 
recently described in cell lines selected for the expression of resistance to multiple drugs. 
Certain of these changes appear to occur only in consort with overexpression of the mdr\ 
gene, suggesting they may be the product of genes passively transcribed along with mdr\ 
amplification. In fact, these type of findings have encouraged investigators to thoroughly 
characterize and define MDR cell lines as "classic" P-gp associated cells with drug 
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accumulation defects, or otherwise. The two best characterized alternative mechanisms for a 
broad multiple drug resistance are changes in the expression of glutathione drug 
detoxification enzymes, and changes in topoisomerase II. 
The multifunctional phase II detoxification enzyme glutathione-S-transferase (GST) 
catalyzes the conjugation of electrophilic substances and endogenous xenobiotics to the 
tripeptide thiol, glutathione (GSH), forming stable, excretable metabolites, and prevents 
oxidative damage through intrinsic, organic peroxidase activity (36, 115). GST has been 
found to be increased in several cell lines associated with resistance to individual alkylating 
agents (220). However, an anionic (7t) isozyme of GST has recently been found to be 
greatly overexpressed in P-gp positive MCF-7/DOX cells selected for MDR with 
doxorubicin (12). Transfection and expression of cDNA clones of this isozyme in drug 
sensitive MCF-7 cells conferred low level (1.5- to 3-fold) resistance to alkylating agents, 
but no increase in resistance to natural product drugs (151). Thus, GST's role in multiple 
drug resistance involving non-alkylating agents has not yet been shown. Other evidence, 
however, does suggest that the GSH system may have some role in ’non-P-gp’ multiple 
drug resistance. For instance, depletion of MCF-7/DOX cellular GSH, the substrate for all 
GST enzymes, with the y-glutamylcysteine synthetase inhibitor buthionine sulfoximine 
(147), resulted in a 5- to 7-fold increase in cellular sensitivity to doxorubicin (54). 
The topoisomerases are enzymes that catalyze the breaking and rejoining of DNA 
required for genomic unwinding, and are necessary for DNA replication (140). Attention 
has focused on the role of topoisomerase II in drug resistance, since it is an enzyme target 
for many DNA intercalating and non-intercalating neoplastic agents such as doxorubicin, 
mitoxantrone, etoposide, tenoposide and mAMSA (39, 156, 221). Alteration in the amount 
or function of topoisomerase II has been suggested as a possible mechanism for cellular 
resistance to this broad group of drugs (190), and in fact, several multiple drug resistant cell 
lines characterized by decreased levels of topoisomerase II activity in the absence of P-gp 
expression or accumulation defects have now been reported (15, 35, 171). 
A great number of other changes in cells resistant to multiple drugs have also been 
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described. For instance, several low molecular weight cytosolic proteins are uniquely 
expressed in MDR, such as the Ca+^-binding protein sorcin (148), and others (59). 
Similarly, several membrane proteins unique to MDR cells have been observed in addition 
to P-gp, such as an 85 kDa glycoprotein in K562/ADM cells (91), and a 150 kDa protein 
immunologically distinct from P-gp (146). Whether these membrane proteins are metabolic 
products of P-gp degradation has not been adequately studied. 
Many biochemical changes have been noted in MDR cells, particularly in MCF-7/DOX 
cells, including changes in phase I cytochrome P450 enzymes like aryl hydrocarbon 
anhydroxylase (114), alterations in the regulation of the hexose monophosphate shunt 
(244), and increased activity of the drug metabolizing enzymes DT-diaphorase and 
glucuronyl transferase (46). 
It is unclear for most of these changes whether their presence or alteration in MDR cells 
have a significant regulators’ or functional role, or are simply a coincidental result of the 
selecting procedure, resulting from co-amplified genes related to P-gp expression by their 
physical proximity to the mdr 1 gene, but having no other functional or mechanistic 
involvement in the MDR phenotype. Thus, numerous opportunities await researchers 
interested in further defining the regulatory mechanisms for "classic” MDR, and in 
exploring the molecular and biochemical basis for alternative forms of multiple drug 
resistance. 
D. Pharmacologic Reversal of Multidrug Resistance by Chemosensitizers 
1 . Introduction 
A major goal in experimental as well as clinical investigations of any form of drug 
resistance is to devise or discover unique methods by which to successfully reverse or 
antagonize this resistance. Great interest, therefore, has been recently focused on the 
pharmacologic reversal of MDR, especially in in vitro models. Through the identification 
of specific compounds or classes of agents which reverse MDR, investigators hope to gain a 
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better understanding of the various biochemical mechanisms involved in this form of cellular 
drug resistance, and to provide possible agents for use in clinical trials. 
The first report of the pharmacologic reversal of MDR came from Takashi Tsuruo and 
his colleagues, who showed that the calcium channel blocker verapamil greatly potentiated 
the antiproliferative activity of vincristine, in association with an increased cellular 
accumulation of vincristine, in a MDR murine leukemia cell line in vitro and in vivo (228). 
Since this original observation, a large number of compounds have been shown to have 
activity in a variety of cell lines and in in vivo tumor models when co-administered with 
cytotoxics, for at least partially reversing MDR . Tables 1-1 through 1- 6 summarize the 
pharmacologic agents, MDR cells lines, and cytotoxic drugs used to date, both in vitro and 
in vivo, for demonstrating reversal of MDR. It must be noted that a variety of assays have 
been used by various investigators to measure the antiproliferative or cytotoxic effects of 
drugs, resulting in a broad range of reported values for similar agents. In general, these 
chemical compounds, termed "chemosensitizers" or "resistance modifiers," act to alter the 
drug accumulation defect present in MDR cells, and cause little or no potentiation of drug 
cytotoxicity in wild-type, or intrinsically sensitive cells. While there are exceptions, 
investigators generally determine the magnitude of chemosensitizers' effects by comparing 
the doses necessary to inhibit cell growth by 50% (IC50) for a cytotoxic drug to which cells 
are resistant in the absence versus presence of a relatively non-toxic, fixed concentration of 
chemosensitizer. The ratio of these two values is referred to by different investigators as the 
the fold-sensitization, Dose Modifying Factor, Degree of Potentiation, or MDR Ratio. This 
standard has been used to calculate the fold reversal of cellular drug resistance for each 
chemosensitizer listed in Table 1-1 to 1-6. 
Very little is yet known regarding the biochemical mechanism, or even the specific 
molecular targets, for any of the structurally diverse group of identified chemosensitizers 
(27), partly because many of these compounds have profoundly different effects on cellular 
physiology, often including significant cytotoxicity of their own. Nevertheless, the results 
from this field of study have generated considerable interest in the possibility of devising 

11 
clinical protocols utilizing relatively non-toxic chemosensitizers to circumvent clinical drug 
resistance in humans (149, 165, 214). 
The chemosensitizers described to date may be grouped into five broad categories: (a) 
calcium channel blockers, (b) calmodulin antagonists, (c) non-cytotoxic anthracycline and 
Vinca alkaloid analogs, (d) otherwise unrelated hydrophobic, cationic compounds, and (e) 
cyclosporines. Though this diverse group of compounds share only broad structural 
similarities, all are extremely lipophilic, and those in the first four groups are all 
heterocyclic, amphipathic substances. This suggests that there may be one or more specific 
receptor sites for anti-MDR drugs, which have unique, though as yet poorly defined, 
structural requirements for efficient binding. 
The following sections will review the literature to date regarding the effects of 
chemosensitizers in vitro, in vivo, and in human trials, and will focus on the need to 
carefully define the structural requirements for antagonism of MDR by chemosensitizers and 
to elucidate their mechanism of action. 
2 . In Vitro Effects of Chernosensitizing Agents 
2a. Verapamil 
Based on the knowledge that certain MDR cell lines displayed an increase in drug efflux 
due to alterations in drug transport at the plasma membrane level (107), Tsuruo's group 
examined the anti-MDR effect of the calcium channel blocker verapamil, presumably 
because of its already known action on a membrane target (62) and its documented 
inhibitor}' effect on several hormonal secretory functions (55). Using a tissue culture 
growth inhibition assay, it was shown that 2.2 to 6.6 (iM verapamil completely reversed the 
approximately 30-fold resistance to vincristine and 7-fold resistance to vinblastine displayed 
by a MDR murine leukemia cell line, P388/VCR (228). Incubation with 6.6 fiM verapamil 
for 5 hours also caused a 10-fold increase in accumulation of [3H]-vincristine in P388/VCR 
cells. In addition, verapamil caused a 3-fold increase in the antiproliferative effect of 
vincristine and vinblastine and a 2-fold increase in [3H]-vincristine accumulation in sensitive 
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P388 cells (228). Doses of verapamil greater than 6.6 |lM had significant cytotoxicity 
alone. Since verapamil was shown not to alter vincristine binding to tubulin, the apparent 
cytotoxic target of Vinca alkaloids (164), it was concluded that verapamil's pharmacologic 
anti-MDR effect was due to alterations in drug accumulation (228). 
In subsequent reports, Tsuruo’s group similarly demonstrated that 6.6 |iM verapamil 
fully reversed the 20-fold vincristine resistance and the 3-fold doxorubicin resistance in a 
MDR human acute myelogenous leukemia line K562/VCR (230), and partially reversed the 
40-fold doxorubicin resistance in P388/ADM cells (229). Again, this anti-MDR effect was 
associated with modest (5-fold) increases in chemotherapeutic drug accumulation, shown to 
be due specifically to inhibition of an energy-dependent efflux mechanism (229). 
Since these early observations, a large number of investigators have demonstrated the 
chemosensitizing activity of verapamil in various cell lines (Table 1-1) using a variety of 
techniques. For example, resistance to chemotherapeutic selecting agents was partially 
reversed by verapamil in vinblastine resistant human leukemic lymphoma CCRF-CEM cells 
(13), and in doxorubicin resistant B16 murine melanoma cells (66), as measured by short¬ 
term cell growth inhibition. Clonogenic assays revealed modest increases in drug 
cytotoxicity by 1 (iM verapamil plus daunomycin in MDR Chinese hamster ovary cells (29), 
and 6 pM verapamil plus doxorubicin in doxorubicin resistant C5 rat glioblastoma cells 
(102). Slater and colleagues (215) showed that 2 to 6 pM verapamil caused significant 
increases in the inhibition of DNA and RNA synthesis by daunomycin in daunomycin 
resistant Ehrlich ascites carcinoma cells, as measured by [-H]-uridine and [^HJ-thymidine 
incorporation. Several samples of fresh human tumor cells from patients who relapsed on 
doxorubicin w’ere show-n to be more sensitive to the drug in the presence of verapamil by the 
human tumor clonogenic assay (80). In addition, the sensitivity of most of the parental, 
wild-type cells from w'hich the MDR lines were derived, as well as other intrinsically 
sensitive cell lines, was not significantly affected by verapamil at non-cytotoxic doses. 
The effect of the verapamil on modifying cellular cross-resistance to chemotherapeutic 
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drugs other than those used for selection is of great interest, both with respect to the 
mechanism and pharmacology of verapamil's anti-MDR activity, and in defining the 
molecular mechanism of MDR itself. However, conflicting results have been reported, 
complicated by the fact that many of these studies occurred before the characterization of cell 
lines using molecular and immunologic probes for P-glycoprotein expression became 
common. Using a MES-SA human uterine sarcoma cell line selected for 100-fold resistance 
to doxorubicin and recently shown to overexpress the mdr\ gene product (211), Harker 
and coworkers showed that 6 [lM verapamil caused a 7-fold enhancement of doxorubicin 
effect, associated with increased [14C]-doxorubicin accumulation and retention (95). 
Verapamil caused a similar partial reversal of this cell line's significant cross-resistance to 
daunomycin, actinomycin D and mitoxantrone, but did not effect cell resistance to agents 
such as etoposide or melphalan, drugs not included in the phenotypic definition of MDR. 
Paradoxically, verapamil resulted in increased accumulation of [?H]-vinblastine in these 
cells, but did not alter MES-SA/Dx5 resistance to vinblastine toxicity. 
Conversely, Beck's group reported that 10 )iM verapamil caused a 75- and 87-fold 
decrease in the 244- and 1163-fold CEM/VLBjqo cell resistance to vinblastine and 
vincristine, respectively, but only a 2- to 5-fold potentiation of doxorubicin and 
daunomycin, to which the cells were 100-fold cross-resistant (17). Fojo el al (64) 
demonstrated that 20 jiM verapamil caused a full reversal of the 20- to 70-fold cross¬ 
resistance to doxorubicin, vinblastine and vincristine in colchicine selected KB human 
carcinoma cells, while causing only a 60-fold reduction in the 220-fold resistance to 
colchicine. Finally, in doxorubicin selected P388/ADR cells, the degree of cytotoxic 
potentiation for a series of five anthrapyrazoles by 10 pM verapamil was shown to be 
linearly related to the level of cross-resistance displayed to these drugs (131). Thus, while 
verapamil equally affects cellular resistance to selecting agents and cross-resistance to other 
drugs in some MDR cell lines, this finding is not true for other MDR cell lines. The 
question of why various MDR cells display different degrees of resistance and cross- 
resistance to drugs, and why some cross-resistance is refractors' to modulation by verapamil 
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is presently unclear. An intriguing possibility is that alterations in the mdr 1 gene at the 
genomic level (40) or post-translational modifications in P-glycoprotein may cause changes 
in the affinity of certain drugs or drug classes for the putative drug-binding site(s), or may 
render P-glycoprotein less susceptible to antagonism by verapamil. Alternatively, multiple 
isoforms of P-glycoprotein, as well as multiple mechanisms of drug resistance to various 
chemotherapeutic agents operating within a single cell line may also explain these 
phenomena. 
While the target and mechanisms for verapamil's pharmacologic effects on MDR cells 
is unclear, the effect of verapamil on the well-characterized changes in drug accumulation 
observed in MDR cells has been carefully documented. Kessel and Wilberding (128) 
probed the effect of verapamil on anthracycline cellular kinetics in P388/ADR cells. Drug 
influx was not altered by verapamil nor by the metabolic inhibitor sodium azide, consistent 
with a diffusional model of anthracycline inward transport. Drug efflux from [^H]- 
daunomycin loaded cells was also not affected by either modifying agent in P388 sensitive 
cells, while MDR cell daunomycin efflux was inhibited by varying degrees with 2 to 20 (iM 
verapamil, suggesting that verapamil specifically inhibits the energy-dependent drug efflux 
mechanism described for these cells (108). More recently, similar studies were performed 
with the human myeloma MDR cell line 8226/DOX40 (19). Accordingly, 10 |iM verapamil 
caused an increase in net [14C]-doxorubicin accumulation in resistant, but not sensitive 
cells, due to a decrease in drug efflux. Verapamil was show'n not to alter initial 
anthracycline influx during the first 60 seconds of drug exposure. Furthermore, the 
quantitative formation of single-stranded, double-stranded and protein-associated DNA 
breaks in both sensitive and resistant cells after a one hour doxorubicin exposure in the 
absence and presence of verapamil was determined by DNA alkaline elution techniques 
(19), since a proposed mechanism for anthracycline cytotoxicity is through topoisomerase II 
mediated DNA strand breaks (189). In resistant cells there was an approximately 5-fold 
decrease in the formation of DNA lesions compared to sensitive cells. However, in the 
presence of 10 pM verapamil, sensitive and resistant cells sustained equivalent amounts of 
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DNA damage by doxorubicin. 
Therefore, it has been clearly shown that verapamil inhibits the energy-dependent drug 
efflux common to MDR cells. In addition, it is highly likely that the drug cytotoxicity' 
potentiated by verapamil is secondary' to the resultant increase in intracellular drug 
accumulation. 
Verapamil is the best studied chemosensitizer to date, and is a potent and effective 
antagonist of resistance to a number of drugs in most MDR cell lines, in vitro. However, 
verapamil possesses potentially life-threatening vasodilatory effects in humans at plasma 
levels in the 2 to 6 pM range (28, 50) and is cytotoxic itself at higher doses to normal (133) 
and tumor tissue (17) in vitro. These facts have led to the search for more potent and less 
toxic anti-MDR agents for possible clinical use. 
2 b. Verapamil Analogs 
An obvious first step in searching for less toxic, more selective chemosensitizing agents 
is to examine the ability of structural analogs of verapamil to antagonize MDR (Table 1-2). 
Kessel and Wilberding (129) studied the anti-MDR effects of the verapamil analog tiapamil, 
and 13 additional analogs of tiapamil, in a P388/ADR cell clonogenic assay. Tiapamil, 
which contains a dithiane tetraoxide substituent on the carbon backbone, was 50-fold less 
potent than verapamil in causing a partial (15-fold) reversal of the 100-fold doxorubicin 
resistance, while the analog Ro 1 1-3651 (DMDP) was only 7-fold less potent, and the 
dithiane substituted analog Ro 11-2933 was 10-fold more potent than verapamil in 
mediating this effect. The degree of doxorubicin potentiation by the four active tiapamil 
compounds was found to correlate with their respective effect on drug accumulation (129). 
Another group further examined the activity of DMDP in the same cell line, and found 
that non-toxic doses of this tiapamil analog (3 |iM) and verapamil (6 pM) caused similar 
effects on doxorubicin cytotoxicity and accumulation, but that DMDP was 6-fold more toxic 
to cells than verapamil when used alone (IC50 = 14 jiM) (175). 
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A Japanese group reported that a synthetic isoprenoid structurally related to verapamil, 
SDB-ethylenediamine, caused a 2- to 5-fold increase in doxorubicin cytotoxicity in the 
P388/ADR cell line, as well as partial reversal of cross-resistance to vincristine, vinblastine 
and daunomycin (242). Antagonism of MDR was also found in P388A;CR cells and in 
colchicine selected MDR human epidermal carcinoma KB-ChR-24 (155, 242). 
Interestingly, this verapamil analog, which has a slightly modified carbon backbone and 
contains a 9 carbon isoprene side group, has negligible activity as a calcium channel 
blocking agent compared to verapamil (242). 
Thus, certain compounds structurally related to verapamil partially reverse MDR, but 
lack other physiological effects of verapamil. While of clear mechanistic interest (see 
Section 4b, below), this also suggests that through structure-activity' relationships it may be 
possible to identify and exploit those structural features necessary for anti-MDR activity, 
while eliminating those important for antagonism of calcium channels or other interactions. 
2c. Other Calcium Channel Blockers 
Since a number of calcium channel blockers structurally dissimilar to verapamil have 
been described and are in clinical use, it occurred to researchers to examine their effect 
against MDR. While it subsequently became clear that these drugs’ pharmacologic effect on 
slow inward calcium transport was completely unrelated to their anti-MDR activity (see 
Section 4b, below), many were nevertheless found to be quite active antagonists of MDR 
(Table 1-2) (96). Indeed, in Tsuruo’s early observations of the anti-MDR effects of 
verapamil, it is also noted that caroverine and prenylamine, agents known to block calcium 
channels (26, 112), w'ere as active as verapamil in altering the sensitivity of P388/VCR and 
K562/VCR cells to vincristine and P388/ADM cells to doxorubicin, though 2- to 3-fold less 
potent (229, 230). 
Additional studies specifically examined the effects of calcium channel blockers in 
MDR cell lines and found that two other classes of structurally dissimilar drugs, diltiazem 
and the nifedipine analogs, had significant anti-MDR activity (181, 227, 231). 
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Interestingly, nifedipine itself, known to be a strong calcium channel blocker (63), was a 
poor antagonist of MDR in P388/VCR and K562/VCR cells (227) and had no effect in 
potentiating doxorubicin in P388/ADR cells (181). However, the dihydropyridine analogs 
niludipine, nimodipine, and nicardapine were found to be potent antagonists of MDR, with 
3.5 to 10 |iM nicardapine fully reversing vincristine resistance in P388A7CR and 
K562/VCR cells (227, 231) and partially reversing doxorubicin resistance in P388/ADR 
cells (181, 227). These studies pointed out what was later proven to be the distinct 
pharmacologic effects of these drugs on calcium channels and on MDR (102). 
Several groups have shown that perhexiline maleate, another structurally unrelated drug 
which has among other effects calcium channel blocking activity (62), can also antagonize 
MDR. Non-toxic concentrations of perhexiline maleate (10 jiM) caused a slight increase in 
the sensitivity of a MDR human breast cancer cell line MCF-7Ad to doxorubicin and 
vinblastine (177), and a more substantial reversal of P388/ADR cell resistance to these same 
drugs (67), along with concomitant increases in [3HJ-drug accumulation. Like verapamil, 
however, perhexiline maleate is a clinically used vasodilator and is an unlikely candidate for 
the modulation of tumor resistance in humans, due to its dose-limiting hemodynamic side 
effects. 
Finally, in the search for a calcium channel blocker with anti-MDR activity and less 
vasodilator)' activity, bepridil was found to be a potent inhibitor of colchicine selected 
Chinese hamster ovary cell resistance to doxorubicin (74-fold reversal) (203). Drug 
concentrations shown necessary for anti-MDR activity in vitro (2 to 4 pM) by this study 
had been reported to be clinically achievable without resultant toxicity (20). When studied 
in the MDR human ovary cell line 2780AD, bepridil was equally as active as verapamil, but 
% 
caused only a 10% increase in sensitivity to doxorubicin. However, of all the calcium 
channel blockers studied to date, bepridil appears to be the most worthy of continued pre- 
clinical development for the in vivo reversal of drug resistance. 
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2d. Calmodulin Antagonists 
The second most studied group of anti-MDR agents are drugs which also possess the 
ability to inhibit CaM-mediated processes, such as the Ca^CaM-dependent form of cyclic 
nucleotide phosphodiesterase (137). While the activity of CaM antagonists against MDR 
was first described by Tsuruo (229), Ganapathi has most extensively studied this group of 
drugs, focusing on the phenothiazine (PTZ) antipsychotic trifluoperazine. 
Based on the finding that verapamil functioned as a chemosensitizer in MDR cells, 
Tsuruo examined several other compounds known to perturb the intracellular calcium 
environment (Table 1-3). Non-toxic concentrations of the well known CaM antagonist, 
trifluoperazine, caused a 5- to 10-fold increase in vincristine and doxorubicin sensitivity in 
20- and 40-fold resistant P388/VCR and P388/ADM cells, respectively (229), and fully 
reversed 17-fold K562/VCR resistance to vincristine (230). Like verapamil, trifluoperazine 
also caused a 4- to 5-fold increase in pHJ-vincristine and pHJ-doxorubicin accumulation in 
these cells, and did not significantly alter drug cytotoxicity or accumulation in their sensitive 
counterparts (229, 230). Although verapamil appeared to be more effective than 
trifluoperazine in antagonizing MDR, higher concentrations of verapamil than the CaM 
antagonist were used (6.6 pM versus 2 to 3 pM trifluoperazine) due to trifluoperazine's 
greater toxicity when used alone (229). Interestingly, equimolar concentrations of 
trifluoperazine and verapamil (6.6 pM) were shown to produce equivalent increases in 
[3H]-drug accumulation in all three cell line (229, 230). Unfortunately, no study directly 
comparing the potency, toxicity and maximal anti-MDR effect of trifluoperazine and 
verapamil in this or any other cell lines has been reported. 
Ganapathi has focused on the effect of trifluoperazine in altering cellular drug 
resistance, cross-resistance and drug accumulation (Table 1-3). In 100-fold doxorubicin 
resistant P388/DOX cells (apparently a different MDR subline than Tsuruo's P388/ADM), 4 
to 5 pM trifluoperazine caused a 5- to 10-fold increased inhibition of cellular proliferation 
and cytotoxicity by doxorubicin in MDR, but not sensitive cells (69, 71), as measured by 
cell growth and clonogenic assays. 5 |iM trifluoperazine also partially antagonized the 
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resistance of a series of L1210 murine leukemia cell lines made variably resistant to 
doxorubicin (5- to 40-fold), with the magnitude of this effect seemingly related to the degree 
of acquired resistance (70) (Table 1-3). 
Trifluoperazine's effect on cross-resistance is less clear. Similar to experiments with 
trifluoperazine and doxorubicin, trifluoperazine enhanced the cellular accumulation and 
cytotoxicity of the anthracycline daunomycin in the 100-fold cross resistant P388/DOX 
cells, but not in sensitive P388 cells (71). However, trifluoperazine had significant effects 
on the cytotoxicity of Vinca alkaloids in both MDR and sensitive cells, causing 2- to 10- 
fold increases in the toxicity of vinblastine and vincristine in the 20- and 100-fold cross 
resistant P388/DOX cells, respectively, as well as in sensitive P388 cells (72). Conversely, 
trifluoperazine's effect on the accumulation of [-H]-vinblastine was not similar in the 
P388/DOX and P388 sensitive cells, causing a 8-fold versus 2-fold increase, respectively 
(72). Thus, trifluoperazine's enhancement of Vinca alkaloid cytotoxicity does not clearly 
parallel its effect on cellular drug levels. 
In fact, Ganapathi has argued extensively against a correlation between actual 
intracellular levels of drug following exposure to trifluoperazine and resultant cellular 
toxicity. For instance, Ganapathi compared the resultant P388/DOX cellular toxicity of 
similar intracellular doxorubicin or daunomycin concentrations achieved by either treating 
with 5 (iM trifluoperazine or by increasing extracellular drug concentration appropriately, 
and found that cell kill occurred only with trifluoperazine treatment (74). Furthermore, the 
cellular accumulation of doxorubicin in the absence and presence of 5 (iM trifluoperazine 
was examined in a series of L1210 cell lines made 5-, 10-, 20-, and 40-fold resistance to 
doxorubicin (70). In the absence of trifluoperazine, cellular doxorubicin accumulation 
progressively decreased with increasing resistance from 15 - 50% of parental L1210 cell 
accumulation. The presence of 5 (iM trifluoperazine caused a constant 1.5-fold 
enhancement of doxorubicin accumulation in each resistant subline, independent of its level 
of resistance. In contrast, the effect of trifluoperazine in modulating doxorubicin 
cytotoxicity was dependent on the level of resistance (Table 1-3), with the magnitude of 
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chemosensitizing activity correlating with the level of resistance. However, if one re¬ 
analyzes Ganapathi's data to calculate the percent modulation of total doxorubicin resistance 
by trifluoperazine in each subline as a function of the total difference in sensitivity from the 
parental line, rather than purely the fold decrease in resistance, one actually finds a 
progressive decrease in the percent reversal of resistance by trifluoperazine in increasingly 
resistant sublines. This finding is in agreement with the calculated decrease in doxorubicin 
accumulation relative to the total accumulation defect in increasingly resistant sublines. 
Obviously, the effects of alterations in drug accumulation are extremely difficult to 
assess since drug accumulation and retention are only one of many factors influencing the 
cytotoxicity of chemotherapeutic agents. Compounding this problem is that drug activity 
tends to be measured in terms of overall cell toxicity, rather than specific effects at a 
biochemical or molecular level. Even independent of the effects of chemosensitizers, it is 
not clear that intracellular drug levels are linearly related to cytotoxicity. In fact, this would 
not be expected, since chemotherapeutic agents often have multiple targets with different 
affinities through which they mediate their toxicity. For example, the basis for doxorubicin 
cytotoxicity has been suggested to be due to a combination of cellular effects, including 
DNA intercalation (53), membrane binding (223), free radical formation (9), transitional 
metal ion binding (152), and topoisomerase II-mediated DNA strand breaks (221). Such a 
multitude of targets implies a complex relationship between drug level and effect. In 
addition, cells themselves have various intrinsic mechanisms for protection from drug 
toxicity, such as phase I and phase II drug-metabolizing enzymes and various DNA repair 
enzymes, so that certain threshold levels of drug may be necessary before cell damage can 
accumulate. 
Nevertheless, the disparity between chemosensitizer modulated accumulation and 
cytotoxicity in Ganapathi's studies suggests that trifluoperazine, a drug known to effect 
many cellular enzymes and receptors (47, 167, 195) may alter cell sensitivity to drugs in 
additional ways unrelated to changes in accumulation. Indeed, several investigators have 
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shown that CaM antagonists such as trifluoperazine modulate cell sensitivity to bleomycin 
through inhibition of DNA repair mechanisms (33, 134). These results also suggest that 
certain N1DR cells may have multiple mechanisms of resistance, and reversing the 
accumulation defect alone may not fully reverse cellular drug resistance. In fact, several 
MDR cell lines have recently been shown to possess alternate mechanisms of resistance in 
addition to P-glycoprotein, such as increased levels of the glutathione conjugating enzyme 
glutathione-S-transferase in MCF-7/DOX cells and an MDR P388 line (12, 51), and 
decreased levels of the drug target topoisomerase II in this same P388 line (52). 
In summary', certain CaM antagonists, such as trifluoperazine, function as moderately 
effective chemosensitizers and enhance cytotoxic drug accumulation and retention in MDR 
cells. Though the PTZs generally are thought to be less active anti-MDR agents than the 
calcium channel blocker verapamil, a comparison of Tables 1-1 and 1-3 reveal that the 
concentrations of verapamil used in most studies are generally greater than trifluoperazine, 
presumably due to the greater toxicity of the latter compound. Since there appears to be a 
dose-response relationship for chemosensitizers' anti-MDR effect (19, 70, 211), 
trifluoperazine's significant toxicity may limit its in vitro use to a less than maximally 
effective chemosensitizing dose range. A number of investigators have clearly shown CaM 
to be a target for the PTZs' cytotoxic actions (87, 113, 239), and it is therefore intriguing to 
speculate on the possible selectivity for anti-MDR activity over cytotoxicity for this class of 
agents if CaM is in fact not directly involved in the pharmacologic reversal of MDR. 
Clearly, more comprehensive studies of the effects and mechanisms for reversal of MDR by 
CaM antagonists are necessary' and indicated. 
2e. Anthracycline and Vinca Alkaloid Analogs 
Soon after the discovery' that MDR cells have reduced drug uptake secondary to an 
increased active efflux mechanism (212), Skovsgaard tested the intriguing and logical 
possibility that a specific drug efflux pump would be competitively inhibited by an excess of 
a non-toxic substrate (213). The ideal anthracycline structural analog for this purpose was 
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A-acetyl-daunorubicin, which lacks the free amino-group of daunomycin essential for 
DNA intercalation, and thus has a lower affinity for DNA resulting in less cytotoxicity and 
higher cytoplasmic concentrations (247). Skovsgaard found that a 30-fold excess of AT- 
acetyl-daunorubicin caused marked inhibition of active daunomycin efflux in MDR, but not 
sensitive, Ehrlich ascites cells, leading to increased net daunomycin uptake (213). In 
addition, A-acetyl-daunorubicin had a 7-fold low'er affinity for both sensitive and resistant 
cell nuclei in whole cell lysate preparations, and did not compete with pHj-daunomycin 
binding to DNA. The effect of A7-acetyl-daunorubicin on cellular resistance to daunomycin 
w-as unfortunately not examined in vitro, though a 1:20 combination of daunomycin and its 
structural analog did cause significant increases in the life span of mice w'ith MDR Ehrlich 
ascites cells inoculated intraperitoneally (i.p.) compared to no effect of either drug alone 
(213). 
Inaba's group subsequently analyzed the chemosensitizing effects of three additional 
non-toxic anthracycline analogs on MDR cells and found significant enhancement of 
vincristine toxicity in P388/VCR cells in vitro when used in 100-fold excess (111). 
Interestingly, one of these analogs also partially reversed the cross-resistance of the cells to 
daunomycin, implying that either a similar drug efflux mechanism effects both 
anthracyclines and Vinca alkaloids, or that the daunomycin analogs competitively inhibited 
two different mechanisms. Similarly, Inaba also reported that a number of relatively non¬ 
toxic Vinca alkaloid analogs, such as vindoline, effectively antagonized both the primary 
resistance and cross-resistance of MDR P388/ADM and P388/VCR cells (110) when used 
in 1000-fold excess (Table 1-4). These analogs were 5- to 10-fold less potent than the 
anthracycline analogs as chemosensitizers and as enhancers of cytotoxic drug accumulation. 
These findings suggest that a single drug-binding site of broad specificity, rather than 
multiple, independent binding sites, is responsible for cross-resistance between at least the 
anthracyclines and Vinca alkaloids. Indeed, these speculations agree with molecular 
studies demonstrating that single base mutations wnthin the mdr 1 gene can alter the levels of 
cross-resistance displayed by the expressed P-gp (40). It would also be of interest to see 
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whether these non-toxic analogs competitively inhibit the binding to the photoaffinity 
labelled vinblastine analog 125I-NASV (2) or the photoactive verapamil analog 12-I-NASAV 
(197) to P-glycoprotein. 
2f. Odxer Hydrophobic Cationic Compounds 
The search for agents to circumvent MDR has led to the identification of numerous 
compounds which are not known to be calcium channel blockers or CaM antagonists, and 
are not otherwise pharmacologically related. Most of these compounds are amphipathic and 
lipophilic in nature, and share a broad structural similarity that includes a tricyclic ring 
nucleus separated by some distance from a cationic group. Chemosensitizing agents as 
diverse as the antiarrythmics amiodarone (37) and quinidine (226), the alkaloid derivative 
cepharanthine (209), the lysosomotropic amines chloroquine and propranolol (208, 245, 
246), the antimalarial quinacrine (109, 246), the indole alkaloid reserpine (16), and the 
antiestrogen tamoxifen and structurally related triparanol analogs (67, 178), have been 
reported to partially overcome resistance and cross-resistance to cytotoxic drugs, and to 
increase drug accumulation and retention in various MDR cell lines (Table 4). Whether 
these many types of pharmacologic agents are acting through a common mechanism to 
antagonize MDR, w-hether numerous drug-target interactions are capable of mediating this 
effect, or whether as a result of their degree of hydrophobicity these drugs simply cause 
non-specific membrane perturbations leading to increased drug accumulation, is presently 
unclear. 
2g. Cyclosporines 
In addition to w'ell-known immunosuppressive and cytotoxic properties, cyclosporines 
have been described as having chemosensitizing activity in sensitive and MDR tumor cell 
lines (233). Structurally and pharmacologically quite different than other known 
chemosensitizers, cyclosporin A (CsA) is an extremely hydrophobic cyclic peptide of 11 
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amino acids. Its primary immunosuppressive activity is through the specific inhibition of an 
early stage of T lymphocyte activation, apparently by interaction with the cytosolic receptor 
protein, cyclophilin (94). Interest in CsA's potential anti-MDR activity was in part due to 
repons of its CaM binding properties (41), though it was later clearly shown that CsA does 
not specifically inhibit CaM-mediated processes (85). 
Though there were several earlier reports that CsA could potentiate various cytotoxic 
drugs in tumor cells (132, 163), Slater et al first studied its effect in MDR cells (217). It 
was found that CsA caused a 3- to 4-fold potentiation of daunomycin toxicity in Erhlich 
ascites cells with a very low level of primary resistance (2-fold) to daunomycin. It is 
difficult to know whether CsA was antagonizing the MDR process per se, or simply 
potentiating anthracycline activity in general, since a 2-fold potentiation of daunomycin 
cytotoxicity was also noted in sensitive Erlich ascites cells (217). Since then, several 
groups have found CsA to reverse resistance and cross-resistance in MDR, but not sensitive 
cells (Table 1-5) (89, 232, 234), while others have shown cytotoxic drug potentiation in 
both sensitive and resistant cells. For example, CsA caused a 10-fold enhancement of 
doxorubicin toxicity in sensitive Chinese hamster ovary Aux B1 cells, and a 90-fold 
enhancement in MDR, colchicine selected CHR-5 cells (34). 
Also unclear is CsA's effect on drug accumulation in MDR cells. Slater et al claimed 
that CsA reversed resistance but had no effect on drug accumulation in a human T cell ALL 
cell line selected for vincristine resistance, with low level cross-resistance to daunomycin 
(216). However, daunomycin accumulation rather than vincristine accumulation was 
measured in this experiment, and since these cells do not display an accumulation defect to 
daunomycin, it is probable that they were not of the MDR phenotype. Hait et al found that 
while treatment with CsA enhanced the sensitivity to doxorubicin in MDR P388/DOX cells, 
but not in sensitive P388 cells, it was associated with 40% increased doxorubicin 
accumulation in both lines (89). Chambers and coworkers reported a similar degree of 
increased doxorubicin accumulation (50%), along with enhanced doxorubicin cytotoxicity, 
in both sensitive Chinese hamster ovary cells and MDR CHR-5 cells (34). Thus, it appears 
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that if, in fact, CsA specifically antagonizes MDR, it is not solely due to modification of 
drug transport. Interestingly, it has recently been reported that CsA itself is accumulated 
less in the P-gp overexpressing CHR-5 cells than the parent Aux B1 line, and that this 
difference could be reversed with the chemosensitizer verapamil (78). This suggests that 
CsA may competitively modify MDR in a manner similar to the non-toxic anthracycline 
analogs, perhaps in addition to other drug potentiating effects. 
More carefully designed experiments probing the effects of CsA on both primary and 
cross-resistance to a wide range of drugs in both sensitive and well-defined MDR cells lines 
are clearly necessary' to determine if the chemosensitizing effects of CsA are unique to the 
cells of the MDR phenotype, or rather if CsA synergistically enhances the effect of certain 
drugs in all tumor cell lines. More specifically, it needs to be determined whether CsA is 
effecting P-gp, cytotoxic drug targets, or both. 
The activity of several non-immunosuppressive cyclosporine analogs on MDR is of 
great interest with regard to their mechanism of action as well as clinical potential. 
Twentyman first described the anti-MDR activity of three analogs, cyclosporin C, G and H 
as correlating with their immunosuppressive effects in a human small cell lung cancer line 
(234). However, this group later found that the non-immunosuppressive cyclosporines 
W8-032 and 133-243 were actually more effective as chemosensitizers than identical 
concentrations of CsA (Table 1-5) (232). Similarly, the non-immunosuppressive 11- 
MeLeu analog has been shown to be less potent, but equally effective as CsA in sensitizing 
P388/DOX cells to doxorubicin (89). These results suggest that cyclophilin binding is not 
essential to the cyclosporines' chemosensitizing effects, and that clinical reversal of drug 
resistance may be possible using analogs which lack the untoward immunosuppressive and 
nephrotoxic effects of CsA. 
In summary-, while the cyclosporines clearly modulate drug resistance in MDR cells, it 
is uncertain whether the mechanism is through reversal of MDR, potentiation of 
chemotherapeutic drug toxicity, or both. Indeed, CsA has been show-n to potentiate a 
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number of drugs in vitro and in vivo both in tumor cells and normal tissues (233). If 
cyclosporine does have additional, specific chemosensitizing activity against MDR cells, it is 
likely that it is mediated through different mechanisms than most other chemosensitizers, 
since it does not consistently alter drug accumulation. This leads to the intriguing possibility 
that CsA, in combination with another chemosensitizing agent, such as verapamil or 
trifluoperazine, may act synergistically to antagonize MDR. 
3. In Vivo Effects of Chemosensitizers 
The goals in studying the in vitro effects of chemosensitizers on MDR are twofold: to 
further elucidate the mechanism(s) involved in MDR through its antagonism, and to identify 
and characterize compounds vshich may act as effective, non-toxic modulators of intrinsic or 
acquired chemotherapeutic drug resistance in clinical tumors. A number of agents identified 
as having anti-MDR activity in vitro have been tested in mouse tumor models with varying 
success, and intense interest surrounds the results from current and proposed clinical trials 
of these agents in humans. 
The potential utility of any chemosensitizing agent in vivo depends both on its ability 
to potentiate the cytotoxicity of anti-cancer drugs at clinically achievable concentrations, and 
its associated toxicity and unwanted side effects. In addition, to obtain the desired 
therapeutic gain by treatment with chemosensitizers, it is crucial that the enhanced toxicity 
against cancer cells is not accompanied by a similar enhancement of drug toxicity to host 
tissue cells. Since an ideal chemosensitizer which specifically and selectively modifies tumor 
cell sensitivity to cytotoxic drugs without intrinsic toxicity or other physiologic effects has 
not been identified, it is necessary to carefully test the effect of the potential 
chemosensitizers in appropriate animal models before human trials begin. 
3a. Effects of Chemosensitizers in Murine Tumor Models 
The role of murine tumor models in identifying efficacious anti-cancer drugs and 
regimens is well documented (145). The standard in vivo model for the study of 
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pharmacologic reversal of MDR has been measurement of the effect on life span of 
combinations of cytotoxic and chemosensitizing drugs, injected i.p. daily for 10 days into 
mice inoculated i.p. with 1x10^ to 1 x 10^ sensitive or MDR ascites tumor cells (214). A 
number of the chemosensitizing agents discussed in the preceding sections have been shown 
to cause an increase in the mean or median life span (ILS) in this model (Table 1-6). For 
instance, daily i.p. administration of verapamil at doses of 50 to 100 mgAg caused 
approximately 30 to 50% ILS in P388/VCR-bearing mice treated with vincristine or 
vinblastine (227, 228, 242), 25 to 40% ILS in P388/ADR-bearing mice treated with 
doxorubicin (175, 227), and 120% ILS in daunorubicin resistant Ehrlich ascites-bearing 
mice treated with daunorubicin (215). Doses of verapamil greater than 125 mg/kg proved 
toxic when given to mice, particularly in combination with doxorubicin or vincristine (228). 
Other calcium channel blockers have shown similar activity in vivo (Table 1-6). 
Accordingly, daily treatment with 125 mg/kg diltiazem, 75 mg/kg nicardipine, or 75 mg/kg 
niludipine in combination with doxorubicin or vincristine caused 30 to 50% ILS in 
P388/DOX and P388/VCR-bearing mice (224, 227). 
Two of the structural analogs of verapamil which possessed chemosensitizing activity 
in vitro have also been tested in vivo. The synthetic isoprenoid SDB-ethylenediamine 
caused up to a 48% ILS in P388/VCR-bearing mice in combination with vincristine (242). 
However, 15 to 60 mg/kg of the tiapamil analog DMDP was not effective in potentiating 
doxorubicin activity in P388/ADR-tumor bearing mice (175). In fact, DMDP caused a 
decrease in the mean survival time, presumable due to enhanced toxicity when in 
combination with doxorubicin, since measurement of intracellular drug levels in ascites 
tumor cells revealed adequate anti-MDR concentrations of the chemosensitizer. 
The chemosensitizers quinidine and quinacrine also possess noteworthy activity in 
vivo (109, 226), with the latter causing a 85% ILS in the P388/VCR model. The 
anthracycline analog, A-acetyl-daunorubicin, which possessed no demonstrable toxicity 
when given in a ratio of 20:1 with daunorubicin, caused a 53% ILS in mice bearing Erhlich 
ascites tumors resistant to daunorubicin (213). 
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There has only been one report of the activity' of CaM antagonists in reversing MDR in 
mouse tumor models. Tsuruo et al (227) found that the relatively low dose of 20 to 30 
mg/kg clomipramine, in combination with vincristine or doxorubicin, caused a 31 to 33% 
increase in mean survival time of mice bearing P388/VCR or P388/ADM tumors. There 
have been no published results of the effect of PTZ CaM antagonists on MDR tumors in 
mice, in contrast to the extensive w'ork done in vitro with these compounds, suggesting that 
this class of chemosensiuzers has proven too toxic to be used effectively in animal studies. 
By far the most successful in vivo murine trial of a chemosensitizer, to date, has been 
with cyclosporin A. Slater et al found that up to 80 mg/kg of CsA could be given to mice 
without toxicity, and that in combination with 0.3 mg/kg daunomycin daily for 5 days, 
caused an ILS of more than 200% in daunorubicin resistant Erhlich ascites tumor bearing 
mice, with 10 out of 10 mice treated surviving for greater than 60 days and apparently cured 
(217). 80 mg/kg CsA or 0.3 mg/kg daunomycin, when used alone, caused only a 26% ELS 
and 11% ILS, respectively, in the MDR murine model, while daunorubicin alone also cured 
mice bearing sensitive Ehrlich ascites cells. Interestingly, when the dose of CsA was 
sequentially reduced, as little as 5 mg/kg CsA together with daunomycin still produced an 
impressive 169% ILS in the MDR tumor bearing mice. 
While these in vivo results provide an important corollary to the in vitro study of 
chemosensitizers, the relative simplicity of the experimental design employed ignores many 
critical factors which contribute to clinical effectiveness. For example, since many 
chemosensitizers are metabolized by the liver, i.p. injection of these drugs leads to extensive 
first-pass metabolism. Also, the pharmacokinetics of chemosensitizers has been poorly 
studied. Measurements of the intracellular drug concentrations achieved in tumors, in 
addition to steady state plasma concentrations, are important for optimizing treatment 
regimens, since most lipophilic chemosensitizers are rapidly sequestered within tissue and 
plasma cells. The pharmacokinetics and anti-MDR activity of chemosensitizer metabolites 
also deserve attention, since they may or may not possess significant activity themselves. 
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The use of human tumor xenografts in nude mice has proven to be a valuable model for 
the study of chemotherapeutic drugs in human disease (77). This system may also prove 
advantageous for study of the effects of chemosensitizers in vivo, through use of either 
previously selected, well-characterized MDR human tumors, or sensitive human tumors 
which have been previously studied and propagated in mouse models, into which a cloned 
human mdr\ cDNA is transfected. The advantage of the latter is that drug sensitivity and 
optimal treatment of the parent line would already be known, and drug resistance in the 
MDR line w-ould be entirely due to expression of the human mdr 1 gene. Inoculation of 
tumors in extraperitoneal, subcutaneous sites also enables a more careful measurement of 
tumor response to anti-MDR treatment, and investigation of intracellular drug accumulation. 
In summary, experiments performed using simple mouse tumor models have thus far 
suggested that the clinical reversal of drug resistance may be feasible. However, it is critical 
to the eventual development of successful chemosensitizer protocols in humans that more 
carefully designed, sophisticated trials of these agents be done in mice, analyzing all the 
available data to optimize the treatment regimens and better screen for activity. 
3b. Effect of Chemosensitizers in Human Trials 
The clinical experience with chemosensitizers for the modification of acquired or 
intrinsic drug resistance in human tumors is as yet extremely limited. The few trials 
reported to date have been problematic due to the significant toxicity of chemosensitizer 
treatment together with the lack of adequate diagnostic analyses verifying tumor resistance 
mechanisms. For example, attempts to combine verapamil with single agent chemotherapy 
have so far failed, due to the intolerable cardiac effects sustained at levels of verapamil 
nearing the in vitro anti-MDR range (3 to 6 jlM). In a phase I study of escalating doses of 
verapamil plus 1.5 mg/m2 vinblastine for 5 days in 17 patients w'ith advanced malignancies 
unresponsive to unspecified chemotherapy, no objective tumor responses w'ere noted, and 
the majority of patients developed significant ECG changes, including first-degree heart 
block and junctional rhythms (21). Peak plasma verapamil concentrations achieved during 
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the constant i.v. infusion (0.12 mg/kg/hr) were 0.45 |iM, well below the concentrations 
necessary to produce anti-MDR effects in vitro (Table 1-1). Similarly, a pilot study of oral 
verapamil and Adriamycin (50 mg/m* even' 3 weeks) in 13 patients with chemotherapy 
resistant tumors (8 to Adriamycin) was limited by verapamil induced nausea, hypotension, 
and cardiac arrhythmias (173). While one partial response and tw'o minor responses were 
noted in patients who had received prior Adriamycin, plasma or tissue levels of Adriamycin 
or verapamil were not measured. However, it is unlikely that oral verapamil administration 
resulted in the necessary' anti-MDR levels, based on other reports of the pharmacokinetics of 
verapamil (68). In neither of these studies did verapamil appear to potentiate the cardiac 
toxicity or myelosuppression of chemotherapeutic drug treatment. 
Finally, a trial of escalating dose i.v. verapamil plus Adriamycin (50 mg/m2) in 8 
patients with refractory' ovarian cancer again produced unacceptable toxicity, manifested by 
severe hypotension, heart block and congestive heart failure, without objective response to 
therapy (165). How-ever, since none of the patients had received previous Adriamycin or 
other natural product drugs, but rather combinations of cyclophosphamide and cisplatin, 
there wras no clear reason to believe that their tumor resistance involved the MDR 
mechanism. The intensive verapamil infusion (9 |ig/kg/min) led to median and peak plasma 
verapamil levels of 2 and 5 |iM, respectively. Though these concentrations are within the 
range of experimentally relevant anti-MDR concentrations, verapamil is clearly too toxic in 
humans to be used in this manner and at these doses. 
In a recently reported trial of the CaM antagonist, trifluoperazine, plus doxorubicin, 36 
patients with either acquired or intrinsic tumor resistance to prior doxorubicin therapy were 
evaluated (149). 60 mg/m2 doxorubicin was given as a constant infusion, with an 
escalating oral dose of trifluoperazine from 20 mg/day to 100 mg/day. Interestingly, of the 
one complete response and 6 partial responses that were seen, all were in patients w'ho had 
acquired, rather than intrinsic, tumor resistance to doxorubicin. Dose-limiting side effects 
of this regimen were the extrapyramidal effects associated with trifluoperazine, such as 
motor restlessness, akathesia, facial dystonia, and resting tremor. Trifluoperazine plasma 
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levels ranged widely, but were all less than 0.3 jiM, and thus at least 10-fold less than those 
found optimal in vitro (Table 1-3). 
The major problem with all of these studies is that the concentrations of 
chemosensitizers at which maximum activity is found in vitro are clinically unachievable 
without severe toxicity and side effects. An additional flaw, however, is that the mechanism 
of tumor resistance in patients has not been determined. With the recent advent of molecular 
diagnostic techniques, measurement of P-gp expression and mdr 1 mRNA levels using 
immunologic and genetic probes will better define the potential for anti-MDR 
chemosensitizer treatment in specific patients. As more specific and potent chemosensitizers 
with less clinical toxicity and side effects enter clinical trials, it wall be critical to carefully 
plan and coordinate therapeutic and diagnostic procedures, by measuring MDR markers 
before and after treatment, and analyzing both tumor and plasma drug pharmacokinetics. 
4. Mechanism of Action of Chemosensitizers in Multidrug Resistance 
The second major goal of studying chemosensitizers is to better understand the 
molecular and biochemical mechanism of MDR through its pharmacologic reversal. Given 
the extremely broad range of compounds which have been shown to effectively alter MDR, 
it is difficult to envision a single common cellular mechanism or target through which these 
actions are mediated. It is possible that a number of interactions with different cellular 
targets may result in a similar effect on cytotoxic drug potentiation and accumulation. 
However, a specific mechanism of action has not been clearly elucidated for a single 
chemosensitizer. The following sections will review' a number of hypothetical mechanisms 
w'hich have been suggested to be relevant to chemosensitizers’ anti-MDR action. 
4a. Effects on Membrane Properties 
Several investigators have made observations regarding differences in plasma 
membrane order or structure in MDR versus sensitive tumor cells. For instance, Ramu et 
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al have noted that P388/ADR cells have altered cellular lipid content and composition, and 
possess a higher degree of plasma membrane lipid structural order than their sensitive 
counterparts (179, 180). Similarly, Seigfreid found that anthracycline resistance in sarcoma 
180 cells correlated with progressive increases in membrane fluidity (210). It has been 
suggested that these membrane differences may contribute to the alterations in drug 
accumulation seen in MDR. Since cationic, amphipathic drugs, like most chemosensitizers, 
are known to interact with polar lipids such as phosphatidylserine (141), it is speculated that 
chemosensitizers may cause perturbations in MDR membrane order or fluidity, resulting in 
further changes in cellular drug accumulation properties. 
As a model of the possible effect of membrane perturbation or destabilization on MDR, 
several investigators have shown that the surface active, nonionic detergent Tw-een 80 
caused alterations in drug accumulation and cytotoxicity quite similar to verapamil, and that 
this effect was seen in MDR, but not in sensitive P388 cells (131, 185). How-ever, using a 
different MDR P388 cell line, Inaba and colleagues could not demonstrate this effect by 
Tw'een 80 (106, 107). 
In further studying the possible membrane related effects of chemosensitizers, Ramu 
found that perhexiline maleate, a compound known to raise phospholipid content in 
fibroblasts (6), also functioned to reverse MDR (177). While this w-as cited as evidence 
favoring a membrane based mechanism of action, perhexiline maleate is also known to 
block calcium channels (62), resulting in vasodilatory activity similar to verapamil and other 
calcium channel blockers known to reverse MDR. 
The "non-specific" membrane effects of PTZ CaM antagonists have also received a 
great deal of attention, both with respect to their anti-MDR activity and their antipsychotic 
and cytotoxic actions (191,204). Indeed, a number of other unrelated chemosensitizers are 
similar to the PTZs in that their high degree of lipophilicity results in a preferential 
partitioning into membrane structures (123). How-ever, this property certainly does not 
preclude their significant interaction w-ith membrane proteins such as P-gp, or other 
intracellular targets, in a specific, if yet undefined, manner. 
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Thus, it is not known at this time how the structural organization of MDR membranes 
or their alteration by chemosensitizers may relate, if at all, to changes in drug accumulation 
properties. It may be that certain chemosensitizers act within the membrane to somehow 
alter the local environment in the vicinity of P-glycoprotein, leading to structural 
modification and inhibition of drug efflux. Alternatively, overexpression of the membrane 
protein P-gp may directly cause the alterations in membrane properties noted in MDR cells, 
and these changes may simply be an epiphenomenon unrelated mechanistically to drug 
accumulation. 
4b. Alteration in Calcium Homeostasis 
The initial discovery that verapamil and other calcium channel blockers could 
antagonize MDR (227, 228, 229) prompted the suggestion that calcium may play a role in 
the development or maintenance of MDR, perhaps through a calcium-dependent efflux 
mechanism, and that chemosensitizers may funcuon by altering calcium fluxes. However, 
mounting evidence indicates that alterations in calcium homeostasis do not effect MDR. For 
example, several investigators have shown that P388 sensitive and MDR cells have similar 
levels of tota.1 intracellular Ca"^ content (128, 153). Furthermore, a number of groups have 
demonstrated conclusively that unlike excitable tissues, neither MDR cells nor their sensitive 
counterparts possess calcium channels, since calcium uptake was not altered by membrane 
voltage potentials or calcium channel blockers in MDR or sensitive cells P388, Chinese 
hamster ovary or glioblastoma cells (29, 102, 128, 181). Similarly, whole-cell and 
single-channel patch-clamp techniques demonstrated that both drug sensitive CCRF-CEM 
and MDR CEM/VLBiqq cells lack voltage-gated calcium channels (135). 
Even more compelling evidence against calcium fluxes effecting MDR was provided by 
two studies which pharmacologically manipulated calcium levels to mimic the effect of 
calcium channel blockers in those excitable tissues which express calcium channels. 
Accordingly, treatment of MDR C6 cells with manganese ion, which produces a reduction 
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in calcium uptake by a non-competitive inhibition of calcium fluxes, or the calcium 
ionophore A23187, which causes increased calcium uptake through artificial channels, had 
no influence on doxorubicin accumulation or cytotoxicity (102). Similar results were found 
by alteration in net intracellular calcium by reduction of extracellular calcium concentrations 
or chelation of calcium ions by EGTA (177). In all of these states of altered calcium 
homeostasis, verapamil maintained its anti-MDR activity without change. Thus, it is 
apparent that alterations in calcium flux do not alter the level of drug resistance in MDR or 
sensitive cells, and that calcium channels are not the target of chemosensitizers in this 
system. 
4c. Inhibition of Calmodulin Mediated Processes 
Similar to the situation for calcium channels blockers, the finding that PTZs and other 
CaM antagonists modulate MDR implicated CaM in the regulation or reversal of MDR. 
However, definitive evidence as to the role of CaM-mediated events in MDR is lacking. It 
is known that CaM is involved in the regulation of a wide variety of critical cellular 
functions (144). Particularly relevant to MDR is CaM's role as an activator of plasma 
membrane Ca -ATPase ion pumps (81, 159), and as a stimulator of protein kinase 
mediated phosphorylation and dephosphorylation (201, 202), all processes which are 
inhibited by CaM antagonists (176, 241). Whether CaM may activate or regulate the 
function of P-gp in MDR is a provocative, but unanswered, question. 
Attempts to compare CaM levels in sensitive versus MDR cells found no gross 
differences levels between P388 and P388/DOX cells (153), nor between CEM and 
CEM/VLBjoo cells (13). Whether the primary structure or function of CaM in MDR cells is 
in any way altered is not known. Several investigators have attempted to correlate the 
potency of CaM antagonists as inhibitors of CaM-mediated processes with their 
chemosensitizing activity in MDR cells, with conflicting results. For example, Ganapathi 
studied three PTZ CaM antagonists, trifluoperazine, prochlorperazine and chlorpromazine, 
and the naphthalene-sulfonamides W12 and W13 in P388/DOX cells, and found that their 
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potency in this system was in general agreement with their relative anti-CaM potency (73). 
Accordingly, trifluoperazine was more potent and more effective at equimolar concentrations 
than prochlorperazine and chlorpromazine, and W13 was more effective than the poor CaM 
inhibitor W12. Unfortunately, a statistical analysis of the degree or significance of 
correlation between anti-CaM and anti-MDR activity was not performed, nor were structural 
analogs or metabolites lacking CaM inhibitor)' properties examined. It is of interest that 
W12 and W13, drugs with similar hydrophobicity and structure (99), displayed relatively 
different effects on MDR (Table 1-3), implying that non-specific hydrophobicity alone is not 
sufficient to alter MDR, as some have suggested for inhibition of CaM (192). However, 
both Tsuruo (229) and Akiyama (5) reported that the chemosensitizing activity of 
trifluoperazine, thioridazine and chlorpromazine in KB-ChR-24 cells, respectively, did not 
correlate with known IC$o’s for the inhibition of CaM by these drugs. Furthermore, 
Akiyama found that the potent CaM antagonists W7 and W5 were equally poor 
chemosensitizers, although W7 was a significantly more potent CaM antagonist (99). 
Clearly, the sample size in each of these studies was far too small to make any definate 
conclusions regarding the role of CaM antagonism in the modulation of MDR. In addition, 
the well known "non-specific" nature of PTZs and other CaM antagonists make attempts to 
analyze their effects on whole cells extremely difficult for any system. Nevertheless, a more 
rigorous and systematic study of the pharmacologic relationship between CaM antagonists 
and reversal of MDR is certainly warranted. While a positive correlation would not directly 
implicate CaM's role in MDR, it may suggests that anti-CaM activity is a useful marker for 
chemosensitizer activity, possibly leading to the identification of novel modifiers of MDR. 
4d. Inhibition of Protein Kinase C 
A great deal of provocative evidence has been reported implicating a possible regulator)' 
role for the phospholipid/Ca^-dependent protein kinase (PKC) in MDR, suggesting that 
interaction of chemosensitizers with PKC may be important. For example, a number of 
chemosensitizers, such as the PTZs and verapamil, are also known to inhibit the activity of 
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PKC in isolated systems (150, 200). Several groups have found increased levels of PKC in 
the MDR human breast cancer line, MCF-7/DOX (59, 166), and preliminary evidence 
suggests that the pattern of expression of PKC isoforms may be altered in MDR cells (1,8). 
Treatment of a variety of cell lines with activators of PKC, such as the phorbol ester 12-0- 
tetradecanoylphorbol-13-acetate (TPA), results in transient increases in cellular drug 
resistance as well as changes in drug accumulation. Specifically, treatment of sensitive 
human KB cells with TPA caused a transient, 2-fold protection against the cytotoxicity of 
VP-16, vincristine and mitoxantrone, which could be circumvented by co-administration of 
verapamil (58). Similarly, phorbol ester increased the resistance of both sensitive MCF-7 
and MDR MCF-7/DOX cells to doxorubicin and vincristine (59), and increased the 
resistance of P388, though not P388/DOX, cells to daunomycin (127). Furthermore, the 
relatively specific PKC inhibitor, l-(5-isoquinolinylsulfonyl)-2-methylpiperazine (FI-7), 
inhibited the phorbol ester induced decrease in P388 cell vincristine uptake (105). 
Since the activation of PKC by phorbol ester in MDR and other cell types results in the 
phosphorylation of several proteins possibly associated with MDR (7, 59), it is intriguing to 
speculate on the possible modulation of P-gp function by PKC. Indeed, it has been 
reported that phorbol ester causes an increase in P-gp phosphorylation (90). Paradoxically, 
verapamil and trifluoperazine also have been reported to cause a hyperphosphorylation of P- 
gp, though apparently at different residues (32). Whether the effect of chemosensitizers on 
P-gp phosphorylation states is mediated by PKC is presently not known. 
Thus, it appears that within the calcium messenger system, PKC is a target for many 
chemosensitizers, and may mediate the regulation or modulation of MDR. However, a great 
deal of work is necessary to better define the doubtlessly complex regulatory mechanisms 




4e. Interaction with P-glycoprotein 
Ln the preceding sections, several theories have been discussed regarding the possible 
modulation of MDR by the known interactions of certain chemosensitizers with aspects of 
the calcium mediated second messenger system. It is also quite possible that 
chemosensitizers act by directly blocking or altering the function of P-gp, and in fact, 
several lines of evidence suggest that this may be the case for certain anti-MDR agents. 
First, with the recent discover}’ of P-gp and its putative role as a membrane drug efflux 
pump (38), it is important to recall the earlier studies demonstrating the chemosensitizing 
effect of non-toxic anthracycline and Vinca alkaloid analogs (110, 213) (discussed in 
Section A.2e). The apparent competitive inhibition of drug efflux in MDR cells displayed 
by these compounds suggests that one or more specific drug binding sites may exist in P- 
gp, and that agents which bind to these sites with similar or greater affinity inhibit P-gp 
mediated cytotoxic drug efflux and result in increased cellular cytotoxic effect 
More recent evidence that cytotoxic drugs and some MDR antagonists bind to P-gp 
came from experiments with preparations of P-gp enriched MDR membrane vesicles. 
Cornwell et al first noted that [3HJ-vinblastine bound with an affinity constant of 1.5 |iM in 
a specific, saturable, temperature-dependent manner to membrane vesicles from MDR KB- 
C4 cells, but did not bind to sensitive KB-3-1 or revertant KB-R1 cell membranes (43). 
This binding was strongly inhibited by excess unlabeled vinblastine, vincristine, and 
verapamil, less so by daunomycin, and poorly inhibited by colchicine (43). Safa and others 
used photoactive analogs of vinblastine ([^Hj-NABV and 125I-NASV) w'hich irreversibly 
bind to MDR cell membrane fractions (45), to identify vinblastine acceptor proteins (198). A 
150 - 180 kDa photoaffinity labelled membrane protein was found specifically in MDR cell 
lines and was immunoprecipitated with a polyclonal antibody known to cross-react with P- 
gp from other cells. In addition, verapamil inhibited 125I-NASV photoaffinity labelling of a 
170 kDa KB-V1 cell membrane protein which was immunoprecipitated with a monoclonal 
antibody to P-gp (44). Further studies of the competitive binding of chemosensitizers to P- 
gp found that (i) KB-VI MDR vesicles bound 15- to 20-fold more verapamil and diltiazem 
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than sensitive KB-3-1 vesicles, in a specific and saturable manner (44), (ii) the 
chemosensitizers verapamil, nicardapine, quinidine, and to a lesser extent trifluoperazine, 
inhibited [^HJ-vincristine binding to K562/ADM membrane vesicles (154), and (iii) INI¬ 
NAS V photoaffinity labeling of KB-V1 and CEM/VLB u<_ P-gp was effectively inhibited by 
10 to 12.5 |iM concentrations of reserpine, cepharanthine, quinidine, and the isoprenoid 
SDB-ethylenediamine, but poorly inhibited by up to 100 pM concentrations of the PTZ 
chemosensitizers trifluoperazine, thioridazine and chlorpromazine (2, 16). These results 
strongly suggest that certain chemosensitizers, such as the calcium channel blockers and 
structurally related isoprenoids, compete with the Vinca alkaloids for a common P-gp 
binding site. Additional experiments with photoactive, radiolabelled verapamil analogs, 
such as [-H]-azidopine and 125I-NASAV, further implicate a common acceptor for these 
drugs, since nifedipine, nicardapine, verapamil and vinblastine effectively inhibit their 
irreversible binding to P-gp, but trifluoperazine, chlorpromazine, doxorubicin and 
colchicine do not (196, 197, 199, 243). 
In addition, MDR cell membrane vesicles have been shown to inwardly transport [3H]- 
vinblastine in an A TP-dependent fashion (101). Using this simplified model of MDR, 
investigators have shown that vinblastine transport is inhibited by competitive and non¬ 
competitive inhibition of ATP, as well as by vinblastine, vincristine, verapamil, quinadine, 
and less potently by daunomycin and colchicine. 
A fourth, independent line of evidence that chemosensitizers may interact w’ith P-gp 
came from the recent purification and partial characterization of P-gp by Hamada and Tsuruo 
(92, 93). Enzymatically active P-gp w'as purified from human K562/ADM cells by 
immunoaffinity chromatography, and found to possess ATPase activity (93). Interestingly, 
while vincristine and doxorubicin did not affect the ATPase activity of immobilized P-gp, 
the chemosensitizers trifluoperazine and verapamil caused increased activity (92). Since 
PTZs are known to inhibit the activity of other ATPases (167, 176), it is possible that 
trifluoperazine interferes with a P-gp mediated drug efflux mechanism in a similar manner, 
although it is paradoxical as to why an increase is seen in ATPase activity. It is anticipated 
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that further studies of the ATPase function of P-gp will focus on its possible role as a target 
for chemosensitizers. 
Thus, it appears that there are at least several sites on P-gp through which 
chemosensitizers may interfere with the MDR process. Since a number of chemotherapeutic 
drugs encompassed by the MDR phenotype, such as doxorubicin, daunomycin and 
colchicine, do not appear to competitively bind to the calcium channel blocker/vinblastine 
acceptor on P-gp, it is possible that there may be other independent drug binding sites 
within the same molecule that lead to active efflux, or that a family of drug binding proteins 
may exist, which display different affinities for various classes of compounds. 
Chemosensitizers such as the PTZs may specifically bind to these additional sites and 
antagonize MDR, although this cannot explain why such agents most often similarly affect 
Vinca alkaloid, anthracycline and colchicine drug accumulation and resistance. 
Alternatively, PTZs and other chemosensitizers may inhibit P-gp activity by interacting with 
physically separate sites on P-gp, such as the ATPase or phosphorylation domains, or act 
by altering the local membrane environment leading to structural or functional changes in P- 
gP- 
4f. Inhibition of Lysosomal Function 
The demonstration by Akiyama and coworkers that verapamil affected the function of 
lysosomes by inhibiting their degradation of cellular proteins (3, 4), led to the discovery that 
certain other lysosomotropic agents, such as propranolol (226) and chloroquine (208, 245), 
could also partially reverse MDR. These findings, together with the fact that cytotoxic 
concentrations of vinblastine or doxorubicin caused an increased number of lysosomal-like 
vacuoles in cells (245), suggested an alternative hypothesis for the cellular mechanism of 
MDR, proposed by both Beck (14) and Sehested el al (205). This theory can be 
summarized as follows: lysosomes or other intracellular acidic compartments in MDR cells 
protonate and entrap weakly basic drugs such as doxorubicin or vinblastine, which are then 
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extruded from the cells by vesicular fusion with the plasma membrane. In this scheme, P- 
gp serves not as a drug efflux pump, but rather to alter or direct membrane turnover or 
vesicular trafficking (14). Since verapamil and chloroquine appear to disrupt lysosomal 
functions, they may therefore interrupt the ability of vesicles to transport drug out of cells, 
resulting in increased drug reaching its cytotoxic target. In support of this, the 
microfilament-disrupting agent, cytochalasin B, also inhibited drug efflux and enhanced 
cytotoxicity, though in sensitive as well as MDR cells (130, 225). Recently, however, 
Beck's group reported that a number of additional lysosomotropic amines, such as 
methylamin, suramin, trypan blue, and epinephrine, did not potentiate the cytotoxicity of 
vincristine in MDR CEM/VLBiqo cells (246), from which it was concluded that the ability 
to impair lysosomal function was not sufficient to alter MDR. It may be that lysosomes 
function as an alternative, unrelated but reversible mechanism for drug detoxification in both 
sensitive and MDR cells, although this remains to be determined. 
5. Future Directions 
The preceding sections demonstrate that while a tremendous amount of data exists 
regarding the effects of a host of chemosensitizers on the cellular pharmacology of MDR cell 
lines, very' little is yet known about their mechanism of action. Since such a wide variety of 
agents possessing remarkably varied cellular effects reverse MDR, it is clearly necessary to 
carefully study the anti-MDR activity of drugs within a single pharmacologic class, 
attempting to define their possible cellular targets and the structural features which enhance 
their interaction with this target. Indeed, if specific structural features determine anti-MDR 
activity, rather than non-specific properties, it is likely that their mechanism of action is 
mediated by classical receptor-ligand interactions, implying that the rational design of 
structurally optimal agents may result in increased specificity and potency. 
To this end, systematic and statistically significant structure-activity relationships of the 




(i) Define the specific structural features, if any, necessary for the 
pharmacological reversal of MDR, and possibly identify an optimal 
'pharmacophore' for this activity' or target 
(ii) Identify the relevant target(s) for the chemosensitizing effects of a 
particular class of drugs and characterize the drug-target interactions 
(iii) Identify more specific, potent and less clinically toxic drugs with which 
to possibly antagonize MDR in a clinical setting 
(iv) Better define and elucidate the molecular mechanism of MDR itself 
(v) Identify the natural substrate for P-gp and define its biological role. 
The present study addresses the first three of these points. Specifically, systematic 
structure-activity relationships for the chemosensitizing effects of a series of closely related 
PTZ CaM antagonists and structurally related compounds were performed, and the role of 
non-specific hydrophobic effects versus specific interactions w’ith CaM assessed. Based on 
the structural determinants found necessary' for PTZ anti-MDR activity, a novel class of 
chemosensitizing agents w-as identified and their effect on MDR in vitro and in vivo was 
extensively characterized. In addition, initial steps were taken toward characterizing their 




Summary of Studies Using Verapamil to Reverse Multidrug Resistance 





6.6 P3 8 8/VCR VCR (31) 122 Tsuruo, 1981 
VLB (7) 7 
2.2 VCR (31) 34 
VLB (7) 7 
3.3 P388ArCR VCR (20) 26 Tsuruo, 1982 
6.6 84 
10 P388/VCR VCR (20) 40 Tsuruo, 1985 
VLB (12) 7 
3.3 P388/ADM DOX (43) 12 Tsuruo, 1982 
6.6 13 
10 P388/ADR DOX (27) 9 Tsuruo, 1985 
DAU (19) 9 
30 P388/ADR DOX (40) 28 Ramu, 1984 
10 P388/ADR DOX (51) 11 Klohs, 1986 
DAU (38) 9 
10 P388/DOX DOX (37) 8 Kramer, 1988 
6 P388/ADR DOX (100) 11 Radel, 1988 
40 EA/DAU DAU (5) 4 Slater, 1982 
6.6 K562A'CR VCR (17) 61 Tsuruo, 1982 
DOX (3) 4 
6 C6/DOX DOX (20) 10 Huet, 1988] 
1 CHO/B30 DAU (100) 8 Cano-Gauci, 1987 
10 8226/DOX40 DOX (50) 40 Bellamy, 1988 
6 MES-SA/Dx5 DOX (100) 7 Harker, 1986 
DAU (100) 14 
MITO (60) 8 
ActD (1200) 9 
VLB (100) 1 











10 CE M/VLB j oo VLB (420) 22 Zamora, 1988 
10 CE M/VLB VLB (930) 21 Beck, 1988 
10 MCF-7/DOX DOX (100) 10 Fine, 1988 
VCR (100) 10 
20 MCF-7/DOX DOX (100) 7 Kramer, 1988 
20 KB-ChR 8-5-11 -24 CH (220) 63 Fojo, 1985 
DOX (21) 23 
VLB (23) 38 
VCR (73) 183 
2 2780^ DOX (100) 4 Schuurhuis, 1987 
1 2780^0 DOX (170) 6 Rogan, 1984 
1 1847^ DOX (5) 6 
22 DC-3F/AD DOX (100) 20 Delaporte, 1988 
ActD (4200) 85 
6.6 NCI-H69/LX4 DOX (85) 19 Twentyman, 1986 
VCR (750) 72 
MOR/DOX DOX (12) 5 
COR-L23/DOX DOX (12) 4 
10 HCT-8 DOX (NE) 4 Klohs, 1988 
Colon 26 DOX (NE) 4 
LoVo DOX (NE) 3 
Abbreviations: ActD, actinomycin D; CH, colchicine; DOX, ADR, ADM, doxorubicin; DAU, 




Summary of Studies Using Verapamil Analogs and Other Calcium Channel 
Blockers to Reverse Multidrug Resistance 





Tiapamil 500 P388/ADR DOX (100) 15 Kessel, 1985 
DMDP 20 P388/ADR DOX (100) 15 Kessel, 1985 
3 P388/DOX DOX (100) 19 Radel, 1988 
Tiapamil Analog 1 P388/ADR DOX (100) 15 Kessel, 1985 
(Ro-2933) 
SDB-ethylene- 34 Jig/ml KB-ChR-24 DOX (28) 35 Nakagawa, 1986 
diamine VCR (89) 55 
1 OOfig/ml P388/ADM DOX (37) 3 Yamaguchi, 1986 
DAU (19) 2 
VCR (17) 3 
ActD(10) 4 
P388/VCR VCR (8) 33 
DOX (10) 10 
Diltiazem 20 P3 8 8/ADR DOX (51) 3 Klohs, 1986 
35 K562/VCR VCR (21) 9 Tsuruo, 1983a 
P3 8 8/VCR VCR (20) 29 Tsuruo, 1985 
VLB (12) 7 
P38 8/ADR DOX (27) 9 
DAU (19) 5 
100 P388/VCR VCR (15) 29 Tsuruo, 1983b 
P388/ADM DOX (49) 16 
Nifedipine 3 P388/ADR DOX (50) 1 Ramu, 1984c 
100 P3 8 8/VCR VCR (15) 12 Tsuruo, 1983b 
P388/ADM DOX (49) 4 
Niludapine 10 K562/VCR VCR (21) 48 Tsuruo, 1983a 
P3 8 8/VCR VCR (15) 26 Tsuruo, 1983b 
P3 8 8/VCR VCR (20) 25 Tsuruo, 1985 
VLB (12) 7 
P388/ADM DOX (49) 10 Tsuruo, 1983b 
P388/ADM DOX (27) 10 Tsuruo, 1985 











Nimodipine 35 K562/VCR VCR (21) 54 Tsuruo, 1983a 
P3 8 8/VCR VCR (15) 26 Tsuruo, 1983b 
P388/ADM DOX (49) 15 
Nicardapine 3 K562/VCR VCR (21) 25 Tsuruo, 1983a 
P388/VCR VCR (15) 33 Tsuruo, 1983b 
P388/ADM DOX (49) 4 
P388/ADR DOX (50) 4 Ramu, 1984c 
10 K562/VCR VCR (21) 52 Tsuruo, 1983a 
P388/VCR VCR (15) 70 Tsuruo, 1983b 
P3 8 8/VCR VCR (20) 70 Tsuruo, 1985 
VLB (12) 7 
P388/ADM DOX (49) 27 Tsuruo, 1983b 
P38 8/ADR DOX (27) 27 Tsuruo, 1985 
DAU (19) 9 
Caroverine 6.6 P388/VCR VCR (20) 19 Tsuruo, 1982 
P388/ADM DOX (40) 8 
K562/VCR VCR (17) 11 Tsuruo, 1983a 
Prenylamine 6.6 P388/VCR VCR (20) 22 Tsuruo, 1982 
P388/ADM DOX (40) 11 
K562/VCR VCR (17) 40 Tsuruo, 1983a 
Bepridil 4 CHR C5 DOX (195) 74 Schuurhuis, 1987 
2780^ DOX (140) 10 Schuurhuis, 1987 
Abbreviations: ActD, actinomycin D; CH, colchicine; DOX, ADR, ADM, doxorubicin; DAU, 




Summary of Studies Using Calmodulin Antagonists to 
Reverse Multidrug Resistance 





Trifluoperazine 3.3 P3 8 8/VCR VCR (20) 10 Tsuruo, 1982 
P38 8/ADM DOX (43) 5 
2 P388/ADR DOX (51) 2 Klohs, 1986 
4 P388/DOX DOX (100) 5 Ganapathi, 1983b 
4 P388/DOX DOX (100) 10 Ganapathi, 1984a 
5 P388/DOX DOX (100) 10 Ganapathi, 1984a 
DAU (100) 15 
2 P388/DOX VLB (20) 5 Ganapathi, 1986 
VCR (100) 7 
3.3 P388/ADM DOX (27) 5 Tsuruo, 1983 
P3 8 8/VCR VCR (26) 10 
K562/VCR VCR (17) 25 
6.6 K562/VCR VCR (17) 25 Tsuruo, 1983a 
5 KB-ChR-24 CH (115) 58 Akiyama, 1986 
DOX (50) 19 
DAU (36) 15 
VLB (40) 40 
VCR (68) 12 
5 LI 210/0.025 DOX (5) 3 Ganapathi, 1988 
LI 210/0.05 DOX (10) 4 
L1210/0.1 DOX (20) 7 
L1210/0.25 DOX (40) 8 
Thioridazine 1 P388/ADR DOX (50) 3 Ramu, 1984c 
4 KB-ChR-24 CH (115) 14 Akiyama, 1986 
DOX (50) 30 
DAU (36) 28 
VLB (40) 44 











Chlorpromazine 4 P388/DOX DOX (100) 3 Ganapathi, 1984b 
10 CEM/VLB jqq VLB (420) 11 Zamora, 1988 
5 KB-ChR-24 CH (115) 4 Akiyama, 1986 
DOX (50) 9 
DAU (36) 7 
VLB (40) 4 
VCR (68) 2 
Prochlorperazine 4 P388/DOX DOX (100) 5 Ganapathi, 1984b 
Clomipramine 10 P3 8 8/VCR VCR (20) 22 Tsuruo, 1982 
P388/ADM DOX (43) 4 
6.6 K562/VCR VCR (17) 14 Tsuruo, 1983a 
6.6 P3 8 8/VCR VCR (26) 12 Tsuruo, 1983 
P388/ADM DOX (27) 4 
K562/VCR VCR (17) 14 
W12 20 P388/DOX DOX (100) 1 Ganapathi, 1984b 
W13 20 P388/DOX DOX (100) 2 Ganapathi, 1984b 
Abbreviations: CH, colchicine; DOX, ADR, ADM, doxorubicin; DAU, daunomycin; VCR, 




Summary of Studies Using Anthracvcline and Vinca Alkaloid Analogs, 
Lysosomotropic Agents, and Other Drugs to Reverse Multidrug Resistance 





ID-8279 2 P3 8 8/VCR VCR (50) 50 Inaba, 1984 
DAU (10) 5 
Vindoline 10 (ig/ml P388/VCR VCR (50) 50 Inaba, 1986 
VLB (20) 50 
DOX (10) 10 
DAU (10) 10 
P388/DOX DOX (200) 100 
DAU (200) 100 
50 CE M/VLB joo VLB (420) >42 Zamora, 1988 
10 CEM/VLB1K VLB (930) 13 Beck, 1988 
Chloroquine 10 P388/ADR DOX (50) 2 Ramu, 1984c 
2 (ig/ml KB-ChR-24 DOX (38) 4 Shiraishi, 1986 
DAU (18) 3 
VCR (139) 3 
VLB (24) 2 
ActD (24) 4 
50 CEM/VLB100 VLB (157) 13 Zamora, 1986 
VCR (600) 10 
DOX (112) 3 
DAU (124) 4 
50 CE M/VLB jog VLB (420) 10 Zamora, 1988 
50 CEM/VLB ii^ VLB (930) 10 Beck, 1988] 
Quinacrine 0.5 (ig/ml P3 8 8/VCR VCR (15) 15 Inaba, 1988 
P388/ADR DOX (240) 5 
5 CEM/VLB ioo VLB (420) 12 Zamora, 1988 
50 CEM/VLB u<^ VLB (930) 10 Beck, 1988 
Quinidine 10 P3 8 8/VCR VCR (16) 82 Tsuruo, 1984 
K562/VCR VCR (65) 50 
P388/ADM DOX (41) 8 











Perhexiline Maleate 10 P388/ADR DOX (20) 12 Ramu, 1984a 
VLB (25) 14 
10 MCF-7Ad DOX (12) 3 Foster, 1988 
VLB (500) 9 
Tamoxifen 3 P388/ADR DOX (32) 12 Ramu, 1984b 
10 MCF-7Ad DOX (12) 3 Foster, 1988 
VLB (500) 8 
Triparanol 3 P388/ADR DOX (32) 10 Ramu, 1984b 
Reserpine 5 CE M/VLB jqq VLB (420) >42 Zamora, 1988 
5 CEM/VLB ^ VLB (930) 120 Beck, 1988 
Cepharan thine 2 pg/ml KB-ChR-24 DOX (117) 25 Shiraishi, 1987 
DAU (17) 16 
VCR (105) 87 
ActD (43) 39 
Amiodarone 4 DHD/K12/TR DOX (NR) 32 Chauffert, 1986 
Dipyridamole 10 P388/ADR DOX (50) 15 Ramu, 1984c 
Aclacinomycin A 5 pg/ml Friend Leukemia DOX (1000) 2 Tapiero, 1988 
DAU (1000) 3 
Abbreviations: ActD, actinomycin D; Ch, colchicine; DOX, ADR, ADM, doxorubicin; 




Summary of Studies Using Cyclosporines to Reverse Multidrug Resistance 





Cyclosporin A 13.2 EA/DAU DAU (2) 3 Slater, 1986b 
13.2 GM3639/L100 VCR (60) 50 Slater, 1986a 
DAU (5) 4 
10}iM Hepatoma 129 DAU (NR) 2 Meador, 1987 
5 NCI-H69/LX4 DOX (60) 25 Twentyman, 1987 
VCR (1200) 200 
2 NCI-H69/LX4 DOX (100) 9 Twentyman, 1988 
VCR (150) 32 
1 CHR C5 DOX (90) 90 Chambers, 1988 
Aux B1 (S) DOX (1) 10 
1 P388/DOX DOX (100) 8 Hait, 1989 
Cyclosporin C 5 NCI-H69/LX4 DOX (60) 8 Twentyman, 1987 
Cyclosporin G 5 NCI-H69/LX4 DOX (60) 90 Twentyman, 1987 
Cyclosporin H 5 NCI-H69/LX4 DOX (60) 2 Twentyman, 1987 
32W8-032 2 NCI-H69/LX4 DOX (100) 9 Twentyman, 1988 
VCR (150) 167 
B3-243 2 NCI-H69/LX4 DOX (100) 55 Twentyman, 1988 
VCR (150) 50 
11-MeLeu CsA 1 CHR C5 DOX (90) 8 Chambers, 1988 
Aux B1 (S) DOX (1) 10 
11-MeLeu CsA 1 P388/DOX DOX (100) 8 Hait, 1989 
Abbreviations: CH, colchicine; DOX, doxorubicin; DAU, daunomycin; EA, Ehrlich ascites; 




Summary of In Vivo Studies to Reverse Multidrug Resistance 
Chemosensitizer Tumor 
_Dose (mg/kg) 
CS Drug Schedule 
ILS 
(+%) Reference 
Verapamil P388/VCR 0 VCR 0.03 qd x 10 0 Tsuruo, 1981 
0 0.2 0 
50 0.1 34 
50 0.2 29 
100 0.03 29 
100 0.1 45 
Verapamil EA/DR 0 DAU 0.4 qd x 5 8 Slater, 1982 
25 0.4 120 
50 0.4 106 
Verapamil P388/DOX 0 DOX 0 qd x 8 2 Radel, 1988 
0 1.0 7 
75 1.0 25 
Verapamil Sarcoma 180 0 BOU 0.6 qd x 4 0 Chitnis, 1985 
10 0.0 5 
10 0.6 45 
Verapamil P388/VCR 100 VCR 0.1 qd x 10 45 Tsuruo, 1983 
P388/ADM 125 ADM 1.0 37 
SDB-ethylene- P388/VCR 0 VCR 0.03 qd x 8 10 Yamaguchi, 1986 
diamine 0 0.1 22 
40 0.0 12 
40 0.03 48 
40 0.1 44 
DMDP P388/DOX 0 DOX 10 qh x 4 (DMDP) 16 Radel, 1988 
60 0 qd x 1 (DOX) 4 
60 10 -36 
Diltiazem P388/ADM 100 DOX 1.0 qd x 10 27 Tsuruo, 1983b 
125 1.0 40 
Diltiazem P388A/CR 125 VCR 0.1 qd x 10 32 Tsuruo, 1983 
P388/ADM 125 ADM 1.0 40 
Nicardapine P388/ADM 75 DOX 1.0 qd x 10 43 Tsuruo, 1983b 
Nicardapine P3 88/VCR 100 VCR 0.1 qd x 10 51 Tsuruo, 1983 
P38 8/ADM 125 ADM 1.0 43 
Niludapine P388/ADM 75 DOX 1.0 qd x 10 33 Tsuruo, 1983b 
Niludapine P388/VCR 100 VCR 0.1 qd x 10 50 Tsuruo, 1983 








CS Drug Schedule 
ILS 
(+%) Reference 
Clomipramine P388/VCR 100 VCR 0.1 qd x 10 31 Tsuruo, 1983 
P388/ADM 125 ADM 1.0 8 
N-Acetyl- EA/DR 0 DAU 1.5 qd x 4 0 Skovsgaard, 1980 
Daunorubicin 30 0.0 0 
30 1.5 53 
Quinidine P388/VCR 0 VCR 0.0 qd x 10 0 Tsuruo, 1984 
0 0.2 19 
125 0.0 2 
125 0.2 41 
Quinacrine P388/VCR 0 VCR 0.0 qd x 5 0 Inaba, 1988 
0 0.1 30 
40 0.0 29 
40 0.1 85 
Cyclosporine A EA/DR 0 DAU 0.0 qd x 5 0 Slater, 1986b 
0 0.3 11 
80 0.3 >215 
12.5 0.3 183 
5 0.3 169 
Cyclosporine Hep 129 0 DAU 0.0 qd x 2 0 Meador, 1987 
0 0.4 26 
10 0.0 10 
10 0.4 69 
Abbreviations: BOU, bouvadin; ; DOX, ADM, doxorubicin; DAU, daunomycin; EA/DR, 




STRUCTURE ACTIVITY RELATIONSHIPS OF PHENOTHIAZLNES 
AND RELATED DRUGS FOR INHIBITION OF CELL GROWTH AND 
REVERSAL OF MULTIDRUG RESISTANCE 
A. Introduction 
The recent demonstration and elucidation of the phenomenon of MDR has led to the 
search for drugs that could sensitize highly resistant cancer cells to chemotherapeutic agents. 
As reviewed in Chapter I (Section D.2), several PTZs have been shown to be among the 
group of drugs known to modify MDR. As a class of chemosensiuzers, the PTZs present a 
unique opportunity to study the importance of molecular structure on the antagonism of 
MDR, since a large number of PTZs and structurally related compounds have been 
synthesized but have not been studied as MDR chemosensitizers. 
PTZs are also known to inhibit the activity of several cellular enzymes (167, 193, 195) 
and block the function of critical cellular receptors, such as those for dopamine (47). 
Among these cellular targets is calmodulin, a mulufunctional calcium-binding protein (137) 
that has been implicated in the regulation of numerous cellular events, including that of 
normal and abnormal cellular proliferation (86, 182, 238). Consistent with these 
observations was the demonstration that PTZs and other CaM antagonists possess 
antiproliferative and cytotoxic effects (113) in proportion to their anti-CaM activity (84, 87, 
136, 239). Although the mechanism by which PTZs and other drugs modulate MDR is not 
clear, it has been suggested that their pharmacological properties may be mediated by the 
calcium messenger system, since the active compounds are known to inhibit voltage- 
dependent calcium channels (62), CaM (241), and protein kinase C (200). 
To elucidate the structural features required for the activity of PTZs and related 
compounds against cellular proliferation and MDR, the effects of a series of drugs with 
single molecular alterations have been studied for their ability to inhibit cell growth and to 
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sensitize the human MDR breast cancer cell line MCF-7/D0X to doxorubicin. Furthermore, 
to clarify the role of CaM in these processes, the anti-CaM effects of these compounds have 
been compared to their effects on cellular proliferation and MDR. 
B . Materials and Methods 
1. Cell Lines and Culture 
MCF-7 human breast cancer cells, and the multidrug resistant subclone MCF-7/DOX 
(kindly supplied by Dr. Ken Cowan, National Cancer Institute, Bethesda, Maryland), 
selected by stepwise exposure of parental cells to increasing concentrations doxorubicin, 
were maintained in exponential growth in Coming 75 cm- tissue culture flasks in RPMI 
1640 medium supplemented with 5% fetal bovine serum in a humidified atmosphere of 5% 
CO2 and 95% air. MCF-7/DOX cells were approximately 200-fold more resistant to 
doxorubicin than the parental cell line, and maintained a stable MDR phenotype while grown 
in drug-free medium for a period of at least 3 months, after which they were discarded. Cell 
lines were routinely tested and found to be free of contamination by mycoplasma or fungi. 
2. Effect of Drugs on Cellular Proliferation and Multidrug Resistance 
Cells in exponential growth were digested with 0.5% trypsin (Gibco, Grand Island, 
New' York) in 10 mM phosphate-buffered saline (PBS), disaggregated into single cell 
suspensions, counted electronically (Coulter, Hialeah, FL), and dispensed in 100 pi 
volumes into 96-well microtiter plates with a multichannel pipet (Flow Labs, Titertek) at a 
concentration of 0.5 x 104 sensitive, or 1.0 x 104 resistant cells per well. Cells were 
allowed to attach to the plastic and to resume growth for 24 hours prior to the addition of 
100 pi of drug-containing medium. Drugs were dissolved in small amounts of sterile water 
or 1% DMSO (final culture concentration < 0.05% DMSO) before dilution with medium. 
Controls were exposed to vehicle-containing medium. Following a 48 hour incubation at 
37° C, the cellular supernatants of each well were gently aspirated, and cells were fixed and 
stained with 100 pi of 0.5% methylene blue (Sigma) in 50% ethanol (w/v) for 30 minutes at 
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room temperature, as previously described (60). Unbound stain was removed by 
decanting, followed by emersion in three, 1-liter washes of distilled, deionized water. The 
plates w'ere dried for 12 hours and the stained protein w'as solubilized with 200 )il of sodium 
N-lauroyl sarcosine (Fluka, Switzerland) solution (1% v/v in PBS). The optical density of 
each well was determined by absorbance spectrophotometry' at a wavelength of 600 nm with 
a microculture plate reader (Titenek Model MCC/340) interfaced to an Apple He computer. 
Inhibition of cell growth was expressed as a percentage of absorbance of vehicle-treated 
control cultures. 
To determine the optimal conditions for this assay, plates were inoculated in duplicate 
with various initial cell concentrations. One half plate w'as assayed daily for five 
consecutive days by standard trypsin digestion and electronic cell counting, while the other 
half of each plate was stained as described above. Figure 2-1 demonstrates the linear 
correlation betw-een A50Q from stained wells and actual cell number for the MCF-7/DOX cell 
line with final cell concentrations between 0 and 50,000 cells per well. Similar results were 
obtained for the sensitive cell line. Final assay conditions were chosen to ensure that optical 
density measurements fell on the linear portion of this curve. This system has proven 
extremely reproducible, with less than 5% variability between IC50 values from dose- 
response curves from different experiments run on different days. 
The effect of PTZs on cellular proliferation was examined by exposing cells grown in 
the dark to 0 - 100 |iM drug as described above with each condition repeated in 
quadruplicate. IC50 was the concentration of drug that reduced staining (A^oo)10 50% of 
vehicle-treated controls. Final IC50 values represent the average of 3 to 5 separate 
experiments. 
The effect of PTZs on MDR was studied by exposing cells to 0 -100 pM doxorubicin 
in the absence or presence of a concentration of PTZ derivative that alone produced 10% 
inhibition of growth (IC10) as determined by 3 to 5 experiments run in quadruplicate. 
Dose-response curves were corrected for the 10% inhibition of cell growth caused by the 
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PTZs alone. The MDR Ratio was defined as the ratio of the IC50 for doxorubicin alone 
divided by the IC50 for doxorubicin in the presence of modifier. This ratio represents the 
increase in apparent potency of doxorubicin produced by each PTZ derivative. 
MDR Ratio = IC50 Doxorubicin Alone + IC50 Doxorubicin + Chemosensitizer 
3. Drugs 
Doxorubicin was obtained from Sigma Chemical Co. (St. Louis, MO) and was freshly 
prepared in distilled water for each experiment. PTZ derivatives and related drugs were 
generously donated as follows: chlorpromazine hydrochloride, trifluoperazine 
dihydrochloride, chlorpromazine sulfoxide hydrochloride, 2-chloro-10-[2-(dimethylamino) 
ethyljphenothiazine hydrochloride, 2-chloro-10-[4-(dimethylamino)butyl]phenothiazine 
hydrochloride, promazine hydrochloride, trifluopromazine hydrochloride, 2-thiomethyl- 
promazine hydrochloride, 1-chloropromazine hydrochloride, 3-chloropromazine hydro¬ 
chloride, 4-chloropromazine hydrochloride and prochlorperazine ethanedisulfonate by Dr. 
Charles Zirkle of Smith Kline and French Laboratories (Philadelphia, PA); 7-hydroxy- 
chlorpromazine, 3,8-dihydroxychlorpromazine, 7,8-dihydroxychlorpromazine, desmethyl- 
chlorpromazine hydrochloride and didesmethylchlorpromazine hydrochloride by Dr. Albert 
Manian of the National Institute of Mental Health (Bethesda, MD); promethazine 
hydrochloride by Wyeth Laboratories (Radnor, PA); chlorproethazine hydrochloride by 
Rhone-Poulenc (Paris, France); imipramine hydrochloride and 2-chloroimipramine 
hydrochloride by Geigy Pharmaceuticals (Summit, NJ); haloperidol, pimozide, penfluridol 
and 4-(4-chloro-a,a,a-trifluoro-m-tolyl)-1 -[4,4-bis(/?-flourophenyl)butyl]-4-piperidinol 
(R-6033) by Dr. Pierre Laduron of Janssen Pharmaceutica (Beerse, Belgium); quinacrine 
dihydrochloride by Sterling-Winthrop Research Institue (Renssalear, NY); fluphenazine by 
Dr. S. J. Lucania of E. R. Squibb and Sons. The following thioxanthene derivatives were 
generously supplied by Dr. John Hyttel of H. Lundbeck (Copenhagen, Denmark): cis- and 
rrans-flupenthixol, cis- and rrarcs-clopenthixol, cis- and rranj-chlorprothixene, N 751, 
N 753 A, N 753 B, N 762 A, N 762 B, N 768 A, N 768 B, N 789, N 796 A, N 796 B, 
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and N 7006. A-(4-amino-hexyl)-5-chloronaphthalenesulphonamide (W7) and its 
derivatives 5-iodo-l-Cg, 5-iodo-l-Cg, 5-iodo-l-C]2> and 5-cyano-l-Cg were kindly 
supplied by Dr. Shiela MacNeil (Northern General Hospital, Sheffield, UK). CGS 9343B 
was a gift of Dr. Jon Norman (CIBA-GEIGY, Summit, NJ). l-(5-isoquinoline-sulfonyl)- 
2-methylpiperazine (H-7), perphenazine and amitriptyline were obtained from Sigma. Other 
reagents were of analytical grade and were obtained from general commercial sources. 
4. Statistical Analysis 
Statistical analysis of each dose-response curve was performed by the method of 
Finney (61). Accordingly, ICso’s ± standard errors for the inhibition of cellular 
proliferation by drugs alone or in combination were determined by linear regression analysis 
of the logit transformed data. The significance of each MDR Ratio was then determined 
using Student’s two-tailed t test, and was expressed in terms of P values. 95% confidence 
intervals for each MDR Ratio were calculated by Fieller's Ratio of Means as modified by 
Bliss (25). Student's t test was also employed to analyze the significance of differences 
between MDR Ratios or ICso’s for inhibition of cellular proliferation by various drugs. 
C. Results 
1. Effect of Modifying the Phenothiazine Nucleus on Cellular 
Proliferation and Multidrug Resistance 
Table 2-1 shows the structures, IC50 values for inhibition of cell growth and MDR 
Ratios for a series of promazine derivatives having different substitutions on the PTZ 
nucleus. The unsubstituted PTZ, promazine, inhibited cell growth (IC50 = 26 pM) and 
sensitized MCF-7/DOX cells to doxorubicin by 20% (MDR Ratio = 1.2, P<0.05 as 
compared to doxorubicin alone). Adding a chlorine at positions 1, 2, 3, or 4 increased 
potency against cell growth by up to 3-fold, with the most potent compound 
(chlorpromazine) having a chlorine at position 2 (IC50 = 8 pM). This latter compound also 
had the greatest effect against MDR, sensitizing resistant cells to doxorubicin by 60% (MDR 
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Ratio = 1.6, PcO.OOl as compared to doxorubicin alone). Similarly, adding a -CF3 group 
at position 2 increased potency against cell growth and MDR. Accordingly, 
trifluopromazine (IC50 = 16 |iM) was a 1.6-fold more potent cytostatic agent than 
promazine (P<0.001), and was 67% more potent (PcO.OOl) against MDR (MDR Ratio = 
2.0). 
Conversely, adding a -OH to the PTZ nucleus decreased the potency against both 
processes. For example, 7-hydroxychlorpromazine was 2-fold less potent than promazine 
in inhibiting cell growth (PcO.OOl), while the dihydroxylated analogs, 7,8- and 3,8- 
dihydroxychlorpromazine, were up to 15-fold less potent than promazine as inhibitors of 
cellular proliferation (PcO.OOl), having ICso's of 63 (iM and 400 pM, respectively. In 
addition, the hydroxylated analogs had no significant chemosensitizing activity, and further 
increased resistance to doxorubicin (MDR Ratios < 1.0). Oxidation of the bridge sulfur 
(chlorpromazine sulfoxide) markedly reduced antiproliferative activity (IC50 = 500 pM), but 
increased activity against MDR (MDR Ratio = 2.2). 
2. Influence of the Side Chain Amino Group on Cellular Proliferation 
and Multidrug Resistance 
Table 2-2 shows that PTZs containing tertiary amines (chlorpromazine and 
chlorproethazine), secondary amines (desmethylchlorpromazine), and primary amines 
(didesmethylchlorpromazine) possess similar activity against cellular proliferation (ICso’s = 
8 - 12 pM). However, PTZs having tertiary amines were more potent antagonists of MDR 
than those with secondary or primary amines, producing a 1.6- to 2.2-fold increase in 
sensitivity to doxorubicin. For example, the ICso's of chlorpromazine and 
desmethylchlorpromazine were equal (8 pM), whereas chlorpromazine was more potent 
than desmethylchlorpromazine against MDR (MDR Ratios = 1.6 versus 1.2, PcO.Ol). 
Other changes in the type of amino group also affected anti-MDR activity. For example, 
piperazinyl derivatives increased potency against MDR. Accordingly, the MDR Ratios for 
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trifluoperazine (3.4) and fluphenazine (2.7), compounds with piperazinyl amino side 
chains, were greater than that of trifluopromazine (MDR Ratio = 2.0, P<0.001 and 0.001, 
respectively), a compound with an identical hydrophobic ring-substitution, but possessing 
an aliphatic side chain. Similarly, perphenazine and prochlorperazine (MDR Ratios = 2.0 
and 2.6) were more potent antagonists of MDR than chlorpromazine (MDR Ratio = 1.6, 
P<0.01 and 0.001, respectively). This series also points out the importance of the -CF3 
substitution at position 2 for anti-MDR activity. For example, the MDR Ratio for 
trifluoperazine (3.4) was greater than that of prochlorperazine (MDR Ratio = 2.6, P<0.01). 
These PTZs have identical structures except that the former has a -CF3 instead of a -Cl at 
position 2. A similar relationship is seen by comparing the MDR Ratio for fluphenazine 
(2.7) to perphenazine (MDR Ratio = 2.0, P<0.01), also identical molecules except for the - 
CF3 ring substitution. Finally, a para-methyl substitution on the piperazine appeared more 
potent than an ethanol group for anti-MDR activity of compounds, as seen by comparing the 
MDR Ratios for prochlorperazine (2.6) to perphenazine (2.0, P<0.05), or trifluoperazine 
(3.4) to fluphenazine (2.7, P<0.001). 
3. Influence of Alkyl Bridge Length on Cellular Proliferation and 
Multidrug Resistance 
Table 2-3 shows the effect on cell growth and on MDR of a series of 10-[alkyl- 
dimethylamino]phenothiazines in which the length of the alkyl bridge connecting the PTZ 
nucleus to the amino group was varied. Increasing the distance between the ring nucleus 
and the amino group from two to four carbons increased the antiproliferative and 
chemosensitizing effects of these compounds. For example, 2-chloro-10-[4- 
(dimethylamino)butyl]phenothiazine, which has a four carbon alkyl bridge, was a more 
potent antiproliferative agent (IC50 = 7 fiM) and anti-MDR agent (MDR Ratio = 2.0) than 
any of the other four compounds w’ith two or three carbon alkyl chains. Conversely, 
promethazine, which has an isopropyl side chain was a less potent inhibitor of cell growth 
than promazine, which has a three carbon chain. 
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4. Influence of Hydrophobicity of Phenolhiazines on Cellular 
Proliferation and Multidrug Resistance 
To determine the influence of hydrophobicity on the effect of PTZs on cellular 
proliferation and MDR, the octanohbuffer partition coefficients were compared for each of 
the 10 ring-substituted promazine derivatives as previously determined (174), to the ICso's 
for inhibition of cell growth and to the MDR Ratios. Figures 2-2 A and B demonstrate the 
excellent correlation between hydrophobicity and both antiproliferative activity (r = - 0.73, P 
= 0.016) and MDR antagonism ( r = 0.86, P = 0.0015). 
To determine if the differences in potency of compounds with side chain alterations 
were also due to changes in overall hydrophobicity, we compared the octanofbuffer 
partition coefficients for each of the drugs in Tables 2-2 and 2-3 that had -Cl substitutions at 
position 2 of the PTZ ring to their ICso's for inhibition of cell growth and to their MDR 
Ratios (Figures 2-2 C and D). In contrast to the results for ring-substituted PTZs, no 
statistically significant correlation was found between hydrophobicity and potency of 
compounds with side chain alterations for inhibition of cell growth (r = 0.54, P = 0.27) or 
antagonism of MDR (r = 0.59, P = 0.21). 
5. Correlation Between Anti-Calmodulin Activity and Inhibition of 
Cellular Proliferation and Multidrug Resistance 
To examine the role of CaM as a possible target for the effect of PTZs on cellular 
proliferation and MDR, the ICso's for the inhibition of CaM by PTZs and structurally 
related compounds (174) were compared to their ICso's for the inhibition of cell growth, 
and to their effect on MDR when used at equimolar (3 |iM) concentrations. Figures 2-3 A 
and B show a good correlation between anti-CaM activity and antiproliferative activity (r = 
0.58, P = 0.0009), whereas no correlation was found between anti-CaM activity and 
chemosensitizing activity (r = 0.17, P = 0.44). Similar results were found for equitoxic 
concentrations of PTZs. 

61 
6. Effect of Plienothiazines and Structurally Related Compounds on 
Doxorubicin-Sensitive Cells 
The activity of all PTZs and structurally related compounds against cell growth and as 
modulators of sensitivity to doxorubicin was examined against the doxorubicin-sensitive 
MCF-7 cell line. Each of the drugs tested were equally potent antiproliferative agents 
against the doxorubicin-sensitive cell line as compared to their activity against the resistant 
MCF-7/DOX cell line (data not shown). No compound sensitized the MCF-7 cells to 
doxorubicin. 
7. Effect of Specific Inhibitors of Calmodulin and Protein Kinase C on 
Cell Growth and Multidrug Resistance 
Table 2-4 shows the reported values for inhibition of CaM and PKC by several 
"specific" inhibitors of each, and their effect on cell growth and MDR, respectively. While 
a wide range of anti-CaM activities are reported for the W7 derivatives, these compounds 
had approximately similar antiproliferative effects (18-22 pM), and showed only little or 
no chemosensitizing activity (MDR Ratios = 1.0 to 1.5). The relatively specific CaM 
antagonist CGS 9343B displayed slightly greater chemosensitizing effects, causing a 2-fold 
reversal of doxorubicin resistance when used at the non-toxic concentration of 6 pM. FI-7, 
a competitive inhibitor of PKC, was an extremely non-toxic substance, showing significant 
antiproliferative effects only at concentrations > 200 |iM. Therefore, much higher ICjo 
doses were used than for most of the PTZs (30 |iM). Nevertheless, FI-7 had no anti-MDR 
activity, and actually caused a significant, though slight, enhancement of doxorubicin 
resistance. 
8. Effect of Compounds Structurally Related to the Phenothiazines on 
Inhibition of Cellular Proliferation and Multidrug Resistance 
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Tables 2-5 and 2-6 show the structures, IC50 values for inhibition of cell growth and 
effect on MDR for several classes of compounds that incorporate certain structural features 
identified as important for activity from the PTZ studies. Penfluridol and quinacrine (Table 
2-5) were potent antiproliferative agents (IC50 = 3 pM), but were relatively poor antagonists 
of MDR (MDR Ratios = 2.0 and 1.3, respectively). 
Table 2-6 shows that many of the thioxanthene isomers were particularly effective 
chemosensitizers. This class of compounds differ from the PTZs by a carbon substitution at 
position 10 of the PTZ nucleus, and an exocyclic double bond to the side chain. 
Each of the active chemosensitizing thioxanthene isomers caused a significantly greater 
potentiation of doxorubicin activity than their respective PTZ homolog (Tables 2-1 to 2-3), 
as demonstrated by comparing the MDR Ratios for rrarcs-chlorprothixene to chorpromazine 
(7.0 versus 1.6, PcO.OOl), trans-16% to chlorproethazine (7.2 versus 2.2, P<0.001), 
trans-196 to trifluoperazine (2.8 versus 2.0, P<0.01), rrart.y-clopenthixol to perphenazine 
(15.0 versus 2.0, P<0.001), and rra«5-flupenthixol to fluphenazine (15.2 versus 2.7, 
PcO.OOl). 
In addition. Table 2-6 demonstrates that the thioxanthenes displayed stereospecificity in 
their effect on MDR, since the trans-isomer of each active pair of thioxanthenes was 2- to 
6-fold more effective then the c/s-isomer for the reversal of MDR at equitotoxic 
concentrations. For example, Figure 2-4 displays representative dose-response curves of 
MCF-7/DOX cells to doxorubicin in the absence or presence of PTZ and thioxanthene 
isomers, and shows that rraAis-flupenthixol was a 3-fold more effective chemosensitizer 
than cfr-flupenthixol, and 6-fold more effective than the PTZ homolog fluphenazine, at 
equitoxic doses. This relationship also was true for equimolar concentrations of PTZs and 
thioxanthenes (data not shown). 
Similar to the PTZs, alterations in the length or type of side chain affected anti-MDR 
activity for the thioxanthenes. Aliphatic side chains of two carbons in length had little 
chemosensitizing activity (cis- or trans-162), while several thioxanthenes with three 
carbon aliphatic side chains possessed increased activity (frarts-chlorprothixene, trans- 
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768). It was also necessary for cyclic ring side chains substituents to be a distance greater 
than tw'O carbons from the thioxanthene ring nucleus for activity, as demonstrated by trans- 
7006 (MDR Ratio = 1.6) compared to rrarts-clopenthixol (MDR Ratio = 15.0), otherwise 
identical molecules except for a two carbon versus three carbon alkyl bridge. 
The most effective thioxanthene chemosensitizers, rrarts-clopenthixol, trans- 
flupenthixol and trans-753, caused an approximately 15-fold reversal of MDR, and each 
possessed cyclic piperazinyl or piperadinyl substituents at a distance of three carbons from 
the thioxanthene ring, in a trans configuration. Slightly higher concentrations of trans- 
flupenthixol (8 |iM) sensitized MDR cells to doxorubicin by 35-fold, a 10-fold greater anti- 
MDR activity than equitoxic (ICjq) doses of trifluoperazine, the most potent PTZ antagonist 
of MDR (data from Section III.C.6). 
In contrast to the anti-MDR effects of these compounds, the thioxanthene isomers 
displayed a relative lack of potency and stereospecificity as antiproliferative agents. For 
example, cis- and trans-flupenthixol possessed only modest activity against cell growth 
(ICso’s of 24 and 25 ^iM), similar in potency to its PTZ homolog fluphenazine (IC50 = 23 
pM) and less potent than many of the other PTZs tested. Similar comparisons may be made 
for each of the thioxanthene isomers and their PTZ homologs. 
D. Discussion 
The results presented in this chapter demonstrate that specific structural features of the 
PTZ molecule affect its activity against cellular proliferation and MDR, that the antagonism 
of CaM does not appear to be direcdy related to the PTZs’ anti-MDR activity, and that the 
thioxanthene class of antipsychotic drugs are more effective chemosensitizers than the 
PTZs. 
The data presented show that even slight modifications in the chemical structure of the 
PTZs can dramatically alter their potencies as antiproliferative and chemosensitizing agents, 
and suggest that these two actions of the PTZs are mediated by different mechanisms. 
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Specifically, increasing the hydrophobicity of the PTZ nucleus increased potency against 
cellular proliferation and against MDR, whereas decreasing the hydrophobicity decreased 
potency (Table 2-1). Thus, the -CF3 substituted compounds were the most potent drugs, 
whereas -OH substitituted compounds were the least potent drugs. Chlorpromazine 
sulfoxide, the oxidative metabolite of chlorpromazine, lost most of its antiproliferative 
effect. However, it retained its effect against MDR, suggesting that first-pass hepatic 
metabolism of these drugs may not present a major impediment to the clinical use of PTZs 
as chemosensitizers. 
The type of amino group also significantly affected potency against MDR but not 
against cellular proliferation. For example, tertiary amines were more potent than primary 
or secondary amines, and piperazinyl amines were more potent than non-cyclic groups. 
Moreover, piperazinyl structures that possessed a para-methyl group had consistently 
greater activity than others (Table 2-2). 
The distance between the amino group and the PTZ nucleus was important for both 
inhibition of cell growth and antagonism of MDR. A four carbon chain was superior to 
alkyl bridges of shorter lengths (Table 2-3). Whether an alkyl bridge of greater than four 
carbons would further increase activity could not be determined in the present study since 
these derivatives were not available. 
It has been postulated that the effects of the PTZs may be due solely to non-specific 
membrane interactions resulting from their high degree of lipophilicity (191). A careful 
analysis of the relationship between hydrophobicity and inhibition of cellular proliferation or 
antagonism of MDR showed a correlation for ring-substituted PTZ derivatives (Figures 2-2 
A and B), but not for compounds with specific side chain alterations (Figures 2-2 C and D). 
Thus, the degree of lipophilicity of each drug, while important, was not the sole determinant 
of potency for the antiproliferative or anti-MDR activity of PTZs. In fact, specific structural 
features of the side chain also determine potency, such as the nature and distance between 
the amino groups and PTZ nucleus, suggesting electrostatic interactions between the 
positively-charged amine and a particular cellular target protein may also be important. 
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This profile is reminiscent of that displayed by the interaction of PTZs with CaM. 
Studies of the structural features of PTZs that influence CaM antagonism revealed that ring- 
substitutions that increased hydrophobicity increased potency, while modifications of the 
type or length of the amino side chain affected potency in a manner unrelated to 
hydrophobicity (174). Similarly, studies with N-(6-aminohexyl)-1-naphthalene- 
sulfonamide (W5) and N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide (W7) (97), 
and a series of 15 derivatives of W7 (143), demonstrated that both halogenation of the 
naphthalene ring with chlorine, iodine or cyano groups, and increasing the length of the 
alkyl side chain from 4 to 12 carbons increased their potency against CaM. 
Drug binding studies with synthetic peptides and molecular modeling provided a 
rationale for the importance of both hydrophobicity and molecular structure for the PTZ - 
CaM interaction. The induction of a-helix formation by the binding of Ca to CaM results 
in two distinct regions, a hydrophobic pocket containing two aromatic phenylalanine 
residues (Phe 89 and 92) oriented to form a charge transfer complex with the aromatic, 
tricyclic nucleus of the PTZs, and a hydrophilic region at a distance of one-half helical turn 
formed by glutamic acid residues (Glu 83, 84 and 87), which interact with the positively- 
charged nitrogen atom of the PTZ side chain (183). The relationship between structure and 
hydrophobicity of the PTZs and their antiproliferative and anti-MDR activities suggests that 
in these systems, similar to CaM, the PTZs interact in both a hydrophobic and electrostatic 
manner with a protein target. Like CaM, it is likely that this target possesses a hydrophobic 
domain in close proximity to a negatively-charged amino acid. 
The site(s) of action of PTZs and structurally related compounds for inhibition of 
cellular proliferation and antagonism of MDR have not been identified. The current data 
demonstrate that the antiproliferative activity of these drugs used individually against the 
malignant breast cancer cell lines MCF-7 and MCF-7/DOX correlate with their potency as 
CaM antagonists (Figure 2-3 A), supporting and extending previous observations with a 
limited number of PTZs in MDA-MB-231 human breast cancer cells (239), C6 astrocytoma 
cells (136), HL-60 human leukemia cells, L1210 murine leukemia cells, and HCT-8 human 
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colonic carcinoma cells (84). These data are consistent with the known role of CaM in 
cellular proliferation (86, 182), and suggest a role for CaM as the PTZ target involved in cell 
growth inhibition by PTZs. However, the complete lack of correlation between anti-CaM 
activity and antagonism of MDR by equimolar (Figure 2-3 B), as well as equitoxic (data not 
shown) concentrations of PTZs, points toward an alternative mechanism of inhibition for 
this effect. This is in contrast to conclusions reached by Ganapathi (73), who compared the 
anti-CaM and anti-MDR activity of trifluoperazine, chlorpromazine, and prochlorperazine in 
murine P388/DOX cells. If one examines the present data for these 3 drugs alone, a 
correlation also is found between anti-CaM and anti-MDR activity (Figure 2-3B). 
However, in the context of the much larger sample size in the present study, this correlation 
does not remain significant. 
Since the PTZs are considered non-specific probes for CaM function in cell systems 
due to their activity as inhibitors of PKC (200) and dopamine receptors (47), the 
chemosensitizing effect of several compounds w'ith relatively increased specificity for CaM 
or PKC were examined. While several analogs of the naphthalene sulphonamide W7 
possess far less PKC inhibitory activity, along w'ith increased anti-CaM activity (143), these 
compounds caused little or no potentiation of doxorubicin toxicity in MCF-7/DOX cells 
(Table 2-5). Similarly, the CaM antagonist CGS 9343B, which also lacks potency as an 
inhibitor of PKC (160), was found to be a fairly poor chemosensitizer in MDR cells (Table 
2-4). These data further support the previous evidence that antagonism of CaM is not 
directly involved in the reversal of MDR by chemosensitizers. However, it appears that 
inhibition of CaM may be a useful marker for potential MDR chemosensitizers, since the 
structural requirements for both are similar, and many of the presently studied 
chemosensitizers are also potent CaM antagonists. 
Finally, the isoquinolinesulfonyl H-7, a potent and competitive inhibitor of PKC (98, 
162), had no chemosensitizing effect on MDR cells, but slightly enhanced the resistance of 
cells to doxorubicin (Table 2-4), in agreement with preliminary results reported by 
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Ganapathi (70). It is interesting to note that Ido et al (105) found H-7 capable of inhibiting 
a TPA-induced decrease in vincristine accumulation in sensitive P388 cells. Therefore, it 
appears that while PKC activation by phorbol esters may induce MDR, the inhibition of 
PKC does not necessarily sensitize MDR cells. 
The information gained from these studies enabled the identification of additional drugs 
with certain of the important structural features for chemosensitizing activity. A number of 
tricyclic compounds with cationic amino group side chains were studied for 
chemosensitizing activity. Several, such as imipramine and 2-chloroimipramine had modest 
anti-MDR activity. Interestingly, quinacrine, a compound described as sensitizing several 
other MDR cell lines (109, 246), showed essentially no anti-MDR activity in the present 
study, probably because a very low does was used due to its potent antiproliferative effects 
(IC10 = 0.75 pM). 
The most interesting results were displayed by the thioxanthene class of antipsychotic 
drugs (Table 2-6). Nearly every rrans-thioxanthene isomer possessed greater 
chemosensitizing activity than their respective PTZ homologs, and several, such as trans- 
flupenthixol, trans-clopenthixol, and trans-153, were 5- to 7-fold more effective at 
equitoxic or equimolar concentrations. Many of the structural features important for PTZ 
anti-MDR activity were also effective for thioxanthenes. For example, thioxanthenes with 
aliphatic or cyclic side chains of three carbons in length were more effective than those with 
two carbon alkyl bridges. Also, piperazinyl or other cyclic side group substitutions resulted 
in greater activity than aliphatic side groups. The most effective pair of thioxanthenes, cis- 
and rra/u-flupenthixol, have a -CF3 substitution at position 2 of the hydrophobic 
thioxanthene ring, possess a piperazinyl amino side chain, and have a 3 carbon alkyl bridge. 
While the thioxanthene isomers are more hydrophobic than PTZs due to the substitution 
of a carbon for a nitrogen in the cyclic ring, this alone cannot explain their cellular effects. 
For example, the octanokbuffer partition coefficients (log P) for both flupenthixol isomers 
= 4.25 versus 4.04 for chlorpromazine (161), but they are less potent antiproliferative 
agents than chlorpromazine and other less hydrophobic PTZs. In addition, while the 
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isomers are equally hydrophobic, frans-flupenthixol is a 3-fold more potent anti-MDR 
agent (Figure 2-4), and both isomers are more potent than agents with greater 
hydrophobicity, such as pimozide (log P = 4.88). 
The orientation of the side chain amine in relation to the tricyclic nucleus was an 
important determinant of anti-MDR activity, but not of antiproliferative activity for the 
thioxanthenes. For example, trans-flupenthixol displayed greater activity than the cis- 
flupenthixol against MDR (Figure 2-4), but was equal to that of the cis-isomer against 
cellular proliferation (Table 2-6). In fact, for every pair of active thioxanthene isomers, the 
trans-isomer was uniformly more effective than the cis- for reversing MDR,while no 
consistent stereoisomerism was seen for the antiproliferative effects of these compounds. It 
is intriguing that compound 789, which is identical to clopenthixol except for a single 
instead of a double bond connecting the piperazinyl side chain to the thioxanthene ring 
nucleus, was nearly as effective as rran^-clopenthixol, and far more effective than cis- 
clopenthixol or perphenazine. This suggests that the superior anti-MDR activity of the 
thioxanthenes may be due to specific binding to a receptor with greater affinity for 
compounds in the trans configuration, or compounds w'hich are able to assume the trans 
configuration, and that drugs locked into a cis orientation by a double bond are unable to 
bind with high affinity possibly due to steric hindrance. 
Taking into account all of the principles derived from this analysis of PTZ-like 
compounds, structural features important for a drug to alter MDR include a hydrophobic 
thioxanthene ring nucleus with a -CF3 substitution at position 2, an exocyclic double bond 
in the trans configuration, and a piperazinyl amine with a para-methyl or ethanol group, 
joined by a 3 or 4 carbon alkyl bridge to the nucleus. These findings agree with similar 
structural features identified as important for modulating MDR in human leukemic cells in a 
recent study with derivatives of indole alkaloids (246). Therefore, the present structure- 
activity studies more clearly define the ’pharmacophore’ necessary for specific anti-MDR 
activity for PTZs and structurally related classes of drugs, and have identified a previously 




Clinical trials of the antipsychotic effects of the thioxanthene flupenthixol in humans 
showed that m-flupenthixol was far more effective than rra«5-flupenthixol, and that the 
latter was far less toxic (116). This observation may be explained by biochemical and 
crystallographic evidence that c/5-flupenthixol is a potent antagonist of dopamine receptors 
(103, 172), whereas rrans-flupenthixol, which displays the greater potency against MDR, 
has virtually no activity as a dopamine antagonist. This may explain the apparent lack of 
extrapyramidal side effects seen with this agent (157). Extrapyramidal side effects have 
proven to be dose limiting in Phase I trials that combined trifluoperazine with bleomycin 
(88) or doxorubicin (149). Therefore, further in vitro and in vivo characterization of 





Effect of Modifying the Phenothiazine Nucleus on Activity Against Cell 
Growth and Multidrug Resistance 
Inhibition of cell growth was determined by exposing MCF-7/DOX cells to 0 - 100 |iM of 
each PTZ. IC50 is the mean concentration ± S.E. that produced 50% inhibition of cell 
growth compared to vehicle-treated controls, as described in Materials and Methods 
(Section B.2). To determine the MDR Ratio, MCF-7/DOX cells were exposed to 0-100 fiM 
doxorubicin in the presence or absence of PTZ at a concentration that alone produced 10% 
inhibition of cellular growth. MDR Ratio is the IC50 for doxorubicin alone divided by the 
IC50 doxorubicin in the presence of PTZ. 95% confidence intervals and P- values for 
comparison of IC5q's for cell growth inhibition by doxorubicin in the absence versus 
presence of each modifier were derived as described in Methods. All values represent the 
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Effect of Modifying the Type of Side Chain Amino Group on Activity 
Against Cell Growth and Multidrug Resistance 
MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR 
Ratios with 95% confidence intervals and P- values for comparison of IC5q's for cell 
growth inhibition by doxorubicin in the absence versus presence of each modifier were also 
determined as described in Table 2-1. Each value represents the mean of three to five 
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Effect of Modifying the Length of the Side Chain Amino Group on Activity 
Against Cell Growth and Multidrug Resistance 
MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR 
Ratios with 95% confidence intervals and P- values for comparison of IC5q’s for cell 
growth inhibition by doxorubicin in the absence versus presence of each modifier were also 
determined as described in Table 2-1. Each value represents the mean of three to five 
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Effect of Specific Inhibitors of Calmodulin and Protein Kinase C 
on Cell Growth and Multidrug Resistance 
MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR 
Ratios w'ith 95% confidence intervals and P- values for comparison of IC5o’s for cell 
growth inhibition by doxorubicin in the absence versus presence of each modifier were also 
determined as described in Table 2-1. Each value represents the mean of two to three 
separate experiments; each experiment was done in quadruplicate. Values for inhibition of 
CaM and PKC are from MacNeil et al (1988) for W7 and derivatives, Norman et al 
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Effect of Compounds Structurally Related to the Phenothiazines 
on Cell Growth and Multidrug Resistance 
Compound Structure Cell Growth Inhibition MDR RaUo 









3 ±.1 1.3 ±0.1 b 
19 ±5 2.5 ±0.9a 
20 ±2 2.0 ±0.6a 





3 ± .2 2.0 ± 0.3a 
50 ±20 1.3±0.5C 
27 ±4 1.1 ±0.2d 
750 ±300 3.3 ±.7a 
a P<0 001 
b P < 0 05 
c P< 001 
a P - not significant 
MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR Ratios with 95% confidence 
intervals and P- values for comparison of IC50's for cell growth inhibition by doxorubicin in the absence versus 
presence of each modifier were also determined as described in Table 2-1. Each value represents the mean of three to 




Effect of Thioxanthene Stereoisomers on Cell Growth 
and Multidrug Resistance 
6 5 4 
R 
X R Name Cal Growtfi hfibtor MDR Rat 
/CH3 as- 762 (B) 
C M + S.E. (jiM) 
30 ± 4 
1»S% C.l. 
1.1 ± 0.2 0 
—Cl =CH—CHj—N 
nch3 Vans- 762 (A) 40 ± 6 
1.3 ±0 1 c 
/CH3 as- chlorprothixene 20 ± 2 20± 0 6 * 
—Cl = C H —C H C H j—N 
nch3 Vans- chlorprothixene 13 ± 2 7.0 ±0 9 * 
/CH2CH3 as- 768 (B) 17 ± 3 4.0 ± 0 3 4 
—Cl = CH —CH 2—CH ^—N 







 as- 796 (A) 28 ± 4 1 8± 0.2 6 
-^F3 = C H —C H ^—C H 3—N 
nch3 Vans- 796 (B) 14 ± 3 2 8 ±0.3 * 
as- 753 (B) 20 ± 3 6.7 ± 1.8 * 
—Cl = C H —C H ^—C H 2— CH2 
Vans- 753 (A) 40 ± 5 15 0 ±2.5 * 
—Cl 
/—V 
= CH—CH^-CH^-N_NH racemic 751 8 ± 2 1.8 ±0.3 6 
—Cl —CH—CH g—N N—CH 2CH2 OH Vans- 7006 13 ± 3 1.6 ±0 4 b 
—Cl = CH—CH^—CH^—N N—CH -CH ~ OH 
y y 
as- clopenthixol 20 ± 2 2.6 ±0 4 * 
Vans- clopenthixol 15 ±2 15.0 ±2.3 1 
-cf3 = CH—CH^—CH^—M N—CH2CH2OH as- flupenthixol 24 ± 4 4.8 ±0.6 * 
Vans- flupenthixol 25 ±4 15.2 ±1.9 * 
—Cl —CH^—CHg—CHg—N^ N—CH2CH2 OH 789 22 ±5 9.7 ±2.7 * 
a P< 0.001 
b P< 0 05 
c P< 0.01 
d P - not significant 
MCF-7/DOX cells were treated as described in Table 2-1. IC50 values ± S.E. and MDR Ratios 
with 95% confidence intervals and P- values for comparison of IC50's for cell growth inhibition 
by doxorubicin in the absence versus presence of each modifier were also determined as 
described in Table 2-1. Each value represents the mean of two to three separate experiments; 
each experiment was done in quadruplicate. 
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Cells per Well ( x 10 ) 
Figure 2-1. Correlation between absorbance (A ^qq) of stained cellular protein 
and cell count. MCF-7/DOX cells were grown in 96-well microtiter plates at initial 
concentrations of 10,000 cells/well and enumerated after 24, 48, 72, 96 and 110 
hour incubations by either absorbance spectrophotometry or with a Coulter Counter, 
as describe in Materials and Methods. Each point represents the mean of 




Ring-Substituted Phenothiazine Derivatives 
2-Chloro Phenothiazine Derivatives 
Figure 2-2. Relationship between hydrophobicity and activity of phenothiazine derivatives as 
antiproliferative and anti-MDR agents. (A) and (B): correlation between octanohbuffer partition 
coefficients, as previously determined (Prozialeck and Weiss, 1982), and the IC50's for inhibition 
of cell growth (r = - 0.73, P = 0.016) and antagonism of MDR (r= 0.86, P = 0.0015)) for a series of 
phenothiazine derivatives with ring-substitutions (Table 2-1). (C ) and (D): lack of correlation 
between octanohbuffer partition coefficients and IC50's for inhibition of cell growth (r = 0.54, P = 
0.27) and antagonism of MDR (r = 0.59, P = 0.21) for a series of 2-C1 substituted phenothiazine 
derivatives with side chain alterations (Tables 2-2 and 2-3). Numbered points represent; (1) 
promazine, (2) 1-chloropromazine, (3) chlorpromazine, (4) 3-chloropromazine, (5) 4- 
chloropromazine, (6) 7-hydroxychlorpromazine, (7) 3,8-dihydroxychlorpromazine, (8) 7,8- 
dihydroxychlorpromazine, (9) thiomethylpromazine, (10) trifluopromazine, (11) 2-chloro-10-[2- 
(dimethylamino)ethylj phenothiazine, (12) 2-chloro-10-[4-(dimethylamino)butyl] phenothiazine, 




Figure 2-3. Relationship between anti-calmodulin activity and antiproliferative or anti- 
MDR activity for phenothiazine derivatives. (A): correlation between the IC^o's for 
inhibition of calmodulin-induced activation of phosphodiesterase and the IC5q's for 
inhibition of cell growth (r = 0.58, P = 0.0009) for phenothiazine derivatives. (B): lack of 
correlation between the IC5q's for inhibition of calmodulin-induced activation of 
phosphodiesterase and antagonism of MDR by modifiers used at a standard concentration of 
3 fiM (r = 0.17, P = 0.44) for phenothiazine derivatives. All IC50 values for the inhibition 
of calmodulin are from Prozialeck and Weiss (1982) and represent the concentration of drug 
necessary to inhibit by 50% the calmodulin-induced activation of the Ca^-dependent form 
of cyclic nucleotide phosphodiesterase. IC5Q values for the inhibition of cellular 
proliferation are from Tables 2-1 to 2-6. MDR Ratios are the mean of two or more 
experiments, each run in quadruplicate, and were determined as described in Materials and 
Methods, except that an equimolar concentration (3 pM ) of each modifier was used instead 
of an equitoxic concentration. Numbered points represent; (1) promazine, (2) 1-chloro- 
promazine, (3) chlorpromazine, (4) 3-chloropromazine, (5) 4-chloropromazine, (6) 7- 
hydroxychlorpromazine, (7) 3,8-dihydroxychlorpromazine, (8) 7,8 dihydroxychlor- 
promazine, (9) thiomethylpromazine, (10) trifluopromazine, (11) 2-chloro-10-[2-(dimethyl- 
amino)ethyl] phenothiazine, (12) 2-chloro-10-[4-(dimethylamino)butyl] phenothiazine, (13) 
didesmethylchlorpromazine, (14) desmethylchlorpromazine, (15) chlorproethazine, (16) 
promethazine, (17) prochlorperazine, (18) trifluoperazine, (19) m-flupenthixol, (20) 
rra/u-flupenthixol, (21) quinacrine, (22) imipramine, (23) 2-chloroimipramine, (24) pen¬ 












































Figure 2-4.Effect on the sensitivity of MDR cells to doxorubicin by PTZs and 
structurally related modifiers. MCF-7/DOX cells were exposed to 0- 00 jiM dox¬ 
orubicin for 48 hours in the absence ( □) or presence of fluphenazine (■ ), 
cis-flupenthixol (o), or trans-flupenthixol (•) at concentrations that alone produced 
10% inhibition of cell growth. Cell growth was determined by a microtiter assay as 
described in Materials and Methods. Each point represents the mean of quadruplicate 




/A7 VITRO CHARACTERIZATION OF THE CHEMOSENSITIZING 
EFFECT OF THE THIOXANTHENES 
A. Introduction 
The analysis of structural determinants important for PTZs' anti-MDR activity, 
discussed in the previous chapter, enabled the identification of a novel class of 
chemosensitizing agents, the thioxanthenes. As outlined in Section I.B.2., the efficacy of 
chemosensitizers may be best evaluated by studying their effect on cytotoxic drug 
resistance, cross-resistance and drug accumuladon in carefully defined MDR cell lines. The 
discovery that rranj-thioxanthene isomers more effectively potentiate doxorubicin in MCF- 
7/DOX cells than m-isomers provides a unique opportunity to probe the stereoisomeric 
specificity of these chemosensitizers on MDR, and to compare their anti-MDR activities with 
their degree of stereoisomerism in other cellular and enzymatic systems, as a means of better 
defining their possible mechanism(s) of action. 
Accordingly, studies were performed comparing the effects the thioxanthene 
chemosensitizers cis- and rrans-flupenthixol, the PTZ homolog fluphenazine, and the 
structurally unrelated chemosensitizer verapamil, on primary drug resistance, cross¬ 
resistance, and accumulation in several MDR cell lines, including three well-characterized, 
P-gp expressing human and mouse MDR lines (MCF-7/DOX, KB-V1, and P388/DOX), a 
murine fibroblast cell line transfected with a human mdr 1 gene expression vector and 
selected for P-gp overexpression and resistance to colchicine (3T3/MDR1), and an 'atypical' 
MDR cell line which displays characteristics of MDR, including cross-resistance and 
decreased drug accumulation, but does not overexpress P-gp. In addition, the thioxanthene 
isomers cis- and rrarcs-flupenthixol were studied for their potency and stereospecificity as 
inhibitors of CaM and PKC, cellular enzymes potentially important for reversing MDR. 
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B . Materials and Methods 
1 . Cell Lines and Culture 
MCF-7 and MCF-7/DOX human breast cancer cells were maintained as described in 
Section II.B.l. The latter cell line has been been shown to uniquely overexpress P-gp and 
the glutathione-S-transferase n isozyme (12, 56). 
Human epidermoid carcinoma KB-3-1 cells and the vinblastine selected MDR subline, 
KB-VI (kindly supplied by Dr. Michael M. Gottesman, National Cancer Institute, 
Bethesda, MD), were grown in monolayer culture at 37° C in Dulbecco's modified Eagle's 
medium with 10% fetal bovine serum and L-glutamine, in the continuous presence of 1 
(ig/ml vinblastine. These cells are > 200-fold resistant to vinblastine, doxorubicin and 
colchicine (206), demonstrate decreased drug accumulation (64), overexpress P-gp (236), 
and possess a 100-fold amplification of the mdr 1 gene (188). 
Murine leukemic P388 cells and the classic MDR cell line P388/DOX (from Dr. Ram 
Ganapathi, Cleveland Clinic Foundation, Cleveland, OH) were grown in suspension in 
RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% fetal bovine serum and 10 
jiM 2-mercaptoethanol. 
Murine NIH 3T3 fibroblasts and a MDR 3T3 line (3T3/MDR1) transfected with a 
retrovirus expression vector containing a full-length cDNA from the human mdr\ gene 
(235) and selected for resistance to colchicine (kindly provided by Drs. Michael M. 
Gottesman and Steven Currier) were grown in monolayer in RPMI 1640 supplemented with 
10% fetal calf serum, in the continuous presence of 1 |ig/ml colchicine. 
MCF-7/MITOX cells (generously supplied by Dr. William S.Dalton, University of 
Arizona Cancer Center, Tucson, AZ), selected for resistance to mitoxantrone, were grown 
similarly to the other MCF-7 lines, except that RPMI 1640 medium w-as supplemented with 
10% fetal bovine serum, and cells were continuously growrn in 8 x 10'8 M mitoxantrone. 
These cells display characteristics of MDR including cross-resistance to anthracyclines and 
Vinca alkaloids and decreased drug accumulation, but do not overexpress P-gp. 
Cell lines grown in the presence of selecting agents were passaged 2 to 3 times out of 
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drug before use in experiments. Cell lines were routinely tested and found to be free of 
contamination by mycoplasma or fungi. 
2. In Vitro Drug Sensitivity Assays 
The individual antiproliferative effect of cytotoxic drugs, PTZs or thioxanthenes in the 
various cell lines were determined using microtiter spectrophotometric assays. All 
monolayer cell lines (MCF-7, KB, and NIH 3T3 derived lines) w-ere assayed using the 
methylene blue cell staining method of Finlay et al (60) as described in Section D.B.2., 
with the following modifications. Correlations between cellular grow-th and spectro¬ 
photometric absorbance were performed for each cell line, as described for MCF-7/DOX 
cells in Figure 2-1, and the initial cell plating density and optimal assay conditions chosen to 
ensure optical density measurements fell on the linear portion of each curve. 0.5 x 104 
MCF-7 sensitive cells, 1.0 x 104 MCF-7/DOX cells, 1.2 x 104 MCF-7/MITOX cells, 0.8 x 
104 KB-3-1 cells, 1.0 x 104 KB-V1 cells, 0.6 x 104 NIH 3T3 cells, and 1.0 x 104 
3T3/MDR1 cells were dispensed in 100 pi volumes medium into each well of 96-well 
microtiter plates. Cells were allowed to attach and grow for 24 hours, at w'hich time 100 pi 
of drug-containing medium was added. Cells were incubated at 37° C with drugs for 48 
hours, except for MCF-7/MITOX cells, which required a 72 hour incubation for optimal 
growth, and stained with methylene blue, solubilized, and their optical density (A6qo) 
determined spectrophotometrically, as described in Section II.B.2. 
Inhibition of growth for the P388 and P388/DOX suspension cell lines was determined 
using the modified MTT assay (30), based on the ability of live cells to reduce a tetrazolium 
based compound 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to 
a blue formazan product that can be measured spectrophotometrically. Briefly, 0.5 x 104 
P388 or P388/DOX cells in 100 pi aliquots growth medium were plated into each well of 
96-well microtiter plates, and allowed to equilibrate for 2 to 4 hours. Drugs dissolved in 
small amounts of sterile water or ethanol (final concentration <0.1%) and diluted in medium 
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were added in 100 pi volumes at appropriate concentrations, with each condition performed 
in quadruplicate. Control wells received 100 pi medium with vehicle, alone. Cells were 
incubated at 37° C for 3 days, at which time 50 pi MTT (Sigma) solution (2 mg/ml PBS) 
was added to each well for an additional 4 hour incubation. Plates were centrifuged at 450 x 
g for 5 minutes, and cellular supernatants gently aspirated, leaving approximately 25 pi 
medium in each well. Insoluble formazan crystals were dissolved by adding 150 pi 100% 
DMSO to each well, and plates thoroughly mixed on a mechanical plate shaker for 10 
minutes. The optical density of each well was determined by absorbance spectrophotometry 
at a wavelength of 550 nm using a Titertek Multiscan MCC/340 plate reader. Correlations 
between cell number and spectrophotometric absorption were performed as described for the 
the methylene blue staining assay, and plating densities and assay conditions chosen to 
ensure linearity. Inhibition of cell growth was expressed as a percentage of absorbance of 
vehicle-treated control cultures. 
The relative resistance and cross-resistance of each cell line to various drugs was 
determined by dividing the IC50 concentration for resistant cell lines to each drug by the 
IC50 for that drug in the respective parental, sensitive cell line. 
The effect of chemosensitizers on drug resistance and cross-resistance was studied by 
exposing cells to a range of concentrations of cytotoxic drugs in the absence or presence of 
equimolar concentrations of chemosensitizers that alone produced < 10% inhibition of 
growth. Except where otherwise indicated, 5 pM concentrations of chemosensitizers were 
used for all experiments. Dose-response curves were corrected for the inhibition of cell 
growth caused by chemosensitizers alone, and MDR Ratios, as defined in Section II.B.2., 
were calculated for each drug plus chemosensitizer combination. 
MDR Ratio = IC50 Drug alone + IC50 Drug + Chemosensitizer 
3. Cellular Accumulation of Thioxanthenes 
Duplicate aliquots of 3 x 106 MCF-7/DOX cells in a total volume of 2 ml were 
incubated at 37° C for 3 hours in the presence of 0 - 100 pM of each drug. Cells were 
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washed three times in cold PBS and centrifuged at 100 x g for 10 minutes, resuspended in 2 
ml of 0.3 N HC1 in 50% ethanol, and sonicated for 10 pulses at 200 watt seconds with a 
Tekmar cell sonicator (Tekmar, Cincinatti, OH). Following centrifugation at 1000 x g for 
30 minutes, the cell supernatant was removed and assayed for drug concentration with a 
Perkin-Elmer 512 spectrofluorometer (Norwalk, CT). Optimal excitation and emission 
wavelengths for both thioxanthene isomers were determined to be 320 nm and 400 nm, 
respectively. Cellular drug content (nmoles/106 cells) was computed from standard curves 
prepared with known amounts of drug in 0.3 N HC1 in 50% ethanol. 
4. Cellular Accumulation of Doxorubicin 
Sensitive and MDR MCF-7 cells were each seeded in three 40 ml volumes of medium 
at a density of 1.67 x 106 cells/ml. 100 pi of concentrated stock drug solutions were added 
to obtain a final doxorubicin concentration of 10 pM, in the absence or presence of either 
equitoxic (ICjq) concentrations of cis- or trans-flupenthixol (3 pM and 6 pM, 
respectively), or equimolar (5 pM) concentrations of all chemosensitizers. Cells were 
incubated at 37° C for 3 hours. At various times after the addition of drugs, three 1.5 ml 
aliquots of cellular suspension were removed from each cell solution, immediately 
centrifuged for 60 sec at 11,000 x g, and washed three times with cold PBS using an 
Eppendorf 5415 microcentrifuge. Control samples were removed at time zero, immediately 
before drugs were added. Cell pellets were extracted with 0.3 N HC1 in 50% ethanol, 
sonicated and centrifuged as described above. Cell supernatants were removed and assayed 
fluorome trie ally for doxorubicin content using excitation and emission wavelengths of 470 
nm and 585 nm, respectively, as previously described (69). Cellular content of doxorubicin 
(pmoles/106 cells) was computed from standard curves prepared with known amounts of 
drug. The presence of chemosensitizers was shown not to effect the absorbance or 
emission spectra of doxorubicin. 
5. Isobologram Analyses 
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After determining the IC50 for doxorubicin and the IC50 for individual chemosensitizers 
against MCF-7/DOX cells, a series of dose-response curves to rrans-flupenthixol in the 
presence of fixed concentrations of doxorubicin were done by the microtiter assay system. 
The individual concentrations of doxorubicin plus rran^-flupenthixol that together resulted 
in 50% inhibition of growth of MCF-7/DOX cells were plotted and this IC50 isobole 
compared to the calculated line of additivity, using criteria previously described (22). 
Similarly, a MDR isobologram analysis was designed to study the in vitro additivity, 
synergy or competitiveness of rrans-flupenthixol plus verapamil for reversing MDR. 
Accordingly, multiple dose-response curves for MCF-7/DOX cells to doxorubicin were 
performed, in the absence or presence of various combinations of rrarcs-flupenthixol plus 
verapamil. Those concentrations of chemosensitizers that together caused a 15-fold reversal 
of MCF-7/DOX cell resistance to doxorubicin were graphed and compared to a theoretical 
line of chemosensitizing additivity. An MDR Ratio = 15 was arbitrarily chosen as the 
defined 'response,' for which particular doses of chemosensitizers were necessary to 
achieve, analogous to the IC50 response as defined for a traditional isobologram. 
6. Inhibition of Calmodulin by Thioxanthenes 
The activity of bovine brain CaM (Calbiochem) was determined by its ability to activate 
a CaM-dependent cyclic nucleotide phosphodiesterase prepared from rat cerebrum, as 
previously described (137). Phosphodiesterase activity was measured by the luciferin- 
luciferase method (246). One unit of CaM was defined as the amount needed to produce 
50% of the maximal activation of phosphodiesterase. Briefly, to assay CaM activation, each 
reaction vessel contained 50 mM glycylglycine buffer, pH 8.0, containing 25 mM 
ammonium acetate, 3 mM MgCl2> 0.1 mM CaC^, 0.25 mM phosphoenolpyruvate, 5 mM 
dithiothreitol, 1 nM ATP, 1 pg myokinase, 0.5 pg pyruvate kinase, 0.4 mM cyclic AMP, 
and the phosphodiesterase preparation in a total volume of 100 pi. Samples were incubated 
at 37° C for 30 min, and then placed in a boiling water bath for 5 min to destroy the 
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phosphodiesterase activity. After cooling, an additional 25 p.1 of glycylglycine buffer 
containing 2 jig of myokinase and 1 jig pyruvate kinase were added and the sample 
reincubated for 30 min at 37° C. The firefly luciferin-luciferase reagent was added, and the 
hydrolysis of cyclic AMP measured using a Luminescence Biometer. The effect of 
thioxanthenes on the activity of calmodulin was determined by their ability to inhibit the 
activation of phosphodiesterase in the presence of 10 units of calmodulin. The specificity of 
this assay was shown by determining the basal inhibition of phosphodiesterase in the 
absence of CaM. 
7. Inhibition of Protein Kinase C by Thioxanthenes 
PKC was partially purified by modifications of previously described methods (57, 
124). Briefly, 1 x 108 MCF-7/DOX cells were washed once with PBS by centrifugation at 
100 x g at 4° C and the pellet resuspended in 1.5 ml of 20 mM Tris HC1 buffer containing 2 
mM EDTA, 0.5 mM EGTA, 2 mM PMSF and 5 mM 2-mercaptoethanol, pH 7.5. The cells 
were allowed to swell for 5 minutes and then gently homogenized with 30 strokes of a 
Dounce Homogenizer with a loose fitting glass pestle. Sucrose was added to a final 
concentration of 0.33 M and the homogenate centrifuged at 100,000 x g for 1 hour. The 
soluble supernatant fraction was then added batchwise to DE52 preequilibrated with sample 
buffer. The resin was washed twice with the sample buffer containing 0.33 M sucrose and 
the enzyme was eluted with 20 mM Tris HCL buffer containing 100 mM NaCl, 2 mM 
PMSF and 5 mM 2-mercaptoethanol. All procedures were carried out at 4° C. The activity 
of the enzyme was purified approximately 15-fold. 
The activity of PKC was determined by measuring the incorporation of 32P from [y- 
32P]-ATP into lysine rich histone by modifications of previously described methods (169). 
A reaction mixture consisted of 40 jig histone, 4 pg/ml diolein, with or without 25 |ig/ml 
phosphatidylserine and 50 |il of the partially purified enzyme (approximately 1 jig) in 20 
mM Tris HC1 containing 10 mM MgCl2, 0.5 mM CaCl2, pH 7.5. The reaction was initiated 
by the addition of 20 pM ATP containing 0.66 pmol of [y-22P]-ATP (6.66 x 106 
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cpm/pmol) in a final volume of 200 pi Following a 10 minute incubation at 30° C, 25 pi 
aliquots of the reaction mixture were spotted onto P81 cation exchange paper. Tie filters 
were washed 3 times in 75 mM phosphoric acid and counted in 5 ml of Ecoscint using a 
Beckman LS 7500 liquid scintillation counter. Assay conditions were chosen to insure 
linearity of the reaction with time of incubation and concentration of tissue. 
8. Drugs and Reagents 
Fluphenazine was provided by Dr. S. J. Lucania (E. R. Squibb and Sons), cis- and 
rrans-flupenthixol by Dr. John Hyttel (H. Lundbeck, Copenhagen, Denmark), bleomycin 
(Blenoxane) by Dr. Emmanuel Losada (Bristol Laboratories, Wallingford, CT), and 
mitoxantrone by Hank Durivage (Section of Medical Oncology, Yale University School of 
Medicine). Doxorubicin, vinblastine sulfate, colchicine, verapamil, adenosine mono¬ 
phosphate, L-phosphatidyl-L-serine, 1,3-diolein, and histone (type III-S) were obtained 
from Sigma. Myokinase and pyruvate kinase were obtained from Boehringer-Mannheim 
(Indianapolis, IN) and firefly luciferin-luciferase was from E.I. Dupont de Nemours & Co. 
(Wilmington, DL). [y-32P]-ATP was obtained from New England Nuclear Research 
Products, Inc. (Boston, MA). Whatman DE52 ion exchange cellulose was purchased from 
Macalaster Bicknell (New Haven, CT). P81 cellulose phosphate paper was purchased from 
Whatman (Hillsboro, OR). Other reagents were of analytical grade and were obtained from 
general commercial sources. 
C. Results 
1. Inhibition of Cellular Proliferation by Chemosensitizers 
Table 3-1 shows the IC50 concentrations for inhibition of cell growth by cis- 
flupenthixol, rrans-flupenthixol, fluphenazine or verapamil in each of the cell lines studied. 
In general, the P388 sensitive and P388/DOX cells were more sensitive, and the NIH 3T3 
and 3T3/MDR1 cells more resistant to the antiproliferative effects of each of the four 
chemosensitizers used alone, than the MCF-7 or KB derived cell lines. C/T-flupenthixol, 
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rrarcj-flupenthixol and fluphenazine were 2- to 10-fold more potent antiproliferative agents 
than verapamil, but were equitoxic to each other in each of the cell lines used. In addition, 
the PTZ and thioxanthene chemosensitizers were equally or slightly more toxic to each of 
the sensitive cell lines when compared to their MDR sublines (1- to 3-fold); no MDR line 
was collaterally sensitive to any of the chemosensitizers. The concentration of 
chemosensitizers necessary to inhibit growth by less than 10% was also determined for each 
cell line (data not shown), and these ICjo doses used for experiments combining 
chemosensitizers with cytotoxic drugs. 5 pM concentrations were found to be appropriate 
for all four chemosensitizers in each cell line except the P388 lines, in which 1 jiM PTZ and 
thioxanthenes were used, and the NLH 3T3 lines, in which up to 12 pM chemosensitizer 
could be used without significant toxicity. 
2. Relative Resistance and Cross-Resistance of Cell Lines to Cytotoxic 
Drugs 
Table 3-2 shows the IC50 values for the inhibition of cell growth by several different 
cytotoxic drugs in each of the cell lines, and the calculated degree of resistance (relative 
resistance) displayed to each drug. As can be seen, each of the resistant sublines displayed 
a typical MDR phenotype, with significant cross-resistance to anthracyclines (doxorubicin, 
mitoxantrone), Vinca alkaloids (vinblastine), and other natural product drugs (colchicine), 
but little or no resistance to bleomycin. Most, but not all, of the MDR cell lines were more 
resistant to the drug used for selection (primary resistance), than to the other drugs tested 
(cross-resistance). For example, MCF-7/MITOX cells were 100-fold resistant to 
mitoxantrone, but only 50-fold, 20-fold and 10-fold resistant to doxorubicin, colchicine, 
and bleomycin, respectively. Conversely, MCF-7/DOX cells were 200-fold resistant to the 
selecting agent doxorubicin, but displayed greater cross-resistance (400-fold) to colchicine. 




3. Reversal of Multidrug Resistance by Chemosensitizers 
To compare the effects of each of the chemosensitizers for reversing primary and cross- 
resistance to cytotoxic drugs in sensitive and MDR cells, the IC^'s for cells to each drug in 
the absence and presence of nontoxic, equimolar concentrations were determined, and MDR 
Ratios calculated for each. Table 3-3 shows the fold reversal of resistance (MDR Ratio) of 
each cell line to different drugs caused by c/s-flupenthixol, rra«5-flupenthixol, 
fluphenazine and verapamil. None of the chemosensitizers displayed significant activity in 
potentiating the effect of any of the cytotoxic drugs tested in the sensitive cell lines, MCF-7, 
KB-3-1, P388 or NIH 3T3, except for verapamil plus doxorubicin in P388 cells (MDR 
Ratio = 2.3), and fluphenazine and vinblastine in MCF-7 cells (MDR Ratio = 2.0). 
Similarly, the chemosensitizers did not alter the primary resistance to mitoxantrone or cross¬ 
resistance to doxorubicin and vinblastine in the non-P-gp expressing MDR cell line MCF- 
7/MITOX, with 5 pM of each resulting in MDR Ratios = 1.0. 
All four chemosensitizers were effective in partially reversing primary or cross¬ 
resistance in the remaining, well-characterized MDR cell lines, with fr<2/is-flupenthixol 
possessing the greatest activity. For example, in the MCF-7/DOX, KB-V1 and P388/DOX 
MDR cells, rrans-flupenthixol caused an 8- to 36-fold, 20- to 40-fold, and 4- to 7-fold 
reversal, respectively, of cell resistance to doxorubicin, vinblastine and colchicine. Trans- 
flupenthixol was stereospecific in its anti-MDR effects, since in these three MDR cell lines, 
equimolar concentrations of frarcs-flupenthixol caused 1.5- to 2-fold greater antagonism of 
MDR than its stereoisomer, c/s-flupenthixol, and 2- to 12-fold greater antagonism than its 
PTZ homolog fluphenazine. In addition, rram,-flupenthixol was up to 3-fold more effective 
for reversing MDR than the chemosensitizer verapamil. Conversely, in the colchicine 
selected 3T3/MDR1 cell line, rra/is-flupenthixol was a 1- to 2-fold less effective 
chemosensitizer than its isomer c/j-flupenthixol, or verapamil, though still significantly 
more effective than fluphenazine. However, both thioxanthenes and verapamil were 
extremely effective at reversing MDR in this mdr 1 transfected line, with nontoxic 
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concentrations of 12 |iM causing approximately 40-fold reversal of the 100-fold colchicine 
resistance, and fully reversing the 20-fold doxorubicin cross-resistance to doxorubicin. 
Finally, the thioxanthenes and verapamil caused a greater reversal of resistance to 
doxorubicin or vinblastine than colchicine in those cells selected with either of the former 
drugs (MCF-7/DOX and KB-V1), while the chemosensitizers caused a significantly greater 
potentiation of colchicine than doxorubicin in the 3T3/MDR1 colchicine selected cells. 
4. Drug Accumulation Studies 
It was next determined whether the difference in the anti-MDR activity of the 
thioxanthenes could be attributed to differences in their cellular accumulation. After a 3 hour 
incubation in 3 - 100 pM concentrations of thioxanthenes, cell associated cis- and trans- 
flupenthixol concentrations (nmoles/106 cells) were 1.29 ±0.11 versus 0.41 ± 0.04 at 3 
pM (P<0.001), 4.34 ± 0.65 versus 2.22 ± 0.16 at 10 pM (P<0.001), and 14.52 ± 0.66 
versus 12.2 ± 330 at 0.66 pM (P >0.1). 
The effect of both equitoxic and equimolar concentrations of chemosensitizers on the 
accumulation of doxorubicin in both sensitive and MDR cell lines was also studied. Figure 
3-1 demonstrates that after a 3 hour incubation in 10 pM doxorubicin, by which time 
steady-state concentrations were reached, MCF-7/DOX cells accumulated approximately 10- 
fold less doxorubicin than the sensitive cell line. The addition of 3 pM cis- or 6 pM trans- 
flupenthixol (IC^q concentrations) had no significant effect on the accumulation of 
doxorubicin in the sensitive MCF-7 line. However, they increased by 2.4 and 4.6-fold, 
respectively, the accumulation of doxorubicin in the resistant MCF-7/DOX cells. 
Similarly, Figure 3-2 shows that after a 3 hour incubation with equimolar (5 pM) 
concentrations of c/s-flupenthixol, rranj'-flupenthixol or verapamil, rra«5-flupenthixol 
caused a 5-fold increase in doxorubicin accumulation, while ciT-flupenthixol caused a 3- 
fold and verapamil caused a 4-fold increase, in MCF-7/DOX cells. 

96 
5. Isobologram Analyses 
To rigorously study the magnitude of potentiation of doxorubicin by trans- 
flupenthixol, their multiple drug effects were studied by isobologram analysis. Figure 3-3 
demonstrates the synergistic action of doxorubicin and rra/is-flupenthixol, evident by 
comparing the actual concentrations necessary for 50% inhibition of cell growth to those 
predicted for drugs which are simply additive. 
To determine whether mznj-flupenthixol and verapamil are additive, competitive, or 
synergistic in their ability to potentiate the cytotoxicity of doxorubicin in MCF-7/DOX cells, 
a series of dose-response curves to doxorubicin were performed in the presence of various 
combinations of the two chemosensitizers. Figure 3-4 shows a plot of the concentrations 
that either alone or in combination caused a 15-fold reversal of doxorubicin resistance in 
these cells. As can been seen, frarcs-flupenthixol and verapamil were exactly additive in 
their chemosensitizing effects. 
6. Potency of Chemosensitizers 
To compare the anti-MDR potency of rra/u-flupenthixol versus verapamil, dose- 
response curves to doxorubicin in the absence and presence of various concentrations of 
individual chemosensitizers were performed. Figure 3-5 shows that while both 
chemosensitizers displayed linearly increasing anti-MDR effects with increasing doses, 
rra/u-flupenthixol was 2- to 3-fold more potent than verapamil in producing equivalent 
effects. For example, to cause a 15-fold reversal of MDR (MDR Ratio = 15), 5 fiM trans- 
flupenthixol versus 12 jiM verapamil were necessary. 
7. Effect of Thioxanthenes on Calmodulin and Protein Kinase C 
Since PTZs and thioxanthenes are both known to antagonize CaM, the effect of cis- 
flupenthixol, rra/u-flupenthixol and fluphenazine as inhibitors of a CaM-dependent form of 
cyclic nucleotide phosphodiesterase were determined and compared to their 
chemosensitizing effects. Table 3-4 showss that c/j-flupenthixol, tranj-flupenthixol and 
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chemosensitizing effects. Table 3-4 showss that c/T-flupenthixol, frarcs-flupenthixol and 
fluphenazine were all potent CaM antagonists. However, their anti-CaM activity did not 
correlate with their effects on MDR. Specifically, while rra/is-flupenthixol was a slightly 
more potent CaM antagonist than m-flupenthixol (IC50 = 7 pM versus 11 pM), both were 
slightly less potent than fluphenazine (IC50 = 5 pM), a far less effective chemosensitizers 
than either thioxanthene. 
Cis- and /ra/ij-flupenthixol were also examined for their effect on the inhibition of 
PKC. Table 3-4 shows that the thioxanthenes were extremely similar in their anti-PKC 
effect, with the trans-isomer being slightly more potent (1.4-fold). 
D. Discussion 
The results presented in this chapter characterize the stereospecific effects of trans- 
flupenthixol and several related chemosensitizers on MDR, and suggest that the 
thioxanthene class of MDR antagonist mediates this effect through P-gp. Specifically, it 
was found that the chemosensitizing activity of the thioxanthenes, verapamil, and to a lesser 
extent fluphenazine, were limited to ’classic' MDR cell lines. For example, trans- 
flupenthixol caused significant reversal of primary and cross-resistance in MCF-7/DOX, 
KB-VI, P388/DOX, and 3T3/MDR1 cell lines, each known to display decreased drug 
accumulation and an increased expression of P-gp or mdr 1 mRNA (56, 64, 71, 206, 235). 
However, neither rra/is-flupenthixol, nor the other chemosensitizers tested, caused any 
potentiation of drug toxicity in the MCF-7/MITOX multiple drug resistant cell line. It is 
interesting to note that while these cells display decreased drug accumulation and cross- 
resistance to a typical MDR spectrum of drugs, extensive studies utilizing Western blot 
analysis with several different monoclonal antibodies to P-gp and Northern blotting with 
cDNA probes to the mdrl gene have failed to detect any expression of P-gp mRNA or 
protein.1 The mechanism of drug resistance is as yet unclear for these cells, although an 
increased amount of a 150 kDa membrane protein has been identified by gel electrophoresis 
Gallon, W„ personal communication. 
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The chemosensitizers studied did not significantly modulate the toxicity of drugs nor 
cause an increased accumulation of doxorubicin in sensitive, parental cell lines. These 
results together suggest that the chemosensitizing effects of the thioxanthenes and verapamil 
were mediated through a target(s) overexpressed in MDR cells, such as the putative drug 
efflux pump, P-gp (38). As discussed in Chapter I, a current hypothesis regarding the 
mechanism by which MDR cells reduce cellular accumulation of anthracyclines and other 
drugs is through the increased expression of this plasma membrane glycoprotein in MDR 
cells (27), and that compounds which antagonize MDR compete with cytotoxic drugs for 
specific drug-binding sites on the protein (44). Though calcium channel blockers such as 
verapamil can inhibit binding of a photoaffinity labelled vinblastine analog to P- 
glycoprotein, PTZs were far less effective (2). The failure of PTZs to block vinblastine 
binding to P-glycoprotein does not rule out the interaction or chemosensitizers with other 
sites on the protein. For example, Hamada and Tsuruo have recently demonstrated ATPase 
activity of the molecule (93), and shown that agents which inhibit active drug efflux, such 
as trifluoperazine and verapamil, cause an increase in P-glycoprotein ATPase activity, while 
doxorubicin and vincristine, agents which may interact with the putative drug-binding 
region, do not affect this ATPase activity (92). Alternatively, Center (32) demonstrated that 
trifluoperazine increased phosphorylation of this protein in MDR Chinese hamster lung cells 
and enhanced doxorubicin accumulation and cytotoxicity, suggesting the PTZs may 
indirectly affect P-gp. 
However, the remarkably similar effects of frans-flupenthixol and verapamil in each of 
the sensitive and MDR cell lines strongly suggests that the thioxanthenes may share a 
common target with verapamil for reversing MDR . In support of this, it was shown in 
Figure 3-4 that rrans'-flupenthixol and verapamil were exactly additive in their in vitro anti- 
MDR effect in MCF-7/DOX cells, implicating a common pharmacologic mechanism. 
Therefore, the decreased P-gp binding shown for PTZs (2) may actually explain the relative 
lack of potency and low MDR Ratios found for fluphenazine, trifluoperazine, and the many 
other PTZs tested for chemosensitizing activity in Chapter II, rather than implicating an 
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alternative mechanisms of reversal. 
It will be critical to the understanding of the thioxanthenes' mechanism of action and 
stereospecificity in antagonizing MDR, to study their interaction with P-gp. In fact, efforts 
are currently in progress to determine the ability of rran^-flupenthixol, m-flupenthixol and 
fluphenazine to competitively inhibit the binding of photoactivatable vinblastine analogs to 
KB-V1 membrane P-gp, similar to previous studies with verapamil (44). Also, 
radiolabelled [-H]-trans-flupenthixol has recently been synthesized, and studies measuring 
its specificity and saturability binding to MDR KB-V1 membrane vesicle preparations will 
commence shortly. 
It is extremely interesting that while rr^Azr-flupenthixol was a more potent and effective 
chemosensitizer than its stereoisomer, c/s-flupenthixol, in each of the in vitro (MCF- 
7/DOX, KB-V1) or in vivo (P388/DOX) derived MDR cell lines, rrans-flupenthixol was 
equal, or even less effective than ds-flupenthixol at antagonizing MDR in the 3T3/MDR1 
line (Table 3-3). The fact that this particular fibroblast line transfected with an mdr 1 gene 
expression vector should theoretically display a particularly 'pure' form of P-gp mediated 
MDR suggests several possible explanations. First, Roninson's group has elegantly shown 
that mutations in the mdr\ gene caused by colchicine selection result in a single amino acid 
change at position 185 of the transcribed P-gp protein, and that this genetic event is 
associated with a preferential increase in resistance to colchicine, possibly due to alterations 
in the affinity of P-gp drug binding sites (40). Since the 3T3/MDR1 transfected cell line 
used in the present studies was also selected with colchicine, in contrast to the other MDR 
cell lines used (selected with doxorubicin or vinblastine), it is intriguing to speculate that the 
apparent loss or reversal of flupenthixol's stereospecificity for antagonism of MDR may 
also be due to this mutation, thereby altering the affinity of a chemosensitizer and/or drug 
binding domain for cis- versus rra^-flupenthixol. This may also explain why all the 
chemosensitizers caused a greater reversal of colchicine resistance than doxorubicin or 
vinblastine resistance in this cell line alone. Indeed, if this hypothesis is true, it may be 
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possible to target individual MDR subtypes, defined by their particular pattern of cross- 
resistance and mdrl sequence, with chemosensitizers that preferentially bind to that P-gp 
molecule. 
Alternatively, cis- and rranj-flupenthixol may possess equivalent effects on P-gp in all 
MDR cell lines, but have stereospecific effects on addiuonal cellular targets which regulate 
or modulate MDR in certain cell lines. This hypothesis could explain rnartf-flupenthixol's 
loss of stereospecificity in the genetically manipulated mdrl transfectant, a line which may 
lack regulatory mechanisms or important co-induced gene products common to the other 
MDR cell lines. To begin exploring this possibility, the effect of thioxanthenes and PTZs 
on several cellular enzymes which may have a regulatory role in MDR was examined. 
Similar to previous reports (161), cis- and rranj-flupenthixol were found to be nearly 
identical antagonists of CaM, and were less potent than their PTZ homolog, fluphenazine 
(Figure 3-6) This data supports that presented in Chapter II demonstrating the lack of 
correlation between antagonism of CaM and reversal of MDR for PTZs. 
Several groups have suggested that PKC may play an important role in MDR (58, 
105). Drugs that stimulate PKC, such as the phorbol esters, produce increased levels of 
anthracycline resistance in MCF-7/DOX cells, and induce a MDR-like phenotype in 
sensitive MCF-7 cells (59). These effects were reversed by PTZs at concentrations similar 
to those used in the present study. Furthermore, MCF-7/DOX cells, in particular, have up to 
a 15-fold increased level of PKC acuvity compared to the parental MCF-7 cells (59, 166). 
In isolated systems, the concentrations of PTZs required to inhibit PKC have been reported 
to be many fold higher than those presently found sufficient to antagonize MDR. For 
example, in one study, the ICsq's for inhibition of PKC by trifluoperazine, chlorpromazine 
and fluphenazine were 38 - 50 |iM, 59 - 84 pM, and 78 - 114 pM, respectively (200), 10- 
to 50-fold greater than those found to antagonize MDR. Many thioxanthenes are particularly 
poor inhibitors of PKC, with IC5q's in the millimolar range reported (200), though the PKC 
inhibitory activity of cis- or rrarts-flupenthixol have not been previously studied. Figure 
3-7 demonstrates that both flupenthixol isomers are potent inhibitors of PKC purified from 
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3-7 demonstrates that both flupenthixol isomers are potent inhibitors of PKC purified from 
MCF-7/DOX cells. While rram'-flupenthixol is slightly more potent for this effect, it seems 
unlikely that the small difference (1.4-fold) can adequately explain their differences in 
chemosensitizing activity in this cell line (3-fold). Thus, while the activation and inhibition 
of PKC offers an attractive hypothesis for the modulation of MDR, it appears that the anti- 
MDR effects of the PTZs and thioxanthenes are not likely to be mediated solely through this 
enzyme. 
Another cellular enzyme of particular relevance to the mechanism of MDR is 
glutathione-S-transferase, shown to be elevated in MCF-7/DOX cells (12). Recent 
evidence has shown that selectively reducing glutathione levels in MCF-7/DOX cells with 
buthionine sulfoximine leads to dramatically increased cellular verapamil toxicity, though 
causes no change in the sensitivity of cells to rran^-flupenthixol.2 Therefore, it appears 
that GST or the GSH redox system may be a target mediating verapamil, but not trans- 
flupenthixol, toxicity and/or chemosensitizing effect in MDR cells. Supporting this is 
preliminary data showing that rrj/w-flupenthixol does not sensitize MCF-7 cells transfected 
with a GSTji expression vector to doxorubicin.3 
Finally, a simple explanation for the differences in anti-MDR activity observed for the 
thioxanthene stereoisomers would be differences in their cellular accumulation and therefore 
differences in access to intracellular targets. However, MDR cells actually accumulate 
significantly more cis- than rrans-flupenthixol at effective anti-MDR doses (3 - 10 jiM), 
the opposite of what would be expected if their potency as antagonists of MDR reflected 
differences in their intracellular accumulation. This implies that the difference in anti-MDR 
activity between these stereoisomeric thioxanthenes is indeed due to differences in their 
ability to interact with a unique cellular target(s). Since the most potent anti-MDR agent 
studied, rrans-flupenthixol, reduced the 10-fold difference in doxorubicin accumulation 
2Ford, J.M. and W.N. Hait, manuscript in preparation. 
3Ford, J.M., J.A. Moscow, K.H. Cowan, and W.N. Hait, manuscript in preparation. 
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chemotherapeutic drug efflux. However, because of the many cellular effects of the PTZs 
and thioxanthenes, it is possible these agents exert their effect through more than one 
mechanism. 
In summary, rrans-flupenthixol was a potent and effective chemosensitizer in each of 
the MDR cell lines studied, and appeared to function through a direct or indirect modulation 
or inhibition of P-gp function. 7><2AL5'-flupenthixors 2- to 3-fold greater potency and 1- to 
3-fold greater efficacy than verapamil (Figure 3-5), along with its previously discussed lack 
of known clinical activity or side effects (Section HD), indicate that future studies of the in 
vivo toxicity and efficacy of rraAis-flupenthixol in combination with doxorubicin and other 
chemotherapeutic agents are warranted to elucidate the potential of this drug for clinical use 




Inhibition of Cellular Proliferation by Chemosensitizers Alone 
IC™ (uM) Chemosensitizers 
Cell Line cL-FPT trans-FPT FLU VRP 
MCF-7 8 9 18 100 
MCF-7/DOX 24 25 23 200 
MCF-7/MITOX 18 18 20 200 
KB-3-1 15 15 15 35 
KB-VI 32 17 32 35 
P388 1.4 0.8 0.8 12 
P388/DOX 0.9 0.6 1.2 12 
NIH 3T3 30 30 60 70 
3T3/MDR1 40 20 60 40 
Inhibition of cell growth was determined by exposing cells to 0 - 100 jiM cL-flupenthixol 
(c/s-FPT), rrans-flupenthixol {trans-FPT), flupenazine (FLU) or verapamil (VER) for 48 
to 72 hours. IC50 is the mean concentration that produced 50% inhibition of cell growth 
compared to vehicle-treated controls, as described in Materials and Methods. All values 





Relative Resistance of Cells to Cytotoxic Drugs 
Cell Line 
ICcn (uM) and Relative Resistance_ 
DOX VLB COLCH MITO BLEO 
MCF-7 .06 (1) .001 (1) .005 (1) 1.0(1) 15 (1) 
MCF-7/DOX 12 (200) 0.1 (100) 2 (400) 20 (20) 15 (1) 
MCF-7/MITOX 3 (50) .03 (30) 0.1 (20) 100(100) 150(10) 
KB-3-1 0.3 (1) .002 (1) .018 (1) 0.2(1) 100 (1) 
KB-V1 60 (200) 1 (500) 3 (166) 4(20) 100 (1) 
P388 .01 (1) .002 (1) .0013 (1) 1 0) 
P388/DOX 1 (100) .04 (20) .016 (12) 1 0) 
NM 3T3 0.5 (1) •05 (1) 
3T3/MDR1 10 (20) 5 (100) 
Inhibition of cell growth was determined by exposing cells to various concentrations of 
doxorubicin (DOX), vinblastine (VLB), colchicine (COLCH), mitoxantrone (MITO) or 
bleomycin (BLEO) for 48 to 72 hours. IC50 is the mean concentration that produced 50% 
inhibition of cell growth compared to vehicle-treated controls, as described in Materials and 
Methods. The relative resistance of each cell line to different drugs was calculated by 
dividing the IC50 of a MDR cell line to a drug by the IC50 of its parental drug-sensitive cell 
line to the same drug. All values represent the mean of two to three separate experiments; 




Reversal of Multidrug Resistance by Chemosensitizers 
Cell Line Drug [CS] (fiM) 
MDR Ratio 
cB-FPT trans-FPT FLU VRP 
MCF-7 DOX 5 1.0 1.0 1.0 1.0 
VLB 5 1.1 1.6 1.3 2.0 
MITO 5 1.5 1.7 1.0 1.0 
COLCH 5 1.1 1.0 1.0 1.0 
MCF-7/DOX DOX 5 7 15 13 3 
VLB 5 25 36 33 20 
COLCH 5 5 8 4 1.3 
MCF-7/MIT0X MITO 5 1.0 1.0 1.0 1.0 
DOX 5 1.0 1.0 1.0 1.0 
VLB 5 1.0 1.0 1.0 1.0 
KB-3-1 VLB 5 1.1 1.2 1.7 1.4 
DOX 5 1.0 1.0 1.0 1.0 
COLCH 5 1.1 1.0 1.1 1.2 
KB-V1 VLB 5 20 40 15 10 
DOX 5 20 35 30 3 
COLCH 5 17 20 20 4 
P388 DOX 1 1.4 1.0 2.3 1.7 
VLB 1 1.0 1.0 1.0 1.0 
P388/DOX DOX 1 5 7 6 2 
VLB 1 3 4 ND 3 
NIH 3T3 COLCH 5 1.2 1.0 1.0 1.0 
DOX 5 1.0 1.0 1.0 1.0 
3T3/MDR1 COLCH 5 10 10 20 3 
COLCH 12 40 37 43 10 
DOX 5 13 14 15 5 
DOX 12 36 20 40 13 
Cells were exposed to various concentrations of doxorubicin (DOX), vinblastine (VLB), colchicine 
(COLCH) or mitoxantrone (MITO), in the absence or presence of cri-flupenthixol (cz's-FPT), trans- 
flupenthixol (trans-¥PT), flupenenazine (FLU) or verapamil (VRP) at concentrations that alone produced < 
10% inhibition of cell growth ([CS]). Each MDR Ratio is the IC50 for cytotoxic drug alone divided by the 
IC50 for drug in the presence of chemosensitizer, and was derived as described in Materials and Methods. 




Inhibition of Calmodulin and Protein Kinase C by Chemosensitizers 
IC5n (uM) Chemosensitizers 
Chemosensitizer CaM PKC 
m-Flupenthixol 11 38 
rraflj-Flupenthixol 7 28 
Fluphenazine 5 
Antagonism of CaM by chemosensitizers was determined by their ability to inhibit by 50% 
the activition of a CaM-dependent form of cyclic nucleotide phosphodiesterase, as 
described in Materials and Methods. Effect of thioxanthenes on PKC was determined by 
their ability to inhibity by 50% the activity of enzyme purified from MCF-7/DOX cells 
approximately 15-fold, as described in Materials and Methods. 
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Figure 3-1. Effect of thioxanthene isomers on the accumulation of doxorubicin in 
sensitive MCF-7 (open symbols) and MDR MCF-7/DOX cells (closed symbols). Cells 
were incubated with 10 jiM doxorubucin in the absence (circles) or presence of 3 |iM cis- 
flupenthixol (triangles) or 6 pM /rarcs-flupenthixol (squares), equitoxic concentrations 
that alone produced 10% inhibition of cell growth. Cell associated doxorubicin at various 
times after the addition of drug was determined spectrofluorometrically as described in 
Materials and Methods. Values are means from triplicate determinations, with standard 





















Chemosensftizer (5 pM) 
Figure 3-2. Effect of equimolar concentrations of chemosensitizers on the accumulation 
of doxorubicin in sensitive MCF-7 and MDR MCF-7/DOX cells. Cells were incubated for 
3 hours with 10 |iM doxorubucin in the absence (No CS) or presence of 5 |iM cis- 
flupenthixol (c/s-FPT), rrans-flupenthixol (rrani'-FPT) or verapamil (VRP). Cell 
associated doxorubicin (pmoles/106 cells) was determined spectrofluorometrically as 














trans -Flupenthixol (pM) 
Figure 3-3. Isobologram analysis of the interaction between doxorubicin and 
/r<3rts-flupenthixol. IC5Q isobole for inhibition of MCF-7/DOX cell growth 
by various combinations of doxorubicin andtrarts-flupenthixol (points) was 
determined by exposing cells to drug combinationsfor 48 hours as described in 
Materials and Methods. The straightline represents the predicted K50 isobole 
for drugs which haveadditive antiproliferative effects. 12 pM doxorubicin and 
25 pM tran^-flupenthixol alone caused 50% inhibition of cell growth. Each 
point represents the mean value of quadruplicate determinations whichliffered 














Figure 3-4. MDR isobologram analysis of the chemosensitizing interaction between 
verapamil and rra/u-flupenthixol. MDR isobole for 15-fold reversal of MCF-7/DOX 
doxorubicin resistance by various combinations of verapamil and rrans-flupenthixol 
(squares) was determined by exposing cells to 0 - 100 fiM doxorubicin plus combinations 
of chemosensitizers for 48 hours and identifying those combinations that together caused 
an MDR Ratio =15. The straight line represents the predicted MDR isobole for modifiers 
which have additive chemosensitizing effects. 10 p.M verapamil and 5 |iM trans- 
flupenthixol alone caused an MDR Ratio = 15. Each point represents the mean value of 




Figure 3-5. Potency of chemosensitizing activity formz/is-flupenthixol and verapamil in 
MDR cells. MCF-7/DOX cells were exposed to 0 - 100 |iM doxorubicin for 48 hours in 
the absence vesus presence of various concentrations of each chemosensitizer. Inhibition 
of cell growth and MDR Ratios were determined as described in Materials and Methods. 
Each point represents the fold reversal of MDR caused by that concentration of 





IN VIVO EFFECT OF 77L4 VS-FLUPENTHIXOL 
ON MULTIDRUG RESISTANCE 
A. Introduction 
The results presented in Chapters II and in demonstrate that tranj-flupenthixol is a 
potent chemosensitizer in MDR cell lines in vitro, equal or more effective than verapamil, 
and much more effective than any of the previously or currently studied PTZs. While 
verapamil has been shown by several investigators to potentiate the effects of both 
doxorubicin and vinblastine in vivo in MDR mouse tumors (Table 1-5), the potent 
vasoactive effects of this drug have severely limited its potential anti-MDR use in clinical 
trials in humans (165). Similarly, the use of the active antipsychotic drug trifluoperazine as 
a chemosensitizer in humans has been limited by CNS side effects associated with its 
neuroleptic activity (88, 149). Conversely, rrarts-flupenthixol has been shown to be 
inactive compared to its c/s-isomer as an antipsychotic agent in humans, and has not been 
associated with any notable side effects at clinically tested doses (116). In fact, in in vivo 
mouse studies, rra^^-flupenthixol has been shown to be 100- to 1000-fold less potent in a 
number of standard assays used to measure the side effects and neuroleptic potential of 
drugs, such as inhibition of spontaneous motor activity, cataleptic reaction, ptosis-inducing 
effects, and inhibition of apomorphine and amphetamine induced stereotypy (157, 158). In 
addition, in vitro studies demonstrate that [3H]-rra/ty-flupenthixol completely lacks specific 
dopamine receptor binding activity (104), in contrast to the highly specific, potent dopamine 
D1 and D2 receptor binding activity displayed by [3H]-ci\y-flupenthixol (103). Also, 
trani'-flupenthixol has little or no a-adrenergic, P-adrenergic or 5-HTj blocking activity 
(104). 
Therefore, the preclinical and clinical data reported for fraAW-flupenthixol suggest it 
may be an excellent candidate for the in vivo clinical modulation of MDR. To begin 
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studying the in vivo activity of rra/u-flupenthixol as a chemosensitizer, the P388 murine 
ascites tumor model was chosen. Using P388 and P388/DOX-tumor bearing mice, the 
toxicity of tra^-flupenthixol and its effect on survival and cellular drug accumulation alone 
and in combination with doxorubicin was studied. 
B . Materials and Methods 
1. Drugs 
Doxorubicin was obtained from Sigma, 7>fl/ty-flupenthixol was generously supplied 
by Dr. John Hyttel (H. Lundbeck, Copenhagen, Denmark). Both drugs were freshly 
dissolved in distilled water immediately before each use. 
2. Tumor Cells 
P388 sensitive and P388/DOX cells (from Dr. Ram Ganapathi) were maintained in 
exponential growth in suspension culture in 75 cm2 Coming tissue culture flasks in RPMI 
1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 10 |iM 2- 
mercaptoethanol in a humidified atmosphere of 5% CO2 and 95% air. The P388/DOX cells 
were approximately 100-fold resistant to doxorubicin, and maintained a stable MDR 
phenotype while grown in drug-free medium for periods of up to 3 months, after which 
they were discarded. Cell lines were routinely tested and found to be free of contamination 
by mycoplasma or fungi. 
3. Toxicity of Trans-Flupentliixol in Mice 
To determine the chronic toxicity of daily i.p. rrans-flupenthixol administration, 5 to 6 
week old female Swiss Webster Mice (Jackson Laboratories, Bar Harbor, Maine) weighing 
18-22 mg were divided into 4 groups of 5 mice each. Tranj-flupenthixol was dissolved 
in small amounts of disdlled water and diluted with physiologic saline. Drug was injected 
i.p. daily for 7 days at doses of 50 to 200 mg/kg in 0.1 ml volumes. Mice were weighed 
daily, food and water consumption and urine and stool production noted, and mortality data 
collected daily. LD5q's were determined by the method of Litchfield and Wilcoxon (139). 
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4. Evaluation of Antitumor Activity 
Exponentially growing P388 and P388/DOX cells were washed once in PBS, and 1 x 
106 cells in 0.1 ml PBS inoculated i.p. into 8 to 10 week old female DBA/2J mice (Jackson 
Laboratories), weighing 19-23 gm each. Mice were divided into groups of 5 each, and 
drugs were administered daily for 10 days, starting 1 day after tumor implantation, by the 
method of Tsuruo (227). Accordingly, rranj-flupenthixol (50 mg/kg) and/or doxorubicin 
(1-3 mg/kg), both dissolved in saline, were injected i.p. into mice in 0.1 ml volumes, with 
rrans-flupenthixol treatment preceding doxorubicin. Response to therapy was evaluated by 
measuring the mean survival time for each group of mice and determining the percent 
increase in life span (%ILS). 
5. Pharmacokinetic Studies 
To determine the accumulation of doxorubicin and rrans-flupenthixol in ascites tumor 
cells in vivo, 2 groups of 5 DBA/2J mice each were inoculated i.p. with 1 x 106 P388 
sensitive or P388/DOX cells. Ascites cells were allowed to grow without drug treatment for 
8 days, at which time tumor bearing mice were injected i.p. with 50 mg/kg trans- 
flupenthixol and/or 1-3 mg/kg doxorubicin in 0.1 ml saline. One hour after drug 
treatment, mice were etherized, and sacrificed by cervical dislocation. Ascites was removed 
by i.p. injection and withdrawal of 3 ml PBS. Cellular drug levels were determined by 
methods similar to those described in Chapter III. Briefly, cells were kept on ice and 
rapidly washed two times in cold PBS by centrifugation at 100 x g. Cells were resuspended 
in PBS, counted electronically (Coulter, Hialeh, FL), and again pelleted by centrifugation. 
Cells were resuspended in 2 ml of 0.3 N HC1 in 50% ethanol, and sonicated for 10 pulses at 
200 watt seconds with a Tekmar cell sonicator, followed by centrifugation for 60 sec at 
11,000 x g using an Eppendorf 5415 microcentrifuge. Cell supernatants were removed and 
assayed spectrofluorometrically for doxorubicin using excitation and emission wavelengths 
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of 475 nm and 585 nm, respectively. Blank, control values were determined by similarly 
assaying ascites cell extracts from a mouse which did not receive drug treatment. 
C. Results 
1. Toxicity of Trans-Flupenthixol 
The toxic effects of chronic frartf-flupenthixol administration to mice were determined 
for a one week period. Figure 4-1 shows the effects of 50 to 100 mg/kg daily i.p. trans- 
flupenthixol on the survival of mice. None of these dosages proved to be acutely toxic, 
with 100% survival after the first day of treatment. Doses greater than 50 mg/kg were 
chronically toxic, causing death of all mice by 7 days of daily treatment Doses of 50 mg/kg 
rrans-flupenthixol daily for 7 days was not toxic to mice, as assessed by survival (100%) 
and weight loss (0 %). 100 to 200 mg/kg rrans-flupenthixol also caused sedation, 
diarrhea, and loss of smoothness of hair. 
Since no mice treated with 50 mg/kg rrans-flupenthixol died after 7 days, in contrast to 
100% of mice treated with the higher doses tested, the LD50 for this 7 day dosing regimen is 
difficult to determine. (The LD50 after a 3 day treatment was 130 mg/kg, for instance). 
However, a dose of 50 mg/kg for 7 days appeared to be the maximally tolerated dose in 
Figure 4-1. 
2. In Vivo Antiproliferative Effect of Trans-Flupenthixol and 
Doxorubicin 
The effects of a 10 day course of 50 mg/kg rranj-flupenthixol and 1-3 mg/kg 
doxorubicin individually, or in combination, on survival in sensitive or MDR P388-tumor 
bearing mice is shown in Table 4-1. Treatment with 1 mg/kg doxorubicin caused a 34% 
ILS in the doxorubicin-sensitive P388-tumor bearing mice, while 1 or 3 mg/kg doxorubicin 
did not significantly alter the median life span of P388/DOX-tumor bearing mice compared 
to control, untreated mice. 
However, doses of 50 mg/kg rruns-flupenthixol alone proved toxic to both groups of 
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tumor bearing mice, causing a 20% decrease in average length of survival. Furthermore, 
rra^-flupenthixol plus doxorubicin displayed significant combined toxicity, regardless of 
tumor type, causing a 31 to 42% decreased survival time in mice than untreated controls. 
3. Pharmacokinetic Studies 
To determine if the doses of chemosensitizer used in this study were able to reverse the 
doxorubicin accumulation defect of MDR cells in vivo, cellular doxorubicin levels were 
determined for ascites cells in mice one hour after treatment with rrans-flupenthixol and/or 
doxorubicin. Table 4-2 shows that when treated with 1 mg/kg doxorubicin alone, 
P388/DOX cells accumulate approximately 8-fold less doxorubicin than the parental cells 
(40.4 versus 344.8 pmoles/106 cells). However, treatment of the MDR tumor bearing mice 
with 50 mg/kg rrans-flupenthixol caused a 28% and 62% increase in doxorubicin 
accumulation for 1 mg/kg and 3 mg/kg doxorubicin, respectively. Treatment with 3 mg/kg 
doxorubicin plus 50 mg/kg rrans-flupenthixol in P388/DOX-tumor bearing cells caused 
nearly equivalent levels of cellular doxorubicin as in the sensitive-tumor cell bearing mice 
given similar doses of drug (301.6 versus 328.8 pmoles/106 cells). Tra/u-flupenthixol did 
not cause an increase in doxorubicin accumulation in P388 sensitive cells. 
D. Discussion 
This chapter presents preliminary results from in vivo studies designed to determine 
the toxicity, appropriate dosage and scheduling, and possible anti-MDR activity of trans- 
flupenthixol. It was first determined that daily i.p. treatment of healthy mice for one week 
with rrans-flupenthixol was toxic for doses > 100 mg/kg, but caused no deaths in animals 
which received 50 mg/kg (Figure 4-1). The only previous toxicological testing of i.p. 
rrarts-flupenthixol in mice found an LD50 for acute toxicity from single i.p. injections of 
270 ± 32 mg/kg,1 while the LD50 (i.p.) for racemic flupenthixol was reported as 150 
mg/kg (237). 
1 Hyttel, J., personal communication. 
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While 50 mg/kg daily i.p. rrans-flupenthixol was well tolerated in healthy mice, for 
tumor bearing mice this dose proved to be toxic, causing a 20% decrease in survival. 
Furthermore 50 mg/kg rrans-flupenthixol in combination with otherwise non-toxic doses 
doxorubicin showed greatly enhanced toxicity in tumor bearing mice (Table 4-2) than either 
drug alone, or no treatment. 
Unfortunately, due to the intrinsic toxicity of rra/iy-flupenthixol, and to the combined 
toxicity of rrarts-flupenthixol plus doxorubicin at the doses tested, the possible anti-tumor 
effects of chemosensitizing therapy with rram^-flupenthixol could not be determined from 
the present results. Additional experiments are therefore in progress with changes in the 
dosage (< 25 mg/kg) and route of administration (i.v., and subcutaneous, slow release 
pellets) of rrans-flupenthixol treatment, to hopefully reduce toxicity and increase available 
concentrations or drug. 
Encouraging results came from pharmacokinetic studies of the alteration in doxorubicin 
accumulation caused by rrarcs-flupenthixol in ascites tumor cells in vivo, however. 
Specifically, while MDR P388/DOX cells accumulated nearly 10-fold less doxorubicin than 
sensitive P388 cells, a single i.p. dose of 50 mg/kg rranj-flupenthixol was clearly sufficient 
to cause up to a 2-fold increase in doxorubicin accumulation in MDR cells, in vivo. Similar 
to in vitro accumulation studies, rrarts-flupenthixol did not cause an increase doxorubicin 
accumulation in the sensitive cells, in vivo. Thus, while the presently studied doses of 
trans-flupenthixol and doxorubicin demonstrated systemic toxicity in mice, they also 
functioned to partially reverse the accumulation defect in MDR cells in vivo. Hopefully, 
reducing the dose of rra/u-flupenthixol will eliminate toxicity but still cause increased 
doxorubicin accumulation in MDR cell in vivo, resulting in an increased %ILS. 
As discussed in Chapter I, there are a number of other mouse tumor models which may 
more realistically reflect clinical MDR tumors in humans. If significant chemosensitizing 
activity is shown for rranj-flupenthixol in combination with doxorubicin in the P388/DOX 
screening model, further studies of the affect of rra/u-flupenthixol plus various cytotoxic 
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drugs or drug combinations on solid tumor growth and drug pharmacokinetics in nude mice 
with transplanted human tumor xenografts such as MCF-7/DOX, or an mdr 1 transfected 
tumor cell line, may provide interesting and clinically useful data. 
While the results from this pilot in vivo murine trial were disappointing due to the 
unexpected toxicides, there is evidence to suggest that franj-flupenthixol may have great 
potential for clinical use as a chemosensitizer. As discussed in Chapter n, clinical trials of 
the antipsychotic effects of thioxanthene isomers have shown rra/u-flupenthixol to 
completely lack dopaminergic activity and extrapyramidal side effects (116). Furthermore, 
sensitive chromatographic and radioimmunoassays have been developed for the 
measurement of tissue and plasma cis- and rrartj-flupenthixol levels for studies of the 
psychopharmacologic effects of thioxanthenes in humans (117, 170, 194) which have 
generated important clinical pharmacokinetics data possibly relevant to their proposed use as 
modulators of tumor resistance. For example, flupenthixol has been shown to undergo 
extensive first-pass hepatic metabolism and to have a high systemic clearance due to its high 
hepatic extraction ratio, with mean systemic availability ranging from 30 - 70% (118). 
Nevertheless, flupenthixol possesses an apparent half-life of elimination of 34 to 36 hours 
due to a large volume of distribution (20 L/kg) (119). Also, flupenthixol's lipophilicity 
results in selective partitioning into tissues (suggesting high tumor tissue levels may be 
possible), making correlations between plasma levels and clinical effects notoriously 
difficult (10). Reported peak plasma levels for cis-flupenthixol treatment (1 mg i.v. or 4 
mg p.o.) have been 3-4 |ig/L ( ~ 7 nmolar) (120), 1000-fold less than concentrations 
necessary for in vitro chemosensitizing activity. However, it is possible that far greater 
doses of martj-flupenthixol may be safely administered to humans, due to its apparent lack 
of clinical activity. In addition, a recent report measuring the steady state levels of cis- and 
f/zms-flupenthixol resulting from 4 to 15 mg daily po doses of a 1:1 mixture of both drugs 
resulted in rra^-flupenthixol levels of up to 20 nmolar, and indicated that 2-fold greater 
rranj-flupenthixol steady state plasma concentrations were achieved in comparison to cis- 
flupenthixol (11). These data suggest that it may be possible to achieve sufficient tissue 
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levels of rr<2rt5-flupenthixol capable of producing anti-MDR activity in human tumors. 
E. Summary and Conclusions 
This thesis has attempted to better define a structural 'pharmacophore' for the reversal 
of MDR, and characterized the in vitro and in vivo chemosensitizing activity of a newly 
described class of anti-MDR agents, and has begun to explore the mechanisms involved in 
the pharmacological reversal of MDR. 
Specifically, systematic structure-activity relationships for the PTZs' ability to reverse 
MDR in a human breast cancer cell line revealed the specific structural features, such as the 
length and type of amino side chain, that in addition to hydrophobicity determined the 
chemosensitizing activity of these drugs. Based on these predictions, the thioxanthene class 
of chemosensitizers was identified, and shown to be potent and stereospecific antagonists of 
MDR. The thioxanthenes cis- and rruns-flupenthixol were further characterized for 
chemosensitizing activity in several in vitro and in vivo MDR tumor cell lines, and shown 
to partially reverse MDR and cause increased cytotoxic drug accumulation in cells which 
overexpress P-gp. Furthermore, the mechanism of chemosensitizing effects of PTZs and 
thioxanthenes was shown unlikely to be due to their known inhibition of CaM and PKC. 
The results presented in this thesis have a number of implications for future basic and 
clinical research in the field of cancer drug resistance. First, based on the structural 
principles derived from the PTZ anti-MDR model, it may be possible to rationally design 
and synthesize novel drugs which possess greater chemosensitizing activity and less toxic 
side effects than those currently known. Also, the identification of thioxanthenes as potent, 
stereospecific chemosensitizers may provide useful pharmacologic probes for exploring the 
biochemical basis of MDR and its reversal. Finally, the preliminary in vivo anti-MDR data 
presented, together with the interesting clinical and pharmacological profile already known 
for rra/ij-flupenthixol, suggest this drug may be a potentially useful candidate for clinical 
trials testing the ability of drugs to modulate tumors resistance in humans. 
In conclusion, a great deal of information has been gathered in the last decade 
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concerning the cellular pharmacology and molecular biology of MDR cell lines in vitro, and 
an understanding of the relevance and mechanism of MDR and P-gp in human tissues and 
tumors in now beginning. The discovery of the chemosensitizer rrans-flupenthixol may 
hopefully assist to further advance the knowledge of the mechanisms of MDR and its 




In Vivo Chemosensitizing Activity of /rarts-FIupenthixo! 
Tumor 
Drugs and Dose (mg/kg) 
Survival 
Days % ILS 
P388/S 
Control 13.0 ± 0.7 0 
DOX(l) 17.4 ± 0.9 +34 
tFPT (50) 10.4 ± 2.1 -20 
DOX (1) + tFPT (50) 7.6 ± 1.5 -42 
P388/DOX 
Control 10.4 ± 1.3 0 
DOX (1) 10.2 ± 0.8 -2 
DOX (3) 9.8 ± 0.4 -6 
tFPT (50) 8.2 ± 2.5 -21 
DOX (1) +tFPT (50) 6.4 ± 2.2 -38 
DOX (3) + tFPT (50) 7.0 ± 0.7 - 31 
Mean survival time in days ( ± S.E.) and percent increase in life span (%ILS) for P388/S 
and P388/DOX-tumor bearing mice (5 mice per condition). 1 x 106 sensitive or MDR cells 
were injected i.p. in adult, female DBA/2J mice on day 0, and drugs given daily from Day 




Effect of /rans-FIupenthixo! on In Vivo Doxorubicin Accumulation 
in Sensitive and MDR Tumor Bearing Mice 
Doxorubicin (pmoIes/106 cells') 
Drugs and Dose (mg/kg) P388 P388/DOX 
tFPT (50) 0.0 0.0 
DOX(l) 344.8 40.4 
DOX (3) ND 185.8 
DOX (1) + tFPT (50) 296.2 51.8 
DOX (3) + tFPT (50) 328.8 301.6 
DBA/2J mice were injected i.p. with 1 x 106 P388 or P388/DOX cells, and received no 
treatment for 8 days. Drugs w'ere injected i.p. in 0.1 ml saline one hour before ascites cells 
were removed and assayed spectrofluometrically for doxorubicin accumulation (pmoles/106 
cells) as described in Materials and Methods. Control ascites cell levels were from a mouse 














-■— 50 mg/kg 
— a-.- 100 mg/kg 
—A— 150 mg/kg 
— *-•- 200 mg/kg 
Figure 4-1. Toxicity of rrans-flupenthixol in mice. Adult, female Swiss Webster mice 
were divided into 4 groups of 5 mice each and various doses of drug in 0.1 ml saline were 
injected i.p.daily for 7 days. Surviving animals were observed daily for 2 weeks, and 
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